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 I 
Abstract 
 
Many human diseases such as malaria, Chagas disease, chikunguniya and dengue fever are 
transmitted via insect vectors. Control of human disease vectors is a major worldwide health issue. 
After decades of persistent use of a limited number of chemical insecticides, vector species have 
developed resistance to virtually all classes of insecticides. Moreover, considering the hazardous 
effects of some chemical insecticides to environment and the scarce introduction of new 
insecticides over the last 20 years, there is an urgent need for the discovery of safe, potent, and 
eco-friendly bioinsecticides.  
 
To this end, the entomopathogenic fungus Metarhizium anisopliae is a promising candidate. For 
this approach to become viable, however, limitations such as slow onset of death and high cost of 
currently required spore doses must be addressed. Genetic engineering of Metarhizium to express 
insecticidal toxins has been shown to increase the potency and decrease the required spore dose. 
Thus, the primary aim of my thesis was to engineer transgenes encoding highly potent insecticidal 
spider toxins into Metarhizium in order to enhance its efficacy in controlling vectors of human 
disease, specifically mosquitoes and triatomine bugs. As a prelude to the genetic engineering 
studies, I surveyed 14 insecticidal spider venom peptides (ISVPs) in order to compare their 
potency against key disease vectors (mosquitoes and triatomine bugs) 
 
In this thesis, we present the structural and functional analysis of key ISVPs and describe the 
engineering of Metarhizium strains to express most potent ISVPs. To facilitate this, an E. coli 
expression system was developed to produce sufficient amounts of each ISVP for functional and 
structural studies.   
 
The five most potent ISVPs, namely U2-CUTX-As1a (As1a), ω/κ-hexatoxin-Hv1a (Hybrid), µ-
DGTX-Dc1a (Dc1a), U1-AGTX-Ta1a (Ta1a), and ω-hexatoxin-Hv1a (Hv1a) were successfully 
expressed in Metarhizium anisopliae-1630 (a mosquito specialist strain) and M. anisopliae-1548 (a 
bug specialist strain). Mosquitocidal assay of recombinant M. anisopliae-1630 strains revealed a 
significant improvement in virulence compare to wild type strain, with the engineered strains 
requiring less time to kill mosquitoes.  
 
This work described in this thesis represents the first step towards the development of engineered 
Metarhizium strains with the potential to control vectors of human disease. 
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                  1               Introduction                 	  
1.1 Vector-borne disease   
 
In the context of human disease, vectors are living organisms that serve as vehicles to transmit a 
pathogen (a disease-causing agent such as a virus or parasite) from a host to a human. Some 
vectors actively transmit pathogens, whereas others are passive transmitters1. Mosquitoes are the 
most important vector of human disease as they actively transmit diseases such as malaria and 
dengue2. Houseflies in comparison passively transmit diseases. Ticks are a typical example of 
vectors that can transmit diseases to humans as well as both domestic and farm animals (e.g., 
dogs or cattle). Birds and mammals can also be vectors (e.g. rats and mice, which can carry and 
transmit diseases)3.  
 
According to the World Health Organization (WHO), a vector-borne disease is a disease in which 
the pathogenic microorganism is transmitted from an infected individual to another individual by an 
arthropod or other agent, sometimes with other animals serving as intermediary hosts (see Table 
1.1 for examples). Vector-borne diseases have a direct and significant negative impact on human 
and animal health and wellbeing as well as an indirect impact by affecting the livelihood of people, 
resulting in a huge economic burden on the global economy. Although vector-borne diseases are 
currently only considered a major health hazard in tropical and subtropical regions, global warming 
could create appropriate conditions for outbreaks in temperate regions as well4. 
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Table1.1. List of WHO recognized vector-borne diseases5,6.  
Disease Manifestation Causative 
Agent 
Vector Geographic 
Distribution 
Treatment/ 
Prevention 
Malaria Severe chills, 
fever, sweating, 
anaemia 
Plasmodium Anopheline 
mosquitoes 
Tropic; 
Subtropics 
Anti-malarial 
drugs and vector 
control 
Chikungunya Fever, joint pain, 
fatigue, nausea 
and rash 
Alphavirus of 
the family 
Togaviridae 
Aedes 
mosquitoes 
Africa; Asia; 
Indian 
subcontinent 
Supportive 
treatment and 
vector control 
Lymphatic 
filariasis 
Inflammation of 
lymphatic system 
Nematodes  
of family 
Filariodidea 
Culex, Aedes 
and Ano-
pheles 
mosquitoes. 
Tropic; 
Subtropics 
Albendazole + 
Ivermectin and 
vector control 
Onchocerciasis Blindness, sever 
itching 
Onchocerca 
volvulus 
Blackflies of 
species 
Simulium 
damnosum 
Africa;  
Latin America 
Ivermectine and 
vector control 
Schisto-
somiasis 
Haematuria, 
bladder and 
urethral fibrosis 
Schistosoma 
flatworm 
Water snails Tropic; 
Subtropics 
Anthelmentics  
African trypano-
somiasis 
(sleeping 
sickness) 
Joint pain, 
swollen lymph 
nodes, sleep 
disturbances 
Trypano-
soma brucei 
Tsetse fly Sub-Saharan 
Africa  
Various drugs 
and vector 
control 
Leishmaniasis  Fever, damage to 
spleen and liver 
and anaemia  
Leishmania 
(protozoan) 
Phlebotomine 
sandfly 
Southern 
hemisphere; 
Mediterranean 
Countries 
Treatment of 
infection and 
vector control 
Babesiosis  Fever and red 
urine 
Babesia Tick South Europe 
and Africa 
Antibiotics and 
Vector control 
Chagas disease 
(American 
trypano-
somiasis)  
Facial oedema, 
fever, headache 
and, in chronic 
phase, 
arrhythmia, 
cardiomyopathy, 
digestive lesions  
Trypano-
soma cruzi 
Various 
assassin bugs 
of subfamily 
Triatominae 
Central and 
South America 
Antiparasitic 
drugs, treatment 
of symptoms, 
and vector 
control 
Dengue fever  Fever and 
arthritis 
 
Flavivirus  Aedes 
mosquitoes 
Tropics;  
Subtropics; 
Southern 
Europe 
Supportive 
treatment and 
vector control 
Yellow Fever Fever, 
bradycardia, 
bleeding 
 
Yellow fever 
virus 
Mosquitoes  Africa; South 
America 
Vaccine, 
supportive 
treatment, and 
vector control 
 
1.2 Vector control  
 
Vector control refers to any preventive method used to eradicate or control vector populations and 
thus limit the transmission and spread of vector-borne diseases. Different vector control methods 
include: (i) Chemical control: use of larvicides, insecticides, and rodenticides to control disease-
causing vectors (see Table 1.2 for list of chemical insecticides and larvicides)7; (ii) Personal 
protection methods: agents that reduce the risk of exposure to disease causing vectors by acting 
as barriers for vectors (e.g., bed nets, and window and door fly screens)8. Repellent oils and 
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creams, smoldering coils, and liquid vapourizers are popular methods9. Plant oils are being used 
for repelling mosquitoes in many countries (e.g., turmeric, gingili, mustard, lemon grass and neem 
oil)10; (iii) Habitat control: methods that reduce the number of places where vectors can breed. 
(e.g., removal of stagnant water, which serves as a mosquito breeding habitat11);  (iv) Biological 
control: use of predators (natural enemies), bacterial toxins, insect killing viruses, and fungal 
pathogens. Biological agents that have been used successfully against mosquito larvae include 
fishes such as Gambusia, Tilapia, and Poeciellia10. Two bacterial species, Bacillus thureingiensis 
israelensis (Bti) and Bacillus sphaericus (Bs), are also effective against mosquito larvae12. Other 
promising insecticides include the fungal entomopathogens Metarhizium anisopliae and Beauveria 
bassiana13. 
 
1.2.1 Importance of vector control  
 
 
Prevention of the emergence and spread of disease is always a better alternative to treating the 
disease. Considering that vector-borne diseases have a devastating impact on humans and 
animals, vector control plays a vital role in public health and livestock management programs 
around the world. In the absence of vector control measures, dangerous vector-borne diseases 
would proliferate and spread globally. It is thus crucial for reducing disease incidence, especially 
for diseases where there are no effective treatment or preventive medical options available (e.g., 
dengue fever, Chikungunya, and Chagas disease). Even for vector-borne diseases such as 
malaria for which effective medical treatment is available, other issues such as cost, diagnosis and 
drug resistance makes the use of drug treatment alone a fragile option. Both vector control 
measures and medical treatment are necessary for effective disease management.  
The focus of this thesis is primarily on controlling spread of two of the most devastating vector-
borne diseases, malaria and Chagas disease. 
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Table 1.2. Insecticides used for malaria vector control. Insecticides are categorized 
according to type of application and their chemical nature1,8,14. 
Type of application Class of insecticides Insecticidal compounds 
Indoor residual spraying 
(IRS) 
Organochlorines DDT 
Organophosphates Chlorpyrifos 
Chlorpyrifos-methyl 
Fenthion 
Fenitrothion 
Malathion 
Pirimiphos-methyl 
Temephos 
Carbamates Bendiocarb 
Propoxur 
Pyrethroids Cypermethrin 
Bifenthrin 
Cyfluthrin 
Deltamethrin 
Etofenprox 
Lambda-cyhalothrin 
Permethrin 
Treatment of mosquito nets Pyrethroids Alpha-cypermethrin 
Cyfluthrin 
Delatmethrin 
Etofenprox 
Lambda-cyhalothrin 
Permethrin 
Larviciding Organophosphates Chlorpyrifos 
Chlorpyrifos-methyl 
Fenthion 
Fenitrothion 
Malathion 
Space spraying Organophosphates Clhlorpyrifos, Fenthion, Fenitothrion, 
Temephos. 
Pyrethroids Cypermethrin, Bifenthrin, 
Deltamethrin, Permethrin. 
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1.3 Malaria 
 
 
Malaria is the most common vector-borne disease in many tropical and subtropical regions, 
specifically Africa, Asia, and some parts of America. Despite more than 120 years of research 
since discovery of the malaria parasite in 1880 by Charles Laveran, it continues to be major health 
problem15. This life-threatening disease is caused by one of four plasmodial species Plasmodium 
falciparum, P. ovale, P. vivax and P. malariae16. Mosquito vectors are solely responsible for 
transmitting this disease, which results from multiplication of malaria parasites within red blood 
cells. Symptoms include severe chills, fever, and headache, with severe cases progressing to 
coma and death.  
 
Currently, about 3.3 billion people, almost half of the world’s population, is at risk of contracting 
malaria (see Figure 1.1). In 2010, there were 219 million cases of malaria and 660,000 deaths. 
Though malaria is a serious problem across the world, it is predominantly a problem in Africa. In 
Africa, a child under the age of 5 dies every minute from malaria, accounting for 20% of overall 
childhood deaths. The prevalence of malaria has a significant negative impact on the economy of 
countries with high levels of transmission, accounting for a decrease in the gross domestic product 
(GDP) by as much as 1.3%17. In some heavily malarious countries, the disease accounts for up to 
40% of all public health budgets17. 
 
 
Figure 1.1: Global distribution of Malaria. Malaria is prevalent in 108 tropical and semitropical countries. The most 
severely affected areas are Sub-Saharan Africa, south Asia (India, Nepal, Bhutan, Bangladesh, Srilanka and Indonesia), 
and east and south-east Asia (Vietnam, Malaysia, Myanmar, Cambodia, Singapore, Brunei, Philippines). Taken from 
WHO world malaria report, 201217. 
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The complicated life cycle of the plasmodium parasite, which involves several different life stages, 
is a major obstacle for malaria management (see Figure 1.2). Plasmodium are transmitted through 
the bite of female Anopheles mosquitoes (sporozoites from the parasite are transmitted from the 
mosquito into the human bloodstream). Within 30 min, sporozoites enter liver cells. They multiply 
for 5–7 days and form thousands of merozoites infecting liver cells. The merozoites burst out of the 
liver into the bloodstream and invade red blood cells. Within the red blood cell, the parasite 
multiplies to form new merozoites. This takes about 2 days. The infected erythrocyte then bursts, 
releasing merozoites, which infect new cells.  Few merozoites invade the red blood cells and 
develop into gametocytes, which is the sexual stage of the parasite. The mosquito, while taking a 
blood meal, also takes up these gametocytes. In the mosquito gut the gametocytes develop into 
gametes and fuse to form a zygote. After fertilization, the zygote transforms into a motile ookinete. 
The ookinete becomes an oocyst, which divides to produce about 1000 sporozoites. After 5–7 
days, the sporozoites move to the salivary glands, ready to infect another human.13,18-20. 
 
 
Figure 1.2. Life cycle of malaria parasite illustrating the different life stages of the parasite during infection of 
mosquitoes and humans. (Taken from Su et al, 2007).20 
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1.3.1 Malaria management  
 
There are two main approaches to malaria management, prevention (vector control and vaccines) 
and medical treatment (anti-plasmodial drugs). 
 
Malaria	  drug	  treatment	  
	  
There are several different generations of drugs for the treatment of malaria. These drugs act on 
specific life stages of the malaria parasite21 (see Table 1.3). Regrettably, malaria parasites have 
developed resistance to most anti-malarial drugs, including the aminoquinolines and their analogs 
(chloroquine, mefloquine, halofantrine and quinine), guanidine, and the antifolates22. Artemisinin 
derivatives offer a promising alternative approach, as these are effective against P. falciparum, 
which is resistant to the older generation of drugs23. Many questions regarding their neurologic 
toxicity, however, remain unresolved24,25.  Furthermore, artemisinin treatment is expensive and 
beyond the reach of many patients in poor countries26. Thus, effective treatment of infected 
patients remains under threat of widespread drug resistance across all malaria endemic regions27. 
More recently, resistance of Plasmodium falciparum to artemisinin has emerged in Thailand and 
along the Cambodian border28.  
  
Table 1.3. List of anti-malarial drugs and their parasite life-cycle specificities22,29. 
Drugs  Life stage of malaria parasite 
Chloroquine, amodiaquine, mefloquine  Schizonts, blood stage 
Primaquine  Hypnozoite stage, hepatic stage schizonts 
Atovaquone-proguanil Hepatic stage schizonts 
Sulfadoxine-pyrimethamine Gametocyte stage 
Artemisinin derivatives Gametocyte, tropozoites, other blood stages 
 
Malaria	  vaccine	  	  
 
Research scientists have been trying to develop an effective malaria vaccine for more than five 
decades but there are still no approved vaccines for this disease30. There have been many 
challenges in developing malaria vaccines, including: (i) malaria parasites have a complex life 
cycle with different life stages; (ii) four known species of malaria parasites infect people and each 
of these species are genetically different and have different life stages; (iii) currently we do not fully 
understand the complex immune responses that protect against the disease31. Therefore, a viable 
malaria vaccine must address the genetic diversity of the parasites and the host and the need to 
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provide immunity against the different life cycle stages of the parasite32,33. 
 
Malaria	  Vector	  control 
Because of increasing drug resistance in the malaria parasite and challenges in malaria vaccine 
development, considerable emphasis is placed on vector control by world health authorities. 
Insecticides remain the primary vector control tool throughout the world34. 
Dichlorodiphenyltrichloroethane (DDT) was the first synthetic organic insecticide used successfully 
for malaria vector control. However, in 1972, due to ecological toxicity concerns, the Environmental 
Protection Agency (EPA) in the United States of America announced a ban on DDT. This ban, 
however, excludes uses in public health emergencies, which includes indoor residual spraying 
(IRS) in sub-Saharan Africa. Other classes of insecticides (see Table 3) used for malaria vector 
control are pyrethroids, carbamates, and organophosphates7. IRS and more recently long-lasting 
insecticide-treated nets (LLINs) are the mainstream of insecticide-based malarria vector control. 
Organochlorines (DDT), organophosphates, carbamates, and pyrethroids are used for IRS (see 
Table 3). Currently, pyrethroids are the only class of insecticides approved by the World Health 
Organization Pesticides Evaluation Scheme (WHOPES) for use in LLINs. 
 
1.3.2 Why has malaria control failed?  
 
 
There are many reasons that explain the failure of efforts to control malaria: (i) The malaria 
parasite exists in two hosts, humans and female anopheline mosquitoes. Hence, controlling 
malaria involves three living beings, the malaria parasite itself, the human and the mosquito host. 
Humans and mosquitoes keep moving and travelling, spreading disease from place to place, 
making it difficult to track these parasite carriers; (ii) malaria parasites have a great ability to 
escape the human immune system. They can survive within human hosts for years without 
causing harm but nevertheless facilitating the spread of the disease through mosquito vectors35; 
(iii) malaria parasites are highly adaptive and can develop resistance against drugs; (iv) malaria 
vectors (mosquitoes) have developed resistance to most available insecticides17; (v) malaria is 
predominantly present in poor countries, where infrastructure, treatment options, and monitoring of 
treatment success is often not available36. 
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1.4 Chagas Disease 
 
Chagas disease is a potentially life-threatening illness caused by the protozoan parasite 
Trypanosoma cruzi. It is a vector-borne disease predominant in Latin America, where it is mostly 
transmitted to humans by the faeces of triatomine bugs. It can also be transmitted through blood 
transfusions and organ transplantation. Triatomine bugs occur in both forested and dry areas in the 
Americas. A number of species have adapted to living in and near houses, where there is a 
presence of domesticated animals such as chickens, cattle, goats, cats and dogs37. They normally 
hide in dark crevices during the day staying close to their host. Their bite is not usually painful but 
in some cases severe itching and other skin problems occurs. Triatomine bugs prefers to feed on 
blood from the face and they defecate straight after feeding, so bites are often contaminated with 
faecal matter containing the trypanosome that cause the disease38. These bugs can also cause 
anemia in extreme circumstances. Common vectors are Triatoma infestans, T. dimidiata, Rhodinus 
prolixus, T. sorida, and T. sanguisuga39. There is geographical variation in the predominance of 
Chagas disease vectors. T. infestans is the most important vector in southern parts of South 
America whereas R. prolixus is typically more important in northern South America and Central 
America. T. dimidiata occupies Central and South America and extends up to Mexico40. 
Approximately 8 million people are infected with T. cruzi causing Chagas disease and more than 
25 million people are at risk. In 2008, Chagas disease killed more than 15,000 people but actual 
figures could be substantially higher because of under-reporting and difficulties in diagnosis of the 
disease41. Almost 30% of chronically infected people develop cardiac alterations and 10% develop 
digestive, neurological and mixed alterations6,42. 
 
1.4.1 Chagas disease management 
 
Vector control (primary), blood transfusion screening, and medical care of the patient (secondary) 
are the basic strategies of Chagas disease management40,43. 
 
Vector	  control	  	  
Methods of Chagas disease vector control include IRS to eliminate domestic and peridomestic 
populations and housing improvements to eliminate cracks in walls and ceilings where triatomine 
bugs seek shelter during the day43. In the past, organophosphates were used for Chagas vector 
control but in recent times pyrethroids (see Table 1.4) have become the favoured insecticides for 
IRS because of their better safety profile and effectiveness. Peridomestic and domestic 
populations are controlled in the same way and should be treated at the same time, as the bugs 
may walk or fly from peridomestic habitats to domestic habitats. The most common peridomestic 
locations are chicken coops, corrals, woodpiles etc44. Another way to control triatomine bugs is to 
improve the building quality of houses with crack-free, smooth walls and ceilings to limit available 
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shelters for the bugs. This is an expensive option, but in the long-term it can help to eradicate 
domestic bug populations43,45.  
 
Medical	  Care	  	  
 
The overall aim of the medical care approach is to eliminate the parasites (T. cruzi) with specific 
drug treatments, and to manage the symptoms and health conditions associated with the disease. 
Two antiprotozoal agents, benznidazole and nifurtimox are available for specific treatment of T. 
cruzi infections. These drugs are effective only in acute parasitemia and not in chronically infected 
patients. In general, the younger the patient and the closer to the time of parasite acquisition, the 
more chances of parasitologic cure with benznidazole and nifurtimox46,47. The chronic phase of this 
disease is incurable and treatment decisions are made on case-by-case basis after thorough 
assessment and continuous monitoring of cardiac and gastrointestinal symptoms of the 
patient43,48,49. 
Table 1.4. Pyrethroids used for Chagas disease vector control. Formulation and 
required dose for insecticidal activity is given44,50,51. 
 
Pyrethroids Formulation Target dose (mg a.i./m²)3 
Deltamethrin 2.5% SC1 or 5% WP2 25 
Cyfluthrin 10% WP 50 
Beta-cyfluthrin 12.5% SC 25 
Cypermethrin 20-40% WP 125 
Lambda-cyhalothrin 10% WP 30 
 
1SC, suspension concentrate; 2WP, wettable powder; 3a.i./m2, amount of active 
ingredient applied per surface area of house (m2) in a 1 litre spray solution. 
 
 
1.4.2 Why has Chagas disease control failed?  
 
There are many reasons to explain the failure to control Chagas disease, including: (i) there is no 
vaccine available; (ii) effective diagnostics are not available to identify disease at an early stage, 
and thus patients may remain unaware of the infection for several years52; (iii) the antiprotozoal 
drugs benznidazole and nifurtimox both have severe side effects, require long courses of 
treatment, and are effective only in the acute phase of the disease53; (iv) due to environmental and 
human health hazards, many chemical insecticides are restricted for IRS use50; (v) vector control in 
the peridomestic population is rarely satisfactory and peridomestic bugs migrate to residential 
areas; (vi) more recently, triatomine bugs have developed resistance to nearly all insecticides 
including pyrethroids50, and no new insecticides for IRS have been introduced in the last 20 
years54; (vii) no novel drugs have been introduced for decades; (viii) lack of research and political 
support to take up the challenges of developing new insecticides and drug leads54,55. 
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1.5 The problem of insecticide resistance 
 
 
The effectiveness and sustainability of insecticide-based vector control relies on the continuing 
susceptibility of the vectors to available chemicals. Although there appears to be a vast array of 
commercially available chemical insecticides, they mostly act on one of only five nervous system 
targets (see Table 1.5) (i.e., acetylcholinesterase, voltage-gated sodium (Nav) channels, nicotinic 
acetylcholine receptors, and γ-aminobutyric acid (GABA)- and glutamate-gated chloride 
channels)56. This reliance on just a handful of targets has promoted the evolution of insecticide 
resistance. Widespread and long-term use of limited insecticides in public health situations has 
caused the selection and spread of resistance in disease-causing vectors14,57. An increasing 
incidence of insecticide resistance has been reported in the major African malaria vectors 
Anopheles gambiae58,59, A. funestus60 and A. arabiensis61,62. Mosquitoes can become resistant to 
both DDT and pyrethroids through a single point-mutation in the Nav channel gene63. This so-called 
target-site resistance prevents mosquito paralysis and hence it is known as knockdown 
resistance16,64,65. Enzymes that metabolically degrade insecticides can also cause resistance. 
Mosquitoes with elevated levels of monooxygenases, esterases or glutathione S-transferases have 
shown resistance to insecticides (see Figure 3)16,66,67. In some cases, resistant insects show 
resistance to other compounds in the same insecticide class (e.g., resistance against one 
pyrethroid usually results in resistance against the whole group of pyrethroids). This is known as 
cross-resistance. Cross-resistance can even arise between different classes of insecticides (e.g., 
organophosphates and carbamates16). Insecticide resistance in anopheline populations in several 
parts of Africa and triatomine populations in Latin America has led to a significant reduction in the 
effectiveness of insecticide-based vector control. 
 
Table 1.5. Molecular targets of insecticides68. 
Nervous System Targets Insecticides 
Nav channels DDT, pyrethroids 
Nicotinic acetylcholine receptors Imidacloprid, spinosad 
Acetylcholinesterase Organophosphates and carbamates 
GABA-gated chloride channels Fipronil 
Glutamate-gated chloride channels Avermectin 
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1.6 How to manage insecticide resistance? 
 
 
The management of insecticide resistance, or more precisely, the management of vector 
susceptibility, is crucial. It is considered one of the most challenging issues in modern applied 
entomology. Currently there are only four WHO-approved chemical classes of insecticides 
(organochlorines, organophosphates, carbamates and pyrethroids) addressing just two different 
insect target sites. Hence, approaches to manage insecticide resistance include: (i) rotation of 
different insecticides with different modes of action ; and (ii) most importantly, the development of 
new insecticides with a different mode of action compared to current classes of chemical 
insecticides14,69-71. Hence, in order to control both malaria and Chagas disease vectors, a novel, 
cost effective, potent and environment-friendly insecticide is urgently required. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Fig. 1.3. Mechanisms of mosquito resistance to the four classes of WHO-approved public health insecticides. 
The two major target-site mechanisms are kdr (knock-down resistance), resulting from a mutation in the NaV channel 
(pink), and MACE (modified acetyl-cholinesterase) (green). Large spots indicate the most important mechanisms (from 
Nauen, 2007)14. 
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1.7 Entomopathogens as a biological control agent  
 
Entomopathogen are pathogens that kill or seriously disables insects. There is a wide range of 
entomopathogens—bacterial, viral and fungal, —which have been studied and used as 
bioinsecticides. Examples include the soli bacterium Bacillus thuringiensis, baculoviruses, and 
entomopathogenic fungi such as Metarhizium anisopliae (See Appendix B). Entomopathogens 
plays a vital role in natural regulation of insect pests that vector diseases and destroy crops72. 
 
Bacillus	  thuringiensis	  	  
 
Bacillus thuringiensis (Bt) is a naturally occurring spore forming bacterium from the family 
Bacillaceae. It is widespread in soil and lethal to a range of insects. Sporulation results in formation 
of insecticidal crystal protein (ICP) to form protoxin crystals (Bt crystals). Bt crystals contain Cry 
toxins73. Cry toxins are pore-forming toxins responsible for the insecticidal activity of Bt. Cry toxins 
are toxic to specific species of insects, especially larval stages, and they have proved to be safe to 
humans and other vertebrates. Bt crystals have to be ingested to cause mortality in insects. After 
ingestion, Bt crystals cleaved within the insect gut and form the active toxin (Cry toxin). The Cry 
toxin binds to receptors in the midgut to form pores, which results in insect paralysis and/or 
bacterial septicaemia73,74. Most of the Bt species are active against Lepidoptera, Diptera and 
Coleoptera. The sub-species Bt israelensis is effective against the larval stage of mosquitoes75. 
Despite their potential, limited Bt products have been used as sprayable insecticides. The 
revolutionary transgenic Bt crops expressing Cry toxin were introduced in 1996. Within 3 years of 
its introduction, 29 million acres of Bt cotton, potato and corn were grown worldwide76. By 2010, Bt 
crops had been planted in 29 countries covering 148 million hectares of cropland74. Recently, 
resistance to Bt toxins has been reported, especially in diamondback moths77,78, triggering the 
need to investigate novel toxins to replace or augment Cry toxins in transgenic insect-resistant 
crops. 
 
Baculoviruses	  	  	  
Baculoviruses are one of a diverse group of viruses only pathogenic to insects, mostly of the order 
Lepidoptera, Hymenoptera and Coleoptera79. The most widely studied baculovirus is Autographa 
californica nuclepolyhedrovirus (AcNPV)80. Baculoviruses occurs in nature on plants, plant 
wreckage, and in the soil in the form of virions. Virons are responsible for the insecticidal activity of 
baculovirus. They are occluded within proteinaceous crystals called polyhedra. Similar to Bt, 
baculovirus have to be eaten by insect to cause mortality to insects. The infection cycle starts 
when insects ingest polyhedra, which results in the release of hundreds of virons in the gut. Virions 
then pass through the peritrophic matrix to enter midgut cells. The virus then replicates in the 
nuclei of epithelial cells of the midgut, producing a large number of virions. Infected insects 
continue to feed up to 5–14 days following the infection, until they die79.Baculoviruses have been 
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registered and successfully used for decades as safe and effective bioinsecticides against crop 
and forest pests. Natural baculovirus-based products are used in North America for forest pest 
control81. They are used in Brazil on over a million hectares of farmland to control the velvet bean 
caterpillar Anticarsia gemmatalis82, the major pest of soybean. Although baculoviruses have been 
used successfully for soybean and forest pest control, they have not been able to compete 
successfully with chemical insecticides. Many crops can tolerate only minimal fruit or foliar 
damage. Natural baculovirus takes 5–14 days to kill the insect pest and during this time the insect 
continues to feed, whereas chemical insecticides usually kill within a day. In the field, several 
baculovirus species may need to be applied in combination to control multiple pests because of the 
narrow host specificity. Furthermore, baculovirus is effective only at the larval stage of the pest. 
Some of these issues have been addressed using genetic engineering technology to produce 
transgenic nucleopolyhedroviruses that express insecticidal venom peptides from venomous 
animals such as scorpion or spiders83. The introduction of venom-peptide transgenes reduced the 
time to kill and the time taken until insects stopped feeding84. Though natural baculovirus have 
their own limitations, transgenic baculovirus have great potential for development as 
bioinsecticides considering their safety profile, specificity and efficacy.  
 
Entomopathogenic	  fungi	  
Entomopathogenic fungi act as parasites of insects and kill or seriously disable them85,86. Almost 
400–500 species of fungi are known to have insect pathogenic properties, and they have been 
used for biocontrol of pest insects for ~150 years. All five sub-divisions of fungi (Mastigomycotina, 
Zygomycotina, Ascomycotina, Basidiomycotina and Deuteromycotina) contain entomopathogenic 
species85. Compared to other microorganisms, fungi infect a broader range of insects including 
Lepidoptera, Homoptera, Hymenoptera, Coleoptera and Diptera87. Therefore entomopathogenic 
fungi can be found to infect hosts in a wide variety of ecological niches88. Many fungi have been 
shown to be highly virulent towards a number of economically and medically important 
arthropods87. Fungi can be applied as conidia or blastospores. Both spore types are robust and 
have evolved to withstand a range of environmental conditions. Most other insect pathogens 
require living insects or complex culture systems for inoculum production. On contrary, fungal 
spores have the capacity for mass production and conidia can be mass-produced on simple 
artificial media such as rice89. Fungal spores can also be applied in a range of formulation types, 
which could be water-based, oil-based, powders or granules90. Mass produced conidia can be 
dried and stored at low temperatures either as a powder or formulated in oil for comparatively long 
periods of time with minimal loss of viability91,92. Over the past three decades there has been much 
research on developing fungal bioinsecticides to control arthropod pests, mostly insect pests of 
crops and pastures. Most research has been directed to the genera Beauveria and Metarhizium 
whose distribution is cosmopolitan. B. bassiana and B. brongniartii are the most widely used and 
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studied Beauveria species while M. anisopliae is the most widely used Metarhizium species 
throughout the world. It was recently found that pyrethroid resistance in the malaria vector 
A. gambiae and the Chagas disease vector T. infestans leads to increased susceptibility to the 
entomopathogenic fungi M. anisopliae and B. bassiana93,94.   
 
Most importantly, the ability of entomopathogenic fungi to directly parasitise arthropods via 
penetration of the host integument (e.g., cuticle or shell) sets them apart from bacteria and viruses, 
which must be ingested to gain host entry86,95. Hence the focus of thesis is to explore selected 
Metarhizium strains engineered to express insecticidal venom peptides for development as 
bioinsecticides to control malaria and Chagas disease vectors.  
 
1.7.1 Metarhizium—mode of infection and pathogensis  
 
 
Metarhizium spores are small (2–6 µm) hydrophobic propagules that can attach to the insect 
cuticle through hydrophobic interactions96. Under suitable (moist) conditions they can germinate 
and produce germ tubes (see Figure 1.4). After germination the germ tube may swell to form an 
appressorium as a prerequisite for host penetration. An appressorium is a “cushion” of cells 
produced on an invasion surface. Roles attributed to the appressorium include: anchorage for 
penetration, softening of the cuticle through enzyme production, and concentration of components 
involved in penetration97. A range of cuticle degrading enzymes are produced during penetration; 
the three most important classes are lipases, proteases, and chitinases. There is immense 
variation in the type and quantity of enzymes produced by different species and even different 
strains of the same species98-100. Once the pathogen has penetrated the host cuticle it is believed 
to proliferate within the haemocoel as hyphal bodies. This growth form helps the fungus in 
overcoming insect defence mechanisms101. Hyphal bodies are quickly disseminated throughout 
insect fluids, thus evading host immune cells. During this stage a number of toxic metabolites may 
be produced by the pathogen. For M. anisopliae, the primary toxins is destruxin, a cyclic 
depsipeptide toxin that appears to have various effects on the host, usually leading to paralysis102. 
Insect death may result from a combination of actions, including depletion of nutrients, physical 
obstruction, or invasion of organs or toxicosis103. This infection process takes several days, with 
the overall time to death depending mostly on fungal dose and virulence of the fungal isolate. 
When humidity is high enough, the fungus can grow out of the dead insect and produce conidia 
that can infect new insects98,104. 
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Figure 1.4. Mechanism of pathogenesis of entomopathogenic Metarhizium103. Infection steps are: (1) Conidia 
adherence to the host cuticle through hydrophobic interactions and thin mucilaginous material; (2) Conidia germination 
and development; (3) Germ-tube differentiation into apressoria; (4) Cuticle penetration; (5) Hyphae differentiation into 
blastospores; (6) Host colonization; (7) Extrusion to the host cadaver surface; (8) Conidiophore formation and conidia 
production (from Acevedo, 2007). 
 
 
1.7.2 Metarhizium as a bioinsecticide   
 
 
The fungus Entomopthora anisopliae, later renamed Metarhizium anisopliae Sorokin, was used for 
the first time in the 1880s to infect and kill healthy larvae of the scarab beetle Anisoplia 
austriaca105. A few years later in 1884 Isaak Krassilstschik mass produced Metarhizium spores and 
applied them to field plots to control larvae of the root weevil (Cleonus spp.)105. Studies using 
insects as bait for entomopathogenic fungi suggest that Metarhizium is a part of the soil flora 
worldwide106. It is believed that Metarhizium has co-evolved in association with insects. Because of 
the worldwide distribution of this fungus, local isolates can be easily obtained from the soil or dead 
mycosed insects107. In Australia, there are currently four fungal bioinsecticides produced from 
endemic isolates of Metarhizium by Becker Underwood and CSIRO Entomology in conjunction 
with the Australian Plague Locust Commission. These products are registered for the control of 
locusts (Green Guard ULV; Green Guard SC), greyback cane grub (BioCane), and scarab beetle 
larvae (Chafer Guard).  
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Metarhizium is an anamorphic fungus producing asexual conidia (spores) from hyphae108. The 
conidia are produced on conidiophores in a candelabrum-like arrangement109. The compact 
conidiophores form on a cushion-like hymenial layer or sporodochium (see Figure 1.4). 
Metarhizium species are easily identified by the green cylindrical conidia produced in chains, which 
form a dense compact layer of dry powdery spores110. A revision of the genus Metarhizium based 
on a phylogenetic analysis of rDNA sequence recognised three species: M. anisopliae, M. 
flavoviride and M. album111. 
 
1.7.3 Commercial development of entomopathogens as bioinsecticides  
 
More than 100 fungus-based insect control products have been registered for commercial use by 
the USA EPA since 1995 and undergone the required stringent environmental safety tests112,113. 
Mycotrol, for example, is a Beauveria-based mycoinsecticide that is commercially produced in the 
USA. Mycotrol formulations can be used on crops for control of grasshoppers, whiteflies, thrips and 
aphids, and conidia can remain infective for 12 months when stored at 25°C113. GreenMuscle is a 
mycoinsecticide that is commercially produced in Africa; it contains spores of M. anisopliae var. 
acridum, which are selectively pathogenic to locusts and grasshoppers. Green Muscle was 
developed during a 12 year research programme called LUBILOSA114, in which substantial 
advances were made in mass-production, formulation, and application of Metarhizium115. The 
product can be sprayed with ultra-low-volume sprayers, and it can remain infective for >12 months 
when stored at 30°C115,116. Green Muscle showed no detrimental effects on non-target organisms 
and is now registered and recommended for locust and grasshopper control by the United 
Nations116. These and several other environmental risk studies demonstrate that fungal 
biopesticides are relatively safe for the environment, especially when compared to chemical 
pesticides106. 
 
1.7.4 Obstacles using Metarhizium as a bioinsecticide 
Metarhizium may take 1–3 weeks to kill its host because of low virulence. This slow kill time, along 
with its inconsistency in performance, is a major obstacle for widespread use of Metarhizium to 
control vectors of human disease. To some extent, field conditions such as UV and high 
temperature affect the performance of Metarhizium. Moreover, Metarhizium is more expensive 
than chemical insecticides. Thus, to improve the insecticidal market share of fungal pathogens, 
genetic modification is likely to be required. 
 
1.7.5 Genetic engineering of Metarhizium to improve virulence and tolerance  
 
With advances in recombinant DNA techniques, it is possible to significantly improve the 
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insecticidal potency of Metarhizium and its tolerance to UV radiation. For example, genetic 
engineering of Metarhizium to express insecticidal toxins can improve its pathogenicity. Addition of 
a transgene encoding the insecticidal scorpion toxin AaIT1 in M. anisopliae strain 549 enabled the 
same mortality rates in the tobacco hornworm Manduca sexta to be obtained at a 22-fold lower 
spore dose (LC50 – spore concentration required to kill 50% of test population) compared to the 
wild-type strain. Similar results were obtained with mosquitoes, where the LC50 was reduced by 9-
fold117,118. 
 
Another possibility for increasing the ability of the fungus to reduce the spread of malaria would be 
to engineer it to express a transgene with anti-plasmodial properties in addition to an insecticidal 
toxin transgene. This approach would provide a dual mechanism to control the disease. Recently it 
was also demonstrated that the overexpression of CPD (cyclobutane pyrimidine dimer) 
photolyases increases the tolerance of Metarhizium robertsii to UV radiation. Thus, genetic 
engineering provides opportunities for improving the bioinsecticidal properties of Metarhizium. 
 
 
1.7.6 Spiders: source of insecticidal toxins for Metarhizium genetic engineering 
 
Spiders are the most successful insect predators on earth. There are more than 3,900 genera and 
44,000 extant species of spiders119,120. They use their venom to paralyse or kill their prey. Only five 
genera of spiders are potentially lethal to humans121 and their venom is mostly toxic only to their 
targeted prey (i.e., insects). The major constituents of spider venoms are small disulfide-rich 
peptides. Many of these contain an inhibitor cystine knot (ICK) motif. This ICK motif provides 
resistance to extremes of pH, high temperature, and proteolytic enzymes122,123. A large number of 
spider toxins have been identified and studied for their insecticidal activity against different insect 
targets. Currently the ArachnoServer database (a manually curated database of spider toxins 
which provides information on their sequence, structure and biological activity) holds 1078 spider 
toxin records of which ~70% have characterised insecticidal activity. The molecular target for 162 
spider toxins has been experimentally determined119,120 . Thus, spider toxins have a well-
established efficacy against insects and represent promising candidates for Metarhizium genetic 
engineering. 
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1.8 Aim & objectives 
 
 
The work presented in this thesis is aimed to develop environmentally friendly bioinsecticides for 
the control of vectors of human diseases (specifically mosquitoes and triatomine bugs). The first 
part of the research was focused on production, characterisation, and prioritisation of potent 
insecticidal venom peptides that could be used for genetic engineering of fungal 
entomopathogens. The second part of the thesis is focused on genetic engineering and testing of 
fungal entomopathogens that express insecticidal venom-peptide trangenes. The specific research 
objectives were as follows: 
Aim 1:  Compare the insecticidal potency of selected insecticidal spider-venom toxins  against 
mosquitoes and triatomid bugs. 
Aim 2:  Determine the structure and mode of action of the most promising toxins. 
Aim 3:  Engineer transgenes encoding the most potent insecticidal spider toxins into 
 Metarhizium anisopliae.  
Aim 4: Compare the insecticidal potency of the recombinant and wild-type fungi against 
 mosquitoes and triatomine bugs. 
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1.9 Thesis Outline  
 
Chapter 2 provides details of recombinant production of the selected insecticidal spider-venom 
peptides (ISVPs) in E. coli as well as assessment of their insecticidal activity. This chapter 
describes an in-house insecticidal bioassay on sheep blowflies (L. cuprina). It also describes the 
insecticidal bioassay of these ISVPs in mosquitos (A. gambiae) and triatomine bugs (R. prolixus) 
which were performed in collaboration with Dr Luciano Moreira at Fiocruz, Brazil. 
 
Chapter 3 is a manuscript published in Biochemical Pharmacology that describes the recombinant 
production, 3D structure, and molecular target of an ISVP known as Aps III.  
 
Chapter 4 is a manuscript submitted to FEBS Journal that describes the recombinant production, 
3D structure, molecular target determination and insecticidal activity of an ISVP known as Sf1a.  
 
Chapter 5 is a manuscript accepted in Nature Communications and currently in press that 
describes the recombinant production, 3D structure, and molecular target determination of an IVSP 
known as Dc1a. 
 
Chapter 6 describes genetic engineering of Metarhizium to express the most promising ISVPs and 
comparison of the insecticidal efficacy of the parental wild-type strain and the recombinant 
Metarhizium strains against mosquitoes.  
 
Chapter 7 provides a summary of the research findings and discusses future prospects for use of 
fungal bioinsecticides for controlling vectors of human diseases and agricultural pests. 
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                      2  
Recombinant	  expression	  and	  assay	  of	  
insecticidal	  spider	  venom	  peptides	  (ISVPs)	  	  
	  
 
2.1 Introduction  
 
 
Recombinant production of venom peptides is often challenging due to the presence of multiple 
disulfide bonds, which cannot be formed in the cytoplasm of most prokaryotic and eukaryotic cells 
due to the reducing intracellular environment. An approach that has proved successful for 
expression of disulfide-rich spider toxins is production in the periplasm of E. coli, where the 
enzymes involved in disulfide-bond formation are located124. Eleven of the most potent insecticidal 
spider-venom peptides (ISVPs) described in the literature were selected from a curated database 
of spider toxins (ArachnoServer)120 (see Table 2.1). In order to obtain sufficient quantities of these 
peptides for functional and structural studies, they were produced recombinantly using an E. coli 
periplasmic expression system optimised for production of disulfide-rich peptides124.  After 
production of the ISVPs, insecticidal assays were performed on sheep blowflies (Lucilia cuprina), 
mosquitoes (Aedes aegypti) and triatomine bugs (Rhodnius prolixus). On the basis of these 
insecticidal assays, a panel of the five most potent ISVPs were selected for Metarhizium 
transformation.  
 
2.2 Methods  
 
2.2.1 Periplasmic expression of ISVPs in E. coli  
 
Synthetic genes for all ISVPs were ordered from GeneArt (Invitrogen, Regensburg, Germany). 
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Genes encoding the peptide of interest were codon optimised for E. coli expression and inserted 
into the specially designed pLIC-MBP expression vector. This vector (pLIC-NSB) contains the LacI 
promoter, which can be induced with isopropyl β-D-1-thiogalactopyranoside (IPTG), and it encodes 
ampicillin resistance. The plasmid encodes the ISVP as a fusion protein (see Figure 2.1A) 
containing a MalE signal sequence for export to the periplasm, MBP (maltose binding protein) to 
increase protein solubility, His6 tag for nickel affinity purification, plus a TEV (tobacco etch virus) 
protease recognition site between the MBP and toxin-encoding regions to facilitate cleavage of the 
ISVP from the fusion protein125,126.  
 
 
Table 2.1. Selected insecticidal spider toxins. 
LD50, Lethal Dose, 50%; PD50, Paralysing Dose, 50%; DSBs, disulfide bonds 
 Data from ArachnoServer (www.arachnoserver.org)120. 
 
Spider toxin name Number of residues and 
disulfide bonds 
LD50 /PD50 in insects 
ω/κ -hexatoxin-Hv1a 39 residues; 3 DSBs – 
ω-hexatoxin-Hv1a 37 residues; 3 DSBs LD50: Acheta domesticus 89 pmol/g; 
Musca domestica 77 pmol/g; PD50: 
Heliothis virescens 250 pmol/g 
 
κ-hexatoxin-Hv1c 37 residues; 4 DSBs LD50: Spodoptera frugiperda 
3070 pmol/g; A. domesticus 167 
pmol/g; M. domestica 91 pmol/g; 
H. virescens 3195 pmol/g 
 
U1-AGTX-Ta1a 50 residues; 3 DSBs PD50: 780–900 pmol/g in 
lepidopterans;  
 
µ-DGTX-Dc1a 56 residues; 4 DSBs PD50: H. virescens 380 pmol/g;  
 
U2-CUTX-As1a 37 residues; 4 DSBs LD50: M. sexta 133 pmol/g 
 
U2-SGTX-Sf1a 46 residues; 4 DSBs LD50: H. virescens 2011 pmol/g;  
 
U1-PLTX-Pt1a 46 residues; 5 DSBs LD50: M. sexta 13.8 pmol/g 
 
U1-CUTX-As1c 76 residues; 4 DSBs LD50: M. sexta 2.4 pmol/g 
 
δ-CNTX-Pn1a 48 residues; 5 DSBs LD50: M. domestica 36 pmol/g 
 
µ-AGTX-Aa1d 37 residues; 4 DSBs LD50: M. domestica 30 pmol/g 
 
 
 
 
The MBP-toxin fusion protein can be obtained from the periplasm by osmotic shock, sonication, or 
whole cell lysis. The fusion protein is then purified using nickel affinity chromatography and 
cleaved by recombinant His6-taggedTEV protease to yield the mature ISVP. The cleaved His6-
MBP and His6-TEV are removed by one of three methods: (i) passing the cleaved fusion protein 
over a charged Ni-NTA Superflow resin (Qiagen, Chadstone, Australia);,(ii) passing the solution 
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through a Solid-Phase Extraction (SPE) column; (iii) precipitating MBP and TEV with 1% 
trifluoroacetic acid (TFA) .The pure peptide is then recovered using reverse-phase HPLC (RP-
HPLC).     
 
 
 
Figure 2.1. Production of ISVPs. (A) Schematic representation of the pLicC-NSB vector used for periplasmic 
expression of ISVPs. The coding region includes a MalE signal sequence (MalESS) for periplasmic export, a His6 affinity 
tag, an MBP fusion tag, and a codon-optimized gene encoding the ISVP, with a TEV protease recognition site inserted 
between the MBP and toxin coding regions. The locations of key elements of the vector are shown, including the 
ribosome-binding site (RBS). (B) E. coli periplasmic expression system. Upon induction with IPTG, the MBP-toxin fusion 
protein is expressed and transported to the periplasm via the SecYEG translocase system. The DsbA machinery handles 
oxidative folding of the ISVP in the periplasm (Figure 2.1B from Klint et al., 2013)124 
 
 
2.2.2 Blowfly toxicity assay  
 
 
To determine the toxicity of ISVPs in sheep blowfly (Lucilia cuprina), the method described in 
Bende et al. 2013127 was used. In short, ISVPs were dissolved in insect saline (composition: 200 
mM NaCl, 3.1 mM KCl, 5.4 mM CaCl2, 4.0 mM MgCl2, 2.0 mM NaHCO3 and 0.1 mM Na2HPO4; pH 
adjusted to 7.2) and injected into the ventro-lateral thoracic region of sheep blowflies with mass of 
19.5–23.3 mg. A 1.0 ml Terumo Insulin syringe (B-D Ultra-Fine, Terumo Medical Corporation, 
Maryland, USA) with a fixed 29 G needle fitted to an Arnold hand micro-applicator (Burkard 
Manufacturing Co. Ltd., England) was used to inject a maximum volume of 2 µl per fly. Three 
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separate experiments were run with various doses of each ISVP injected into 10 flies. After ISVP 
injection, each blowfly was individually housed in a plastic tube and provided with a 20% sugar 
solution. Insect saline was used as a control. Paralytic and lethal effects were measured 24 h post-
injection. The insect is declared as paralysed with the only sign of life being minor movements of 
the proboscis. All PD50 and LD50 values were calculated separately for each experiment by plotting 
dose (in pmol.g-1) vs. percentage of deaths at 24 h post injection. Then log dose–response curves 
were fitted using following equation128.      
                                                
 
Where y is the percentage of deaths in the sample population at 24 h postinjection, x is the toxin 
dose in pmol.g-1, n is the variable slope factor, a is the maximum response and b is the minimum 
response.  
2.2.3 Mosquito and triatomine bug toxicity assay  
 
 
Mosquito and triatomine bug assays were performed in the lab of Dr Luciano Moreira at Fiocruz 
Institute, Brazil. The method used was adopted from Luna et al. (2007)129 with some modifications. 
Due to time constraints, toxicity assays were performed using ω/κ-hexatoxin-Hv1a ("hybrid" toxin) 
and ω-hexatoxin-Hv1a ("omega" toxin). ISVPs (Hybrid, Omega) were dissolved in insect saline 
and injected into the lateral thoracic region of female adult mosquitoes (Aedes aegypti) with an 
average mass of 2.5 mg. Microinjection needles were made by pulling borosilicate glass capillaries 
with a needle puller (Sutter Instrument CO, CA, USA) and fitted on a Nanoject II auto injector 
(Drummond Scientific Company, Broomall, PA, USA). Mosquitoes were anesthetized with CO2/dry 
ice and placed on a pre-cooled petri dish for injections. A maximum volume of 69 nl was injected 
per mosquito. Experiments were performed in triplicate using various doses of ISVP, with each 
dose injected into 10 mosquitoes. The control group was injected with insect saline. After 
injections, mosquitoes were transferred into plastic cages and kept at 27ºC with 80% relative 
humidity. Cotton balls soaked in 80% sugar solution were provided. Lethal effects were measured 
24 h post-injection. LD50 values were calculated as described in Herzig & Hodgson (2008)130 and 
averaged to produce a final LD50 for each IVSP.  
 
ISVPs toxicity was also tested in the triatomine bug Rhodnius prolixus, the second most important 
vector of Chagas disease, using same experimental set-up with minor changes. Second instar 
nymphs of R. prolixus with an average mass of 1.4 mg were injected with various doses of ISVPs 
in the lateral thoracic region. Three separate sets of experiments were performed for each ISVP 
dose, with 7 bugs injected per dose. The control group was injected with insect saline. After 
injection, the bugs were transferred to plastic cages and maintained at 26ºC with 50% relative 
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humidity. As a food source, 80% sugar solution was provided. Lethal effects were measured 24 h 
post injection and LD50 values were calculated as described previously130.  
 
2.3 Results and Discussion 
 
2.3.1 Production of recombinant ISVPs 
 
E. coli is the most widely used recombinant protein expression system as it offers high yields and 
involves simple plasmid constructs. The proteins are expressed in the cytoplasm of the bacterium 
where the intracellular thioredoxin and glutaredoxin disulfide-reducing pathways keep cytoplasmic 
cysteine residues in the reduced state131,132. This problem can be overcome by transport of the 
expressed protein by SecYEG translocase system to the periplasmic space, where the 
endogenous bacterial machinery for disulfide bond formation is located133,134 (see Figure 2.1B). 
Bacterial expression further facilitates facile and high yield 15N/13C isotopic labelling of proteins for 
subsequent structural studies using nuclear magnetic resonance (NMR) spectroscopy.   
 
An efficient E. coli expression system was established for the production of selected ISVPs. Cell 
growth and purification conditions were optimized for individual toxins. The outcome of 
recombinant toxin production is outlined in Table 2.2. In summary, seven peptides were produced 
in sufficient quantities for insecticidal bioassays against blowflies, mosquitoes and triatomine bugs, 
namely ω/κ -hexatoxin-Hv1a (Hybrid), ω-hexatoxin-Hv1a (Omega), κ-hexatoxin-Hv1c (Kappa), U1-
AGTX-Ta1a (Ta1a), µ-DGTX-Dc1a (Dc1a), U2-CUTX-As1a (As1a), and U2-SGTX-Sf1a (Sf1a). 
Sufficient amounts of Hybrid, Omega and Kappa were obtained in crude form from Vestaron 
Corporation, USA (www.vestaron.com) and re-purified to >95% purity using RP-HPLC. Details on 
production of As1a, Sf1a and Dc1a are covered in Chapter 3, Chapter 4 and Chapter 5 
respectively.  Throughout the course of this project extensive efforts were made, without success, 
to optimize E. coli expression of U1-CUTX-As1c (As1c), U1-PLTX-Pt1a (Pt1a) and µ-AGTX-Aa1d 
(Aa1d). Further studies using these toxins may be possible using other recombinant expression 
techniques or via chemical synthesis, but these approaches were not explored here.  
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Table 2.2: Production of recombinant spider venom peptides 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
‘++’  = > 1mg expression of soluble peptide per litre; ‘+++’ = > 3mg  expression of soluble peptide per litre 
 
 
2.3.2 ISVPs are paralytic and lethal to sheep blowflies  
 
 
As previously stated, seven ISVPs were produced in sufficient amounts for use in insect toxicity 
assays. In the first instance, sheep blowflies (L. cuprina) were used to assess the relative 
insecticidal toxicity of the ISVPs. At 24 h post-injection, six ISVPs (Ta1a, Hybrid, Omega, Kappa, 
Dc1a, and Sf1a) caused a high level of blowfly mortality. As1a induced flaccid paralysis and flies 
remained paralysed after 24 h; the PD50 measured 24 h after injection was 700 ± 35 pmol/g (see 
Figure 2.2 G). The assay used does not allow measurement of toxic effects for periods extending 
beyond 24 h as the survival rate in control blowflies begins to decrease. However, flies paralysed 
by a high dose of As1a did not recover but died two days post-injection. We conclude that As1a 
produces an irreversible paralysis in blowflies that eventually results in death. More details about 
As1a is covered in Chapter 3. 
 
Toxin Plasmid vector E. coli expression Yield of 
pure toxin 
Expression  of 
13C/15N-labelled 
toxin 
ω/κ -hexatoxin-
Hv1a 
Yes Yes +++ Yes 
ω-hexatoxin-Hv1a Yes Yes +++ Yes 
κ-hexatoxin-Hv1c Yes Yes +++ Yes 
U1-AGTX-Ta1a Yes Yes +++ Yes 
µ-DGTX-Dc1a Yes Yes ++ Yes 
U2-CUTX-As1a Yes Yes +++ Yes 
U2-SGTX-Sf1a Yes Yes +++ Yes 
µ-AGTX-Aa1d Yes Yes (Unfolded) - No 
U1-PLTX-Pt1a Yes Yes (Unfolded) - No 
U1-CUTX-As1c Yes Yes (Insoluble) - No 
δ-CNTX-Pn1a Yes Yes (Unfolded) - No 
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LD50 values were calculated from dose-response curves for the remaining six ISVPs (Figure 2.2). 
Ta1a stands out as the most potent ISVP with LD50 of 198 ± 33 pmol/g (see Figure 2.2D) followed 
by Dc1a with LD50 of 231 ± 32 pmol/g (see Figure 2.2E). Hybrid and Kappa were found to be 
almost equipotent with LD50 of 259 ± 17 pmol/g and 278 ± 7 pmol/g respectively (see Figure 
2.2A,B). Sf1a was found to have very weak insecticidal activity with LD50 of 32,0000 ± 8,600 
pmol/g (see Figure 2.2F). More details about Sf1a and Dc1a are covered in Chapters 4 and 5, 
respectively.  
 
`  
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Figure 2.2. Acute toxicity of ISVPs in sheep blowflies (L. cuprina). Dose-response curves for the lethal or paralytic 
effects of ISVPs determined 24 h after injection. The ISVPs exmained were (A) ω/κ -hexatoxin-Hv1a (Hybrid); (B) ω-
hexatoxin-Hv1a (Omega); (C) κ-hexatoxin-Hv1c (Kappa); (D) U1-AGTX-Ta1a (Ta1a); (E) µ-DGTX-Dc1a (Dc1a); (F) U2-
CUTX-As1a (As1a); and (G) U2-SGTX-Sf1a (Sf1a). 
 
2.3.3 ISVPs are lethal to mosquito and triatomine bugs  
 
 
Initial toxicity screens revealed that all chosen ISVPs except Sf1a were potent against sheep 
blowflies. Mosquitoes (dipterans) and triatomine bugs (hemipterans) are not closely related, with 
their last common ancestor dating back more than 300 million years135, and therefore we wondered 
whether these dipteran-toxic IVSPs would also be toxic to triatomines. We therefore compared the 
toxicity of the Hybrid and Omega IVSPs against mosquitoes (Aedes aegypti) and triatomine bugs 
(R. prolixus). LD50 values were calculated 24 h post-injection. In mosquitoes, the Hybrid toxin (LD50 
of 37.4 ± 9.7 pmol/g) was found to be approximately 2-fold more potent than the Omega toxin 
(LD50 of 64.4 ± 3.5 pmol/g; Figure 2.3). Remarkably, both toxins were even more toxic to 
triatomine bugs, with the Hybrid toxin (LD50 of 15.8 ± 4.5 pmol/g) again being more potent than 
the Omega toxin (LD50 of 47.4 ± 14.5 pmol/g) (see Figure 2.4).  
 
 
Figure 2.3. Acute toxicity of ISVPs in mosquitoes, A. aegypti. Dose-response curves for lethal effects of (A) ω/κ-
hexatoxin-Hv1a (Hybrid) and (B) ω-hexatoxin-Hv1a (Omega) determined 24 h after injection into mosquitoes. 
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Figure 2.4 Acute toxicity of ISVPs in triatomine bugs, R. prolixus. Dose-response curves for lethal effects of (A) ω/κ-
hexatoxin-Hv1a (Hybrid) and (B) ω-hexatoxin-Hv1a (Omega) determined 24 h after injection into triatomine bugs. 
 
 
2.3.4 ISVPs for Metarhizium genetic engineering  
 
 
There are no standard assays or target species for comparison of the insecticidal potency of 
venom peptides. Several experimental factors could affect the measurement of insecticidal 
potency, including the route of toxin application, site of injection, dose of injection, injection volume, 
type of injector used, the time intervals between toxin injection, development stages of the insect, 
the temperature, and relative humidity at which test insects are kept post-injection. Hence, the 
insecticidal values reported in the literature for different toxin peptides cannot be directly 
compared136. Here, for the first time, we produced ISVPs and performed toxicity assay against 
blowflies, mosquitoes and triatomine bugs under identical experimental conditions. These assays 
allowed a more accurate comparison of the relative potency (LD50 and PD50) of the ISVPs, which in 
turn allowed us to select a panel of the five most potent ISVPs for engineering toxin-encoding 
transgenes into Metarhizium. The selected ISVPs cover a range of pharmacologies including block 
of NaV channels (As1a; see Chapter 3), block of both KCa and CaV channels (Hybrid137); activation 
of NaV channels (Dc1a; see Chapter 5); selective block of CaV channels (Hv1a138), and Ta1a, for 
which the molecular target remains to be determined.  
 
The selected ISVPs all have high potency, environmental stability, insect specificity and in some 
cases novel molecular targets, all ideal attributes for development as bioinsecticides139.  
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1. Introduction
Insects serve as vectors for a wide range of debilitating and
potentially lethal human diseases such as malaria, dengue, Chagas
disease, and yellow fever [1]. About 3.3 billion people, almost half
of the world’s population, are at risk of contracting vector-borne
disease [2]. Moreover, despite intensive control measures, insect
pests reduce world crop yields by 10–14% annually [3,4].
Despite the widespread introduction of insect-resistant trans-
genic crops, chemical insecticides remain the dominant method for
controlling insect pests in both the agricultural and public health
arenas. These chemicals target a very small number of molecular
targets in the insect nervous system [5]. As a result, their
widespread use over several decades has promoted the evolution
of resistant insect populations, with >600 insects and mites now
resistant to one or more classes of chemical insecticides [6]. In
addition, key classes of insecticides have been withdrawn from
sale or their use has been restricted by regulatory authorities due
to growing environmental and human health concerns [7]. Thus,
there is an urgent need to develop novel classes of insecticides or
alternative methods of insect pest control.
A promising approach in the agricultural sector is to engineer
crops to produce insecticidal toxins. By 2010, 148 million hectares
of genetically modiﬁed (GM) crops had been planted in 29
countries, representing 10% of all cropland [8]. While the
introduction of GM crops that express Bacillus thuringiensis (Bt)
toxins has provided an alternative and potentially safer method of
insect control than chemical insecticides, alternative insect-toxin
transgenes are urgently needed as constitutive expression of Bt
toxin in transgenic plants is likely to expedite resistance
development [9].
There are very few well characterised toxins that could be
considered as alternatives or adjuncts to Bt. However, some of the
most promising candidates are novel insecticidal peptides that
have been isolated from the venom of spiders [7,10–12], the most
successful insect predators on the planet. Most of these peptides
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are highly stable because they contain an inhibitor cystine knot
(ICK) motif [13,14] that provides them with resistance to
extremes of pH, high temperatures, and proteolytic enzymes
[7,15]. One of the ﬁrst insecticidal spider-venom peptides to be
reported was Aps III from the venom of the trapdoor spider
Apomastus schlingeri [16]. With a reported LD50 of 133 pmol/g
against the tobacco hornworm Manduca sexta, this peptide is one
of the most potent insect toxins described to date according to
ArachnoServer [17,18]. Aps III comprises 37-residues with four
disulﬁde-bonds, but its three-dimensional structure and mode of
action are unknown.
Here we describe the development of an efﬁcient E. coli
expression system that was used to produce recombinant Aps III
(rAps III) for functional and structural studies. The 3D solution
structure of rAps III determined using NMR spectroscopy revealed
an inhibitor cystine knot motif that is commonly found in spider-
venom peptides. However, rAps III contains an additional disulﬁde
bridge that is employed as a molecular staple to tie together the
ends of a very large b-hairpin loop. We demonstrate that the
insecticidal activity of rAps III results from a potent block of insect
voltage-gated sodium (Nav) channels in combination with a
weaker block of insect voltage-gated calcium (Cav) channels.
However, in striking contrast to previously characterised Nav
channel blockers from spiders, all of which are gating modiﬁers
[19], rAps III appears to be a pore blocker that plugs the outer
vestibule of insect Nav channels.
2. Material and methods
2.1. Chemicals
All chemicals were purchased from Sigma–Aldrich Australia
(Castle Hill, NSW, Australia), Sigma–Aldrich USA (St Louis, MO,
USA), or Merck Chemicals (Kilsyth, Victoria, Australia) with the
exception of isopropyl-b-D-thiogalactopyranoside (IPTG) and
streptomycin (Life Technologies, Victoria, Australia), tetrodotoxin
(Alomone Labs, Israel), and HPLC-grade acetonitrile (RCI Labscan,
Bangkok, Thailand). 13C6-glucose and
15NH4Cl were from Sigma–
Aldrich Australia. Recombinant His6-TEV protease (EC 3.4.22.44)
was produced in-house used a published protocol [20].
2.2. Production of recombinant Aps III
A synthetic gene encoding Aps III, with codons optimised for
expression in Escherichia coli, was produced and cloned into a
variant of the pLIC-MBP expression vector [21] by GeneArt
(Invitrogen, Regensburg, Germany). This vector (pLIC-NSB1)
encodes a MalE signal sequence for periplasmic export [22], a
His6 tag for afﬁnity puriﬁcation, a maltose binding protein (MBP)
fusion tag to aid solubility [23], and a tobacco etch virus (TEV)
protease recognition site directly preceding the codon-optimised
Aps III gene (Fig. 1A).
The plasmid encoding Aps III was transformed into E. coli strain
BL21(lDE3) for recombinant toxin production. Protein expression
and puriﬁcation were performed as described previously [24] with
minor modiﬁcations. Brieﬂy, cultures were grown in Terriﬁc Broth
at 37 8C with shaking at 120 rpm. Toxin gene expression was
induced with 1 mM IPTG at an OD600 of 1.1–1.2, then cells were
grown at 18 8C for a further 12 h before harvesting by centrifuga-
tion for 15 min at 8000 rpm. For production of uniformly 13C/15N-
labelled rAps III, cultures were grown in minimal medium
supplemented with 13C6-glucose and
15NH4Cl as the sole carbon
and nitrogen sources, respectively.
The His6-MBP-toxin fusion protein was extracted from the
bacterial periplasm by cell disruption at 26 kPa (TS Series Cell
Disrupter, Constant Systems Ltd, Northants, UK), then captured by
passing the extract (buffered in 40 mM Tris, 500 mM NaCl, pH 8.0)
over Ni-NTA Superﬂow resin (Qiagen). Proteins bound non-
speciﬁcally were removed by washing with 10 mM imidazole
then the fusion protein was eluted with 500 mM imidazole. The
eluted fusion protein was concentrated to 10 ml and the buffer was
exchanged to remove imidazole. Reduced and oxidised glutathione
were then added to 0.6 mM and 0.4 mM, respectively, to maintain
TEV protease activity and promote folding of the protein.
Approximately 100 mg of His6-tagged TEV protease was added
per mg of rAps III, then the cleavage reaction was allowed to
proceed at room temperature for 12 h. The cleaved His6-MBP and
His6-TEV were removed by passing the solution over Ni-NTA
Superﬂow resin, while the eluate containing rAps III was collected
for further puriﬁcation using reverse-phase HPLC (RP-HPLC). RP-
HPLC was performed on a Vydac C18 column (250  4.6 mm,
particle size 5 mm) using a ﬂow rate of 1 ml/min and a gradient of
20–40% Solvent B (0.043% triﬂuoroacetic acid (TFA) in 90%
acetonitrile) in Solvent A (0.05% TFA in water) over 20 min. rAps
III contains a non-native N-terminal serine residue (a vestige of the
TEV protease cleavage site), making it one-residue longer than
native Aps III (Fig. 1B).
2.3. Mass spectrometry
Toxin masses were conﬁrmed by matrix assisted laser
desorption ionisation–time of ﬂight mass spectrometry (MALDI-
TOF MS) using a Model 4700 Proteomics Bioanalyser (Applied
Biosystems, CA, USA). RP-HPLC fractions were mixed (1:1 v:v) with
a-cyano-4-hydroxy-cinnamic acid matrix (5 mg/ml in 50/50
acetonitrile/H2O) and MALDI-TOF spectra were acquired in
positive reﬂector mode. All reported masses are for monoisotopic
[M+H]+ ions.
2.4. Insecticidal assays
rAps III dissolved in insect-saline [25] was injected into the
ventro-lateral thoracic region of sheep blowﬂies (Lucilia cuprina;
mass 19.7–23.9 mg) using a 1.0 ml Terumo Insulin syringe (B-D
Ultra-Fine, Terumo Medical Corporation, MD, USA) with a ﬁxed 29
gauge needle ﬁtted to an Arnold hand micro-applicator (Burkard
Manufacturing Co. Ltd., England). A maximum volume of 2 ml was
injected per ﬂy. Thereafter, ﬂies were individually housed in 2 ml
tubes and the paralytic activity was determined after 24 h. A total
of three tests were carried out and for each test seven doses of rAps
III (n = 10 ﬂies per dose) and the appropriate control (insect saline;
n = 30 ﬂies each) were used. PD50 values were calculated as
described previously [26].
2.5. Electrophysiological measurements
2.5.1. Primary cell culture
Dorsal unpaired median (DUM) neurons were isolated from
unsexed adult American cockroaches (Periplaneta americana) as
described previously [27,28]. Brieﬂy, terminal abdominal ganglia
were removed and placed in normal insect saline (NIS) containing
(in mM): NaCl 180, KCl 3.1, N-hydroxyethylpiperazine-N-ethane-
sulfonic acid (HEPES) 10 and D-glucose 20. Ganglia were then
incubated in 1 mg/ml collagenase (type IA) (EC 3.4.24.3) for 40 min
at 29 8C. Following enzymatic treatment, ganglia were washed
three times in NIS and triturated through a ﬁre-polished Pasteur
pipette. The resultant cell suspension was then distributed onto
12-mm diameter glass coverslips pre-coated with 2 mg/ml
concanavalin A (type IV). DUM neurons were maintained in NIS
supplemented with 5 mM CaCl2, 4 mM MgCl2, 5% foetal bovine
serum and 1% penicillin and streptomycin, and maintained at
29 8C, 100% humidity.
N.S. Bende et al. / Biochemical Pharmacology 85 (2013) 1542–1554 1543
Author's personal copy
2.5.2. Patch-clamp electrophysiology
Ionic currents were recorded in voltage-clamp mode using the
whole-cell patch-clamp technique employing version 10.2 of the
pCLAMP data acquisition system (Molecular Devices, Sunnyvale,
CA). Data were ﬁltered at 5–10 kHz with a low-pass Bessel ﬁlter
with leakage and capacitative currents subtracted using P-P/4
procedures. Digital sampling rates were set between 15 and 25 kHz
depending of the length of the protocol. Single-use 0.8–2.5 MV
electrodes were pulled from borosilicate glass and ﬁre-polished
prior to current recordings. Liquid junction potentials were
calculated using JPCALC [29], and all data were compensated for
these values. Cells were bathed in external solution through a
continuous pressurised perfusion system at 1 ml/min, while toxin
solutions were introduced via direct pressurised application via a
perfusion needle at 50 ml/min (Automate Scientiﬁc, San Fran-
cisco, CA) to a bath volume of 300 ml. To avoid issues of
desensitisation or rundown of currents, particularly with CaV
channel currents, recording periods were kept as short as possible
with the effect of toxin recorded within 5 min of control
recordings. Control data was not acquired until at least 20 min
after whole-cell conﬁguration was achieved. This was to eliminate
the inﬂuence of fast time-dependent shifts in steady-state
inactivation resulting in current rundown, particularly when
recording NaV channel currents (INa). Time-dependent shifts in
steady-state NaV channel inactivation are typically of the order of
2–3 mV beyond this period and do not signiﬁcantly inﬂuence
current amplitude. Experiments were performed with a single
concentration of toxin tested on one cell, which was subsequently
repeated in separate experiments using unexposed cells. The
number of independent recordings for each type of experiment is
provided in the relevant sections of the results. All experiments
were performed at ambient room temperature (20–23 8C).
To record INa, the external bath solution contained (in mM):
NaCl 80, CsCl 5, CaCl2 1.8, tetraethylammonium chloride (TEA-Cl)
50, 4-aminopyridine (4-AP) 5, HEPES 10, NiCl2 0.1, and CdCl2 1,
adjusted to pH 7.4 with 1 M NaOH. The pipette solution contained
(in mM): NaCl 34, CsF 135, MgCl2 1, HEPES 10, ethylene glycol-
bis(2-aminoethylether)-N,N,N0,N0-tetraacetic acid (EGTA) 5, and
ATP-Na2 3, adjusted to pH 7.4 with 1 M CsOH. Due to the reported
current rundown with calcium as a charge carrier [30], BaCl2
replaced CaCl2 in all experiments on voltage-activated calcium
(CaV) channels.
Fig. 1. Production and functional analysis of recombinant Aps III. (A) Schematic representation of the pLicC-NSB1 vector used for periplasmic expression of Aps III. The coding
region includes a MalE signal sequence (MalESS) for periplasmic export, a His6 afﬁnity tag, an MBP fusion tag, and a codon-optimised gene encoding Aps III, with a TEV protease
recognition site inserted between the MBP and toxin coding regions. The locations of key elements of the vector are shown, including the ribosome binding site (RBS). (B)
Primary structure of rAps III. The non-native N-terminal Ser residue is highlighted in grey and the triglycine sequence is underlined. The disulﬁde framework of rAps III as
determined in the current study is shown above the amino acid sequence. (C) SDS-PAGE gels illustrating different steps in the puriﬁcation of rAps III. Lanes are as follows: M,
molecular weight markers; lane 1, E. coli cell extract prior to IPTG induction; lane 2, E. coli cell extract after IPTG induction; lane 3, lysate resulting from cell disruption; lane 4,
soluble periplasmic extract; lane 5, Ni-NTA beads after loading the cell lysate (the His6-MBP-Aps III fusion protein is evident at 49 kDa); lane 6, eluate from washing Ni-NTA
resin with loading buffer; lane 7, eluate from washing Ni-NTA resin with 10 mM imidazole; lane 8, eluate from washing Ni-NTA resin with 500 mM imidazole; lane 9, puriﬁed
fusion protein before TEV cleavage; lane 10, fusion protein sample after TEV protease cleavage, showing complete cleavage of fusion protein to His6-MBP. (D) RP-HPLC
chromatogram showing the ﬁnal step in the puriﬁcation of rAps III. The asterisk denotes the peak corresponding to correctly folded rAps III. Inset is a MALDI-TOF MS spectrum
showing the [M+H]+ ion for the puriﬁed recombinant toxin (obs. = 3846.58 Da; calc. = 3846.49 Da). (E) Dose–response curve for the paralytic effects of rAps III determined
24 h after injection into sheep blowﬂies (L. cuprina).
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The external bath solution for barium current (IBa) recordings
contained (in mM): Na acetate 140, TEA-Br 30, BaCl2 3 and HEPES
10, adjusted to pH 7.4 with 1 M TEA-OH. The external solution also
contained 300 nM tetrodotoxin (TTX) to block NaV channels.
Pipette solutions contained (in mM): Na acetate 10, CsCl 110, TEA-
Br 50, ATP-Na2 2, CaCl2 0.5, EGTA 10 and HEPES 10, adjusted to pH
7.4 with 1 M CsOH. The external bath solution for recording global
voltage-activated potassium (KV) channel currents (IK) contained
(in mM): NaCl 200, K gluconate 50, CaCl2 5, MgCl2 4, TTX 0.3, HEPES
10 and D-glucose 10, adjusted to pH 7.4 with 1 M NaOH. The
pipette solution consisted of (in mM): K gluconate 135, KF 25, NaCl
9, CaCl2 0.1, MgCl2 1, EGTA 1, HEPES 10 and ATP-Na2 3, adjusted to
pH 7.4 with 1 M KOH.
To eliminate any inﬂuence of differences in osmotic pressure,
all internal and external solutions were adjusted to 400  5 mOs-
mOsmol/l with sucrose. Experiments were rejected if there were large
leak currents or currents showed signs of poor space clamping.
2.5.3. Curve-ﬁtting and statistical analyses
Data were analysed using AXOGRAPH X version 1.3 (Molecular
Devices). Curve-ﬁtting of I-V data was performed using GraphPad
Prism version 5.00d for Macintosh (GraphPad Software, San Diego).
Comparisons of two sample means were made using a paired
Student’s t-test and differences were considered to be signiﬁcant if
p < 0.05. All data are presented as mean  standard error of the
mean (SEM) of n independent experiments.
Concentration–response curves were ﬁtted using the following
Logistic equation:
y ¼ 1
1 þ ð½x=IC50ÞnH
(1)
where x is the toxin dose, nH is the Hill coefﬁcient (slope
parameter), and IC50 is the median inhibitory concentration to
block channel currents.
The following equation was employed to ﬁt current-voltage (I-
V) curves:
I ¼ gmax 1 
1
1 þ exp½ðV  V1=2Þ=s
  
ðV  V revÞ (2)
where I is the amplitude of the current at a given test potential V,
gmax is the maximal conductance, V1/2 is the voltage at half-
maximal activation, s is the slope factor, and Vrev is the reversal
potential.
The voltage dependence of steady-state NaV channel inactiva-
tion (h1/V) data were normalised to the maximum peak current in
the control or maximum peak current and ﬁtted using the
following Boltzmann equation:
h1 ¼ A
1 þ exp½ðV  V1=2Þ=k (3)
where A is the fraction of control maximal peak INa (value of 1.0
under control conditions), V1/2 is the midpoint of inactivation, k is
the slope factor, and V is the prepulse voltage.
2.5.4. Two-electrode voltage-clamp recordings from Xenopus oocytes
To prepare cRNA for oocyte injection, separate plasmids
encoding the a-subunit of the NaV1 channel from the German
cockroach Blatella germanica (BgNaV1; [31]) and the Drosophila
NaV1 auxiliary subunit TipE [32] were linearised with NotI,
followed by in vitro transcription using T7 polymerase (mMES-
SAGE mMACHINE kit, Life Technologies, CA, USA). After Xenopus
oocytes were co-injected at 1:5 molar ratio with cRNA encoding
BgNaV1 and TipE, they were incubated for 2–3 days at 17 8C (in
96 mM NaCl, 2 mM KCl, 5 mM HEPES, 1 mM MgCl2, 1.8 mM CaCl2,
50 mg/ml gentamycin, pH 7.6) prior to recording BgNaV1-mediated
currents via two-electrode voltage-clamp recording techniques
using an OC-725C Oocyte Clamp Ampliﬁer (Warner Instruments,
CT, USA) with a 150-ml recording chamber. Data were ﬁltered at
4 kHz and digitised at 50 kHz using pCLAMP 10. Microelectrode
resistances were 0.1–1 MV when ﬁlled with 3 M KCl. The external
recording solution contained (in mM): 96 NaCl, 2 KCl, 5 HEPES, 1
MgCl2 and 1.8 CaCl2, pH 7.6. Experiments were performed at
ambient temperature (22 8C) and leak and background conduc-
tance was subtracted by blocking the residual sodium current
with TTX.
Voltage–activation relationships were obtained by measuring
steady-state currents elicited by stepwise depolarisations of 5 mV
from a holding potential of–90 mV and calculating conductance (G)
using G = I/(Vm  Erev) in which G is conductance, I is peak inward
current, Vm is the test potential, and Erev is the reversal potential.
Reversal potentials were individually estimated for each data set
[33]. After addition of the toxin to the recording chamber (150 ml),
the equilibration between the toxin and the channel was
monitored using weak depolarizations (50-ms test pulse to a
voltage near the foot of the G-V curve, 30 mV) elicited at
intervals of 5 s. We recorded voltage–activation relationships in
the absence and presence of toxin. Off-line data analysis was
performed using Clampﬁt 10 (Molecular Devices, USA) and Origin 8
(OriginLab, MA, USA).
2.6. Structure determination
Recombinant 15N/13C-labelled Aps III was dissolved in 20 mM
sodium phosphate, pH 6.0 to a ﬁnal concentration of 450 mM. 5%
2H2O was added, then the sample was ﬁltered using a low-protein-
binding Ultrafree-MC centrifugal ﬁlter (0.22 mm pore size;
Millipore, MA, USA) and 300 mL was added to a susceptibility
matched 5 mm outer-diameter microtube (Shigemi Inc., Japan).
NMR data were acquired at 25 8C using a 900 MHz NMR
spectrometer (Bruker BioSpin, Germany) equipped with a cryo-
genically cooled probe. 3D and 4D data used for resonance
assignments were acquired using non-uniform sampling (NUS).
Sampling schedules that approximated the signal decay in each
indirect dimension were generated using sched3D [34]. NUS data
were processed using the Rowland NMR toolkit (www.rowlan-
d.org/rnmrtk/toolkit.html) and maximum entropy parameters
were automatically selected as previously described [35]. 13C-
and 15N-edited HSQC-NOESY (mixing time of 200 ms) experiments
were acquired using uniform sampling. All experiments were
acquired in H2O except for the
13C-edited HSQC-NOESY, which was
acquired in D2O.
Dihedral angles (29 f, 30 c) were derived from TALOS+
chemical shift analysis [36] and the restraint range for structure
calculations was set to twice the estimated standard deviation. The
Thr6–Pro7 peptide bond was determined to be in the trans
conformation on the basis of characteristic NOEs and the Ca and Cb
chemical shifts of the Pro residue.
Six backbone amide protons were identiﬁed as being involved
in hydrogen-bonds by comparison of 2D 1H-15N HSQC spectra
acquired either in H2O or 60 min after reconstitution of lyophilised
protein in D2O. The presence of intense NOESY crosspeaks for the
hydroxyl proton of Thr 4 indicated that it is also engaged in a
hydrogen bond. Hydrogen-bond acceptors and disulﬁde-bond
partners were identiﬁed from preliminary structure calculations,
and hydrogen-bond and disulﬁde-bond restraints were applied in
subsequent structure calculations as described previously [37].
NOESY spectra were manually peak picked and integrated, then
peaklists were automatically assigned, distance restraints
extracted, and an ensemble of structures calculated using the
torsion angle dynamics package CYANA 3.0 [38]. The tolerances
used for CYANA 3.0 were 0.025 ppm in the direct 1H dimension,
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0.03 ppm in the indirect 1H dimension, and 0.3 ppm for the
heteronucleus (13C/15N). During the automated NOESY assign-
ment/structure calculation process, CYANA assigned 86% of all
NOESY crosspeaks (1127 out of 1313).
3. Results
3.1. Production of recombinant Aps III
Recombinant production of venom toxins is often challenging
due to the presence of multiple disulﬁde bonds, which cannot be
formed in the cytoplasm of most prokaryotic and eukaryotic cells
because of the reducing intracellular environment. An alternative
approach that has proved successful for expression of disulﬁde-
rich spider toxins [24,39,40] is production in the periplasm of
E. coli, where the enzymes involved in disulﬁde-bond formation are
located [41]. Thus, we attempted to produce rAps III using an IPTG-
inducible construct (Fig. 1A) that allowed export of a His6-MBP-
toxin fusion protein to the E. coli periplasm.
Using this expression system, a signiﬁcant amount of His6-
MBP-toxin fusion protein was recovered in the soluble cell fraction
following IPTG induction (Fig. 1C, lanes 1–4). The fusion protein
was subsequently puriﬁed using nickel afﬁnity chromatography
(Fig. 1C, lanes 5–8) then eluted from the column and cleaved with
His6-tagged TEV protease (Fig. 1C, lanes 9–10). The His6-tagged
MBP and TEV protease were removed by passage over a nickel
column, then the eluted toxin was further puriﬁed using RP-HPLC
(Fig. 1D). rAps III eluted as a single major disulﬁde-bond isomer
with a retention time of 25 min under the chosen experimental
conditions. The purity of recombinant rAps III following RP-HPLC
was >98% as assessed by SDS-PAGE and MALDI-TOF mass
spectrometry (Fig. 1D, inset), and the ﬁnal yield was 1.5 mg of
toxin per litre of culture.
3.2. rAps III induces irreversible paralysis in insects
The insecticidal activity of rAps III was tested using the blowﬂy
Lucilia cuprina. This dipteran pest is the causative agent of ﬂystrike,
which results in annual economic losses in Australia of $280
million [42]. rAps III induced ﬂaccid paralysis in adult L. cuprina,
and the PD50 measured 24 h after injection was 700  35 pmol/g
(Fig. 1E). The toxicity assay used does not allow measurement of toxic
effects for periods extending beyond 24 h as the survival rate in
control cohorts begins to decrease, possibly due to conﬁnement of the
ﬂies in small tubes. However, ﬂies paralysed by a high dose of rAps III
did not recover but died two days post-injection. We conclude that
rAps III produces an irreversible paralysis in blowﬂies and would
most likely produce similar effects in related dipterans such as
mosquitoes and tsetse ﬂies that vector human diseases.
3.3. rAps III is a potent blocker of insect NaV channels
The majority of insecticidal spider toxins that have been
isolated to date modulate the activity of voltage-gated ion
channels [7,11,28,43,44]. We therefore used patch-clamp electro-
physiology to examine the ability of rAps III to modulate the
activity of a variety of ion channels in cockroach DUM neurons.
NaV channel currents (INa) in DUM neurons were elicited using
50-ms depolarising test pulses from a holding potential (Vh) of–
90 mV to 10 mV every 10 s (0.1 Hz) (Fig. 2D). This elicited a
rapidly activating and inactivating ionic current characteristic of
classical INa observed previously in DUM neurons (Fig. 2A,B)
[28,45,46]. This current was conﬁrmed to be mediated by NaV
channels following complete INa inhibition with 300 nM TTX
(Fig. 2B). In separate experiments, perfusion with rAps III produced
a concentration-dependent inhibition of peak INa. This occurred in
the absence of any signiﬁcant changes in the time to peak, time
course of inactivation (decay) kinetics, or time course of tail
currents at the end of the depolarising test pulse, as shown in the
representative current traces in Fig. 2A. At a concentration of
30 nM, rAps III reduced peak INa by 29  6% (n = 5 cells, p < 0.05). In
separate experiments, higher concentrations of 300 nM and 1 mM
rAps III produced a concentration-dependent reduction in peak INa by
43  5% (n = 9 cells, p < 0.001) and 53  5% (n = 5 cells, p < 0.01),
respectively.
The half-maximal inhibitory concentration (IC50) for rAps III on
DUM neuron INa was estimated to be 540 nM (Fig. 2C). However,
the Hill coefﬁcient was signiﬁcantly less than unity (shallower
slope), which may reﬂect incomplete block at higher concentra-
tions, as has been observed with certain m-conotoxin derivatives
[47].
3.4. rAps III is a classical pore blocker
To determine whether toxin inhibition of peak INa was due to a
depolarising shift in the voltage dependence of activation, families
of INa (Fig. 3A,B) were elicited using a test pulse that depolarised
the cell from Vh of 90 mV to +70 mV for 50 ms in 10-mV
increments (Fig. 3F). Peak INa were then normalised against the
maximum peak INa in the control and plotted against membrane
potential (V) to establish an INa-V curve. Peak INa was then ﬁtted to
Equation 2 (Materials and Methods) using non-linear regression
analysis. In the absence of toxin, INa activated around 60 mV. This
threshold did not shift in the presence of any concentration of rAps
III tested as shown by the superimposed control and toxin curves
around 60 mV (Fig. 3C,D). The voltage at half maximum NaV
channel activation (V1/2) in control cells was only marginally
shifted (4 mV) in the hyperpolarising direction in the presence
of 1 mM rAps III (control V1/2 = 35  1 mV versus toxin V1/2 =
31  3 mV; n = 4 cells, p < 0.005). This is more clearly observed
as a lack of any signiﬁcant shift in the voltage dependence of
activation when currents recorded in the presence of toxin were
normalised to the peak inward control current (Fig. 3D). No
signiﬁcant shifts in V1/2 were observed with either 30 nM or
300 nM rAps III. Considering the time-dependent hyperpolarising
shifts in V1/2 of around 5 mV over a 10–15 min period that occur in
whole-cell patch clamp conﬁgurations, this would indicate that the
toxin does not alter the voltage-dependence of activation. Impor-
tantly, only a depolarising shift in the voltage-dependence of NaV
channel activation would reduce INa.
To determine whether toxin-induced block of INa was voltage-
dependent, peak INa in the presence of toxin was calculated as a
fraction of the corresponding control INa from the INa-V relation-
ships. Data were then ﬁtted by linear regression and the slope
coefﬁcient determined. This revealed that the inhibition of NaV
channels by 1 mM rAps III was voltage-independent and the
binding of the toxin to the channel was not relieved at increasing
membrane potentials (Fig. 3E). The slope of the line did not
signiﬁcantly deviate from zero (p > 0.05, n = 4 cells).
In separate experiments, the effects of rAps III on the voltage-
dependence of steady-state inactivation (h1/V) were examined to
determine whether the reduction of peak INa was due to
stabilisation of the inactivated (closed) state of the channel, as
opposed to a pore blocking mechanism. Accordingly, experiments
were conducted using a two-pulse protocol consisting of a 1 s
conditioning pre-pulse (Vprepulse) followed by a 50 ms test pulse
(Vtest) to 10 mV. The conditioning prepulse clamped the
membrane potential from 120 mV to 0 mV in 10-mV increments
(see inset to Fig. 4A,B). Due to increasing levels of depolarisation
during the conditioning prepulse, channels eventually accrue in
the inactivated state and have insufﬁcient time to recover from
inactivation before the test pulse. Thus, INa amplitude decreases
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with increasing prepulse potential (Fig. 4A,C). In the presence of
30 nM rAps III, INa was inhibited to 79  3% (n = 3 cells) of control
amplitude (parameter ‘A’ in Equation 3). Normalisation of the toxin
data to the maximum peak INa during the test pulse revealed that the
curves almost completely overlap (Fig. 4D) with an insigniﬁcant 2-mV
hyperpolarising shift in h1/V from 56  1 mV in controls to
58  1 mV in the presence of rAps III (p > 0.05, n = 3 cells;
Fig. 3D). Thus the 21% reduction in NaV channel current does not
appear to be the result of a reduction in channel availability due to
stabilisation of the channels in the inactivated state. Therefore rAps III
appears to be a classical pore blocker.
3.5. rAps III is a weak blocker of insect CaV channels
We next tested the ability of rAps III to modulate the activity of
insect CaV channels as numerous spider-venom peptides have
been demonstrated to inhibit this channel [48,49]. Two distinct
CaV channel subtypes have been previously observed in DUM
neurons: mid to low-voltage-activated (M-LVA) and high-voltage
activated (HVA) CaV channels [46]. M-LVA and HVA CaV channel
barium currents (IBa) were elicited using alternating 100-ms
depolarising test pulses to 30 mV (M-LVA IBa) and +20 mV (HVA
IBa) from a Vh of 90 mV every 7 s. These elicited inward currents
characteristic of classical IBa observed previously in DUM neurons
[46]. Perfusion with 1 mM rAps III caused weak inhibition of both
M-LVA and HVA CaV channel currents. This occurred in the
absence of changes in M-LVA and HVA IBa activation and
inactivation kinetics, with no alteration in the time to reach peak
or timecourse of current decay (Fig. 5A). The M-LVA CaV channel
currents were reduced by 28  5% (p < 0.01, n = 5 cells) and HVA
CaV channel currents by 31  7% (p < 0.01, n = 6 cells). The small
difference in the block between inhibition of M-LVA and HVA current
was statistically insigniﬁcant (unpaired Student’s t-test, p > 0.05).
Given the weak effects on CaV channel currents at 1 mM rAps III,
experiments were not conducted at 30 nM or 300 nM concentra-
tions. In an additional smaller number of cells there was a partial
recovery from CaV channel current inhibition. In these cells initial
rapid inhibition was followed by partial recovery to a steady-state
level. This resulted in a statistically insigniﬁcant block of both M-LVA
CaV channel currents (18  6% block, p > 0.05, n = 4 cells) and HVA
CaV channel currents (19  12%, p > 0.05, n = 3 cells).
To investigate whether the weak block of CaV channels by rAps
III was due to a shift in the threshold of CaV channel activation, the
IBa-V relationship was examined. The IBa-V relationships were
established from families of IBa generated by 100-ms depolarising
test potentials from Vh of 90 mV to +40 mV, at 5-mV increments
every 7 s. Families of peak inward IBa were normalised against
the maximum control inward peak IBa and plotted against the
membrane potential (Fig. 5Ba). CaV channels activated around
60 mV, and this threshold was not altered in the presence of
Fig. 2. Effects of rAps III on NaV channels in cockroach DUM neurons. (Aa-c) Typical effects of increasing concentrations of rAps III on INa. Traces show superimposed control
(black) and toxin (grey and shaded) current traces elicited by a 50-ms depolarising test pulse (Vtest) shown in panel D. The reduction in INa is highlighted in the inset of panels
Aa-c. (B) Complete block of INa by 300 nM TTX, conﬁrming that ionic currents are solely mediated through NaV channels. Dotted lines represent zero current. (C)
Concentration–response relationship of rAps III to inhibit peak INa. The percentage block at increasing concentrations of rAps III were ﬁtted with a logistic function (Eq. 1; see
Materials and Methods). The median inhibitory concentration (IC50) was determined to be 540 nM. Data points are the mean  SEM of 5–9 cells.
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1 mM rAps III. Additionally, there were no signiﬁcant shifts in the
V1/2 of channel activation (p > 0.05, n = 4 cells) and currents were
essentially superimposable when normalised to the peak IBa
(Fig. 5Bb). The partial block of CaV channels by rAps III was also
voltage-independent (p > 0.05, n = 4 cells, data not shown).
3.6. rAps III does not modulate the activity of insect KV channels
The major outward KV channel current subtypes present
in cockroach DUM neurons include a slowly activating,
non-inactivating delayed-rectiﬁer [IK(DR)], transient ‘‘A-type’’
[IK(A)], and large-conductance Ca
2+-activated [IBK(Ca)] KV channel
currents [28,50]. To determine the effects of 1 mM rAps III on KV
channels, global KV channel currents (IK) were generated by 100-
ms depolarising test pulses to +25 mV from a Vh of 80 mV, every
5 s (0.2 Hz). This generated a large outward IK that displayed fast
activation and partial inactivation, consistent with global IK
previously observed in cockroach DUM neurons [27,28]. Global IK
were measured at the peak and at the end of the test pulse
(100 ms). The early peak global IK results mainly from the
Fig. 3. Effects of rAps III on the voltage-dependence of NaV channel activation in cockroach DUM neurons. Typical families of INa recorded prior to (A), and following (B),
application of 1 mM rAps III. Nav channel currents were elicited by the test pulse protocol shown in panel F. (C-D) Normalised peak INa-V relationships. Currents recorded in
the presence of 1 mM rAps III were normalised to the maximum inward INa in controls (C), or maximum inward INa (D). Data shows INa before (closed symbols), and after (open
symbols and shaded), application of 1 mM rAps III. Data were ﬁtted with Eq. (2) (see Materials and Methods). As can be seen in panel (D), no signiﬁcant shifts in the voltage
dependence of NaV channel activation were observed. (E) Fractional block of INa by 1 mM rAps III showing lack of voltage dependence. Normalised peak INa in the presence of
toxin were calculated as a fraction of peak control INa and plotted against the test potential. Data were taken from panel C and ﬁtted using linear regression. All data are
expressed as the mean  SEM of 4 cells.
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contribution of rapidly activating IK(A) and IK(Ca), while the late
global IK results from the slowly activating IK(DR) and slow
inactivating component of the IK(Ca).
Application of 1 mM rAps III caused minimal inhibition of global
IK. rAps III reduced the peak global IK by only 2  2% (p > 0.05, n = 4
cells; Fig. 5C) while late global IK were inhibited only slightly by
5  2% (p < 0.05, n = 4 cells; Fig. 5C). This lack of overt activity was
mirrored by the lack of effect on the voltage-dependence of global IK
activation. Global IK-V relationships for early and late currents were
not signiﬁcantly altered with no marked differences in V1/2 values
between the IK-V for controls (V1/2 = 3 mV for early and 4 mV for late
IK) versus toxin (V1/2 = 4 mV for early and 9 mV for late IK)
(Fig. 5D). Due to the lack of any overt activity of 1 mM rAps III on
global KV channel currents, the effect of rAps III on individual KV
channel sub-types was not pursued. We conclude that rAps III does
not modulate the activity of delayed-rectiﬁer, ‘A-type’ or BKCa
potassium channels that are the major contributors to the global
outward Kv channel current in DUM neurons [51].
3.7. rAps III is a potent blocker of cloned cockroach NaV channels
To further investigate the ability of rAps III to inhibit insect NaV
channels, we applied the toxin to Xenopus oocytes expressing the
cloned BgNaV1 channel [31]. At 1 mM concentration, rAps III
strongly inhibited BgNaV1-mediated sodium currents over a wide
voltage range (Fig. 6A,B). Boltzmann ﬁts of conductance-voltage
relationships before (V1/2 = 27  1 mV; slope factor = 4.1  0.2)
and after (V1/2 = –27  1 mV; slope factor = 4.6  0.3; n = 3 cells)
toxin addition as well as the steady-state inactivation relationships
(control: V1/2 = 53  1 mV; slope factor = 4.3  0.1 and toxin: V1/
2 = 55  1 mV; slope factor = 4.3  0.2; n = 3 cells) revealed no
signiﬁcant changes in the midpoints or slope factors (Fig. 6C). The
onset of rAps III action is rapid, and there is a fast and complete
recovery of channel current upon toxin washout (Fig. 6D). In contrast
to gating-modiﬁer toxins that inhibit channel opening by interacting
with one or more of the four NaV channel voltage sensors [52], rAps III
decreased INa without shifting the midpoint of activation to more
depolarised voltages (Fig. 6B). Together with the experiments
reported above on DUM neurons (Fig. 3), this is consistent with a
pore-blocking activity.
3.8. High-resolution solution structure of rAps III
The development of an efﬁcient bacterial expression
system allowed us to produce uniformly 13C/15N-labelled
rAps III for structure determination using heteronuclear NMR.
Fig. 4. Effects of rAps III on steady-state NaV channel inactivation (h1). Steady-state inactivation was determined using a two-pulse protocol (see inset). (A and B) Typical peak
INa recorded during the test pulse (Vtest) are shown following 1-s prepulse potentials (Vprepulse) to 120 mV, 60 mV and 40 mV recorded before (left-hand traces), and
following (right-hand shaded traces), perfusion with 30 nM rAps III. Dotted lines represent zero current. (C and D) Peak INa, recorded during Vtest, were expressed as a fraction
of maximum control INa (C), or normalised to peak INa amplitude (D), and plotted against prepulse potential. Panels show the proportion of INa that is available for activation
under control conditions (closed circles), and during perfusion with 30 nM rAps III (open circles and shaded). The h1/V curves were ﬁtted with Eq. 3 (see Materials and
Methods). All data are expressed as the mean  SEM of 3 cells.
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Fig. 5. Effect of rAps III on KV and CaV channel currents in cockroach DUM neurons. (A) Whole-cell M-LVA and HVA IBa in the absence (black traces), and presence (dark grey
and shaded traces), of 1 mM rAps III. M-LVA and HVA IBa were activated by a 100 ms Vtest to 30 mV and +20 mV, respectively, as shown in the inset in panel C. Perfusion with
1 mM rAps III partially blocked M-LVA (Aa) and HVA (Ab) CaV channel currents. Dotted lines represent zero current. (B) Effects of 1 mM rAps III on the voltage-dependence of
CaV channel activation. Families of CaV channel currents were generated by the Vtest protocol shown in the inset of panel C. Currents recorded in the presence of 1 mM rAps III
were normalised to the maximum inward IBa in control (Ba) or maximum inward IBa in toxin (Bb). IBa-V relationships show current recorded before (closed circles), and after
(open circles and shaded), perfusion with 1 mM rAps III. Normalised I-V relationships were ﬁtted using Eq. 2. (C) Typical superimposed global IK recorded prior to (black
traces), and following (dark grey and shaded traces), application of 1 mM rAps III. Currents were generated by 100-ms depolarising test pulses (Vtest) as shown in the as shown
in the inset in panel C. (D) Effects of rAps III on the voltage-dependence of global KV channel activation. Families of outward IK were recorded before (closed circles), and after
(open circles and shaded), application of 1 mM rAps III. Families of IK were generated by the Vtest protocol shown in the inset of panel C. Global IK-V relationships show effects
of the toxin on peak (Da) and late (Db) global IK. Late currents were measured at 100 ms. All data are expressed as the mean  SEM of 4 cells.
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1HN,
15N, 13Ca,
13Cb, and
13C0 resonance assignments for the toxin
were obtained from analysis of amide-proton strips in 3D
HNCACB, CBCA(CO)NH, and HNCO spectra. Sidechain 1H and 13C
chemical shifts were obtained using a 4D HCC(CO)NH-TOCSY
experiment, which has the advantage of providing sidechain
1H–13C connectivities [34]. Complete chemical shift assignments
have been deposited in BioMagResBank (Accession Number
18946).
CYANA was used for automated NOESY assignment and
structure calculation [38]. The disulﬁde-bond pattern (1–4, 2–5,
3–8, 6–7; see Fig. 1B) was unambiguously determined from
preliminary structures calculated without disulﬁde-bond
restraints [53]; this disulﬁde framework is notably different from
the 1–4, 2–5, 3–6, 7–8 framework predicted in the UniProt entry
for rAps III (P49268). Disulﬁde-bond and hydrogen-bond restraints
were used in the ﬁnal round of structure calculations. 200
structures were calculated from random starting conformations,
then the 20 conformers with highest stereochemical quality as
judged by MolProbity [54] were selected to represent the solution
structure of rAps III. Coordinates for the ﬁnal ensemble of
structures are available from the Protein Data Bank (Accession
Number 2M36).
Statistics highlighting the high precision and stereochemical
quality of the ensemble of rAps III structures are shown in Table 1.
The average MolProbity score of 1.67 places the ensemble in the
90th percentile relative to all other structures ranked by
MolProbity. The high stereochemical quality of the ensemble
stems from a complete absence of bad close contacts, very few
unfavourable sidechain rotamers (5%), and reasonably high
Ramachandran plot quality (85% of residues in the most favoured
region). The structural ensemble is also highly precise with
backbone and heavy-atom RMSD values over all residues of
0.32  0.09 A˚ and 0.54  0.07 A˚, respectively. The ensemble of rAps
III structures ranks as ‘‘high resolution’’ based on these measures of
precision and stereochemical quality [55].
Fig. 7A shows a backbone overlay of the ensemble of 20 rAps III
structures, while a schematic of the top-ranked structure
highlighting key secondary structure elements is shown in
Fig. 7B. Three of the four disulﬁde bonds in rAps III form a
classical ICK motif in which the Cys2–16 and Cys9–20 disulﬁde
bonds and the intervening sections of polypeptide backbone form a
13-residue ring that is pierced by the Cys15–Cys36 disulﬁde bond
(Fig. 7A). This region forms a highly structured, disulﬁde-rich core
from which emerges an unusual b-hairpin with a very large
hairpin loop (Fig. 7B). The two b-strands of the hairpin are formed
by residues 19–21 (b2) and 34–37 (b3), while the loop comprises
residues 22–33. Residues 7–9 form a third b-strand (b1) and
residues 11–14 form a single turn of 310-helix (a1) (Fig. 7B). A
summary of the secondary structure of rAps III as judged by
PDBsum [56] is shown in Fig. 7C.
While the compact ICK region of the rAps III structure is similar
to previously determined structures of knottin peptides [57], the
protruding b-hairpin loop, which often houses the pharmacophore
in this class of spider toxins [15], is highly unusual. First, this
hairpin is unusually large, comprising 13 residues (Fig. 7A,B). In
comparison, the average size of the b-hairpin loop in the 35 spider-
venom ICK toxins listed in ArachnoServer [17,18] is 4.8  1.8
residues. Second, the hairpin loop contains a glycine triplet (Gly29–
Gly30–Gly31; underlined in Fig. 1B) that is rare in this class of toxins.
Third, the glycine-rich portion of the loop is poorly deﬁned in the
ensemble of rAps II structures (Fig. 7A). Gly30 and to a lesser extent
Gly32 consistently fall into unfavourable regions of the Ramachan-
dran plot, suggesting that this region is highly dynamic in solution.
Nevertheless, the dynamics of the triglycine loop is likely to be limited
by the Cys27–Cys32 disulﬁde bond (Fig. 7A,B) which forms a
molecular staple that serves to isolate this loop from the remainder
of the b-hairpin, which in contrast is well structured.
It should be noted that the disulﬁde framework has not been
experimentally established for native Aps III. However, the fact
that rAps III is insecticidal and that it contains an ICK motif that is
the deﬁning structural characteristic of this class of toxins suggests
that the recombinant peptide has the same disulﬁde framework
and 3D fold as the native peptide.
Fig. 6. rAps III inhibits BgNaV1-mediated sodium currents. (A) Inhibition of BgNaV1-
mediated sodium currents by 1 mM rAps III at a depolarization to 20 mV from a
holding voltage of 90 mV. (B) Representative INa-V relationship for BgNaV1 before
(black) and after (grey) addition of 1 mM rAps III. Currents were elicited by 5-mV
step depolarizations from a holding voltage of 90 mV. (C) Comparison of the
gating properties of BgNaV1 before (black) and after (grey) addition of 1 mM rAps III.
Shown are the deduced conductance (G)–voltage (ﬁlled circles) and steady-state
inactivation (open circles) relationships. Error bars denote SEM, with n = 3 cells. (D)
Onset of BgNaV1-mediated INa inhibition by 1 mM rAps III at depolarizations to
20 mV (holding voltage was 90 mV) followed by a complete recovery after toxin
washout.
Table 1
Structural statistics for the ensemble of rAps III structures.
Experimental restraints2
Interproton distance restraints
Intraresidue 111
Sequential 159
Medium range (i–j < 5) 93
Long range (i–j  5) 165
Hydrogen-bond restraints3 14
Disulﬁde-bond restraints 12
Dihedral-angle restraints (f, c) 59
Total number of restraints per residue 16.1
R.m.s. deviation from mean
coordinate structure (A˚)
All backbone atoms (residues 1–38) 0.33  0.08
All heavy atoms (residues 1–38) 0.54  0.07
Backbone atoms (residues 2–27, 32–38) 0.13  0.03
Heavy atoms (residues 2–27, 32–38) 0.43  0.06
Stereochemical quality4
Residues in most favoured
Ramachandran region (%)
84.5  2.8
Ramachandran outliers (%) 2.4  1.4
Unfavourable sidechain rotamers (%) 5.0  2.1
Clashscore, all atoms5 0.0  0.0
Overall MolProbity score 1.67  0.15
1All statistics are given as mean  S.D.
2Only structurally relevant restraints, as deﬁned by CYANA, are included.
3Two restraints were used per hydrogen bond.
4According to MolProbity (http://molprobity.biochem.duke.edu).
5Deﬁned as the number of steric overlaps >0.4 A˚ per thousand atoms.
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4. Discussion
4.1. rAps III potently inhibits insect NaV channels
In the present study, the effect of recombinantly produced Aps
III was examined on three families of insect voltage-activated ion
channels: NaV, CaV and KV channels. The main effect of rAps III was
to produce a concentration-dependent inhibition of insect NaV
channels with an estimated IC50 of 540 nM. The pharmacological
properties of rAps III resemble those of ‘pore blocking’ toxins that
target NaV channels such as the guanidinium compounds TTX and
saxitoxin as well as m-conotoxins from marine cone snail venoms
that reduce peak INa [58].
rAps III displays similar activity to m-TRTX-Hhn2b (hainan-
toxin-I) and m-TRTX-Hh1a (huwentoxin-III), depressant neuro-
toxins from the venom of the Chinese tarantulas Haplopelma
hainanum and H. huwenum, respectively. These toxins have been
postulated to block insect NaV channels via binding to neurotoxin
receptor site-1 near the mouth of the channel [59,60]. Both toxins
block insect NaV channels more potently than vertebrate NaV
channels. For example, m-TRTX-Hhn2b blocks Drosophila melano-
gaster NaV channels expressed in Xenopus oocytes with an IC50 of
4.5 mM compared with a 15-fold higher IC50 of 68  6 mM for block
of rat NaV1.2 channels [59]. m-TRTX-Hh1a did not block any of the
vertebrate NaV channel subtypes expressed in rat dorsal root ganglion
neurons but it inhibited insect NaV channel currents in cockroach
DUM neurons with an IC50 of 1.1 mM [60]. Thus, although both m-
TRTX-Hhn2b and m-TRTX-Hh1a selectively block insect NaV channels,
rAps III targets the insect channel with higher afﬁnity, consistent with
its high level of lethality (LD50 = 133 pmol/g) in larvae of the tobacco
hornworm M. sexta [16].
One mechanism that can lead to inhibition of INa is an increase
in the number of NaV channels stabilised in the inactivated state.
m-TMTX-Hme1a (Hm-1) from the venom of the spider Heriaeus
melloteei inhibits mammalian NaV channels expressed in Xenopus
oocytes without an alteration in the activation or inactivation
kinetics of the channel [61]. The reduction in peak INa produced by
m-TMTX-Hme1a results from a shift in steady-state NaV channel
inactivation in the hyperpolarising direction [61]. Thus, the
number of closed channels available for opening is reduced,
resulting in ﬂaccid paralysis. Unlike m-TMTX-Hme1a, neither
rAps III nor m-TRTX-Hh1a produce a signiﬁcant shift in the
voltage-dependence of steady-state NaV channel inactivation.
Thus rAps III does not share a common mode of action with
m-TMTX-Hme1a, despite its ability to inhibit INa.
Interestingly, rAps III displays weak sequence homology with a
range of spider d-toxins (41% homology). All d-toxins are gating
modiﬁers that delay NaV channel inactivation via an interaction
with the voltage sensor of channel domain IV [62–67]. As a result,
cells generate spontaneous and repetitive action potentials at, or
near, the resting membrane potential to induce contractile
paralysis [65]. A similar effect has been noted with spider b-
toxins that shift the voltage-dependence of activation in the
hyperpolarising direction primarily via an interaction with the
voltage sensor of channel domain II [52,68,69]. However, the lack
of any signiﬁcant shifts in the voltage-dependence of NaV channel
activation or slowing of NaV channel inactivation kinetics indicates
that the effect of rAps III on NaV channels is not due a modiﬁcation
of channel gating. Other toxins, such as the depressant toxin b-
TRTX-Cm1a (ceratotoxin-1) from the straight-horned tarantula
Ceratogyrus marshalli, can inhibit INa by shifting the voltage
dependence of activation in the depolarising direction to produce a
depressant phenotype [70]. In contrast, rAps III inhibits insect NaV
channel conductance in the absence of any depolarising shift in the
voltage-dependence of activation. In summary, rAps III does not
cause a hyperpolarising shift (as seen for excitatory spider b-
toxins) or a depolarising shift (as observed for depressant spider b-
toxins) in the voltage-dependence of NaV channel activation, nor
does it slow the kinetics of NaV channel inactivation as observed for
spider d-toxins.
Based on the pharmacology described here, Aps III should be
renamed m-cyrtautoxin-As1a (m-CUTX-As1a) based on the
rational nomenclature recently proposed for spider-venom
peptides [71]. This is consistent with its action to induce ﬂaccid
paralysis in M. sexta by inhibiting neuronal excitability [16], in
contrast with the spastic paralysis observed with d-toxins and
excitatory b-toxins.
4.2. Promiscuous activity of rAps III on insect NaV and CaV channels
While rAps III inhibits insect NaV channels with higher potency
than other insect-selective spider neurotoxins such as m-TRTX-
Hhn2b and m-TRTX-Hh1a, the IC50 value (540 nM) is still relatively
high compared to spider toxins that inhibit vertebrate NaV
Fig. 7. Three-dimensional structure of rAps III. (A) Stereoview of an overlay of the ensemble of 20 rAps III structures. Disulﬁde bonds are highlighted in red and the N- and C-
termini are labelled. The structures are overlaid over the backbone atoms of residues 2–27 and 32–38 in order to highlight the disordered nature of the triglycine loop
(residues 27–32) relative to the well-structured ICK region of the toxin. (B) Ribbon representation of the rAps III structure highlighting the various secondary structure
elements and disulﬁde bonds. The views in panels (B) and (C) are related by a 1808 rotation around the long axis of the molecule. (C) Topology map of the secondary structure
of rAps III. The N- and C-termini are labelled.
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channels [45]. This suggests that rAps III may also target other
voltage-activated channels. Spider toxins can interact with more
than one target often across voltage-activated ion channel families
and/or across channel subtypes to elicit multiple functions. This
non-selective activity is due to the common structural elements
shared between voltage-activated ion channels that are recognised
by these toxins [72]. NaV and CaV channels, in particular, are closely
related and contain shared structural motifs and functional
domains. Thus it is not surprising to ﬁnd toxins with promiscuous
activity across these channel families [49,67]. Promiscuous activity
of spider toxins with high afﬁnity for both NaV and KV, or NaV and
CaV, channels is not without precedence and has been previously
demonstrated by vertebrate active spider toxins including the
NaV/KV channel toxins m/v-TRTX-Hh1a [73] and b/k-TRTX-Cj1a
[74] and the NaV/CaV channel toxin b/v-TRTX-Tp2a (ProTx-II) [75].
Moreover, spider toxins targeting CaV channels with additional low
afﬁnity for NaV channels have also been described including v-
TRTX-Hg1a (SNX482) [76], v-agatoxin-Aa4a (v-Aga-IVA) [77] and
v-hexa toxin-Ar1a [46].
In addition to its effect on NaV channels, 1 mM rAps III produced
a modest 30% block of M-LVA and HVA CaV channel currents
without any change in the voltage-dependence of CaV channel
activation or inactivation kinetics. Most spider v-toxins block
M-LVA and HVA CaV channels in DUM neurons with IC50 values in
the range 270–1000 nM (Table 2). Thus, CaV channels are unlikely
to be the primary target of rAps III, but this pharmacology might
contribute to the depressant phenotype by blocking Ca2+ entry into
nerve terminals and thus inhibiting excitatory neurotransmitter
release.
4.3. Advantages of complementary pharmacologies
rAps III produces marked inhibition of NaV channels to inhibit
action potential generation and propagation as well as partial block
of CaV channels to inhibit neurotransmitter release. Both of these
pharmacological sensitivities would cause inhibition of neuro-
transmission, consistent with the ﬂaccid paralysis induced by rAps
III in insect toxicity assays. While the inhibition of CaV channels by
rAps III is not as potent as other spider v-toxins with highly
selective actions on a single target, the combined inhibition of both
NaV and both CaV channel subtypes by rAps III is likely responsible
for its potent insecticidal activity. It should be noted that insects
have a much smaller repertoire of CaV channels than vertebrates,
with only a single ortholog of the vertebrate CaV1, CaV2 and CaV3
subtypes [48]. Thus, even moderate inhibition of CaV channels can
be lethal to insects [48].
4.4. The unusual structure of rAps III might contribute to its novel
pharmacology
In addition to its novel mode of action, the 3D structure of rAps
III diverges signiﬁcantly from typical spider-venom ICK toxins in
that it contains an unusually large b-hairpin loop. The upper
portion of this loop is stapled together by an additional disulﬁde
bridge that serves to limit the solution dynamics of the unusual
triglycine region of the loop. Although additional studies will be
required to determine the precise mechanism of action and
binding site of rAps III on insect NaV channels, the current data
suggests that it might bind in the outer vestibule of the channel
rather than interact with one of the voltage-sensor domains. The
large b-hairpin loop increases the footprint of this region of the
toxin compared with other ICK-containing spider-venom toxins,
and computer modelling (E. Deplazes and G.F. King, unpublished)
indicates that the b-hairpin loop is an ideal size to ﬁt into the turret
region of the recently determined crystal structures of bacterial
NaV channels [78]. Thus, in addition to being a useful bioinsecticide
lead, rAps III might prove to be a valuable pharmacological tool for
the study of invertebrate NaV channels.
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Spider venoms contain a plethora of insecticidal peptides that act on neuro-
nal ion channels and receptors. Because of their high specificity, potency and
stability, these peptides have attracted much attention as potential environ-
mentally friendly insecticides. Although many insecticidal spider venom
peptides have been isolated, the molecular target, mode of action and struc-
ture of only a small minority have been explored. Sf1a, a 46-residue peptide
isolated from the venom of the tube-web spider Segesteria florentina, is insec-
ticidal to a wide range of insects, but nontoxic to vertebrates. In order to
investigate its structure and mode of action, we developed an efficient bacte-
rial expression system for the production of Sf1a. We determined a high-reso-
lution solution structure of Sf1a using multidimensional 3D/4D NMR
spectroscopy. This revealed that Sf1a is a knottin peptide with an unusually
large b-hairpin loop that accounts for a third of the peptide length. This loop
is delimited by a fourth disulfide bond that is not commonly found in knottin
peptides. We showed, through mutagenesis, that this large loop is function-
ally critical for insecticidal activity. Sf1a was further shown to be a selective
inhibitor of insect voltage-gated sodium channels, consistent with its ‘depres-
sant’ paralytic phenotype in insects. However, in contrast to the majority of
spider-derived sodium channel toxins that function as gating modifiers via
interaction with one or more of the voltage-sensor domains, Sf1a appears to
act as a pore blocker.
Introduction
Despite intensive control measures, herbivorous insects
reduce world crop yields by 10–14% and damage as
much as 30% of stored grain [1,2]. Insects also vector
a wide range of human diseases including malaria,
dengue and Chagas disease [3]. Half of the world’s
population is at risk of contracting insect-borne
diseases [4], with malaria alone causing ~ 3000 deaths
per day [5].
Abbreviations
CaV, voltage-gated calcium channel; DUM, dorsal unpaired median neurons; HVA, high-voltage-activated channel current; ICK, inhibitor
cystine knot motif; KV, voltage-gated potassium channel; MBP, maltose binding protein; M–LVA, mid/low-voltage-activated channel current;
NaV, voltage-gated sodium channel; NIS, normal insect saline; Sf1a, U2-segestritoxin-Sf1a; TEV, tobacco etch virus.
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Chemical insecticides are the primary method of
controlling insect pests [6]. Although there appears to
be a vast array of extant chemical insecticides, there
are, in fact, only a few major classes that act on a very
small number of molecular targets in the insect ner-
vous system [4,7,8]. These conditions have promoted
the evolution of insecticide resistance, with > 1000
arthropod species now resistant to one or more classes
of chemical insecticide [9]. The evolution of insecticide
resistance has led to the withdrawal of chemical insec-
ticides that are no longer considered effective, and
concerns about the adverse impact of certain classes of
chemical insecticides on the environment and human
health have also led to widespread deregistrations and
use cancellations by regulatory authorities [8]. These
developments, along with more stringent requirements
for the registration of new insecticides, have signifi-
cantly reduced the number of available insecticides [8].
For example, over the period 2005–2009 the U.S.
Environmental Protection Agency (EPA) deregistered
or limited the use of 169 insecticides; over the same
period only nine new insecticides were registered [4].
Thus, we are being forced to combat an increasing
insect-pest problem with a rapidly diminishing chemi-
cal arsenal, resulting in an urgent need to discover new
and safe insecticidal compounds.
The success of transgenic plants expressing insecti-
cidal Cry toxins from the bacterium Bacillus thuringi-
ensis has created a renewed interest in protein- and
peptide-based insecticides [10]. Along with predatory
beetles, spiders are the most successful insect predators
on the planet and their venoms are replete with insecti-
cidal peptide toxins [8,11]. Remarkably, the venom of
a single spider can contain as many as 1000 unique pep-
tides [12,13]. Although the EPA recently approved a spi-
der-venom peptide for use as an insecticide (http://
www.vestaron.com/epa-approval), very few insecticidal
spider toxins have been sufficiently characterized to war-
rant consideration as bioinsecticides [8]. One promising
candidate is SFI1 (U2-segestritoxin-Sf1a, hereafter
Sf1a), a 46-residue peptide isolated from the venom of
the tube-web spider Segestria florentina [14]. When
injected into tobacco budworms (larvae of the noctuid
moth Heliothis virescens), Sf1a induced flaccid paralysis
within 15 min and killed larvae within 24 h, with an
LD50 of 10 lgg1 (~ 2 nmolg1) [14]. Moreover, Sf1a
did not induce toxic effects in mice when injected intra-
venously at a dose of 1.5 mgkg1 (~ 300 pmolg1).
Because spiders inject venom into prey via hypoder-
mic-needle-like fangs, there is no evolutionary selection
pressure for spider toxins to be orally active. Although
some insecticidal spider-venom peptides are orally
active [15,16] this is not the case for Sf1a [17]. How-
ever, the oral activity of Sf1a can be markedly
improved by fusion to the plant lectin Galanthus niva-
lis agglutinin, which ferries attached peptide toxins
across the gut epithelium via transcytosis and effec-
tively delivers them to the hemocoel, Malpighian
tubules, fat bodies, ovarioles and central nervous sys-
tem [18–20]. Using this approach, Sf1a was found to
be highly insecticidal when fed to a range of insects,
including the tomato moth Lacanobia oleracea [17],
the peach–potato aphid Myzus persicae [21] and the
rice brown planthopper Nilaparvata lugens [21].
The structure and mode of action of Sf1a remain
unknown. Here, we describe the development of an effi-
cient Escherichia coli expression system for the produc-
tion of Sf1a for structural and functional studies. We
show that recombinant Sf1a is insecticidal to sheep
blowflies (Lucilia cuprina) and we demonstrate that it
acts by inhibiting insect voltage-gated sodium (NaV)
channels and not voltage-gated calcium (CaV) channels,
as initially suggested based on sequence homology.
Moreover, we demonstrate that Sf1a inhibits insect NaV
channels by blocking the pore of the channel and not by
the more typical allosteric voltage-dependent mecha-
nism reported for other spider toxins that act as gating-
modifiers [14]. The 3D solution structure of Sf1a that we
determined using multidimensional heteronuclear NMR
spectroscopy revealed that it contains an inhibitor
cystine knot (ICK) motif that is commonly observed in
spider-venom peptides [8,22,23]. However, Sf1a con-
tains an unusually large and disordered b-hairpin loop
that is stabilized by an atypical fourth disulfide bond
that anchors the ends of the loop. We show that this
large b-hairpin loop contains a conserved sequence
motif that is critical for the toxin’s insecticidal activity.
Results
Production of recombinant Sf1a
Recombinant production of venom peptide toxins is
often challenging because of the presence of multiple
disulfide bonds, which cannot be formed in the cyto-
plasm of most prokaryotic and eukaryotic cells because
of the reducing intracellular environment. An approach
that has proved successful for expression of disulfide-
rich spider toxins is production in the periplasm of
E. coli, where the enzymes involved in disulfide-bond
formation are located [24]. Thus, to produce Sf1a, we
employed an IPTG-inducible construct (Fig. 1A) that
allowed export of a His6–maltose binding protein
(MBP)–toxin fusion protein to the E. coli periplasm.
Using this expression system, a significant amount
of His6–MBP–toxin fusion protein (> 5 mgL1) was
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recovered in the soluble cell fraction following IPTG
induction. The native toxin was recovered after cleavage
of the His6–MBP–Sf1a fusion protein using tobacco
etch virus (TEV) protease. The initial construct, how-
ever, yielded a very small amount of cleaved product
because of the native N-terminal Lys residue, which is
not one of the preferred residues for the P10 position of
TEV protease [25]. To improve the yield of cleaved
protein, a non-native Ser residue, one of the two most
preferred P10 residues for TEV protease, was added to
the N terminus of Sf1a (Fig. 1B). This recombinant
Sf1a (referred to hereafter as rSf1a) was found to be
equipotent with the initial construct that has the native
sequence, and adopted the same tertiary fold as assessed
by 1D 1H NMR. Thus, this construct was used in all
subsequent experiments. However, the amino acid resi-
due numbering used throughout this article is for the
native sequence.
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Fig. 1. Production and functional analysis of rSf1a. (A) Schematic representation of the pLicC–NSB2 vector used for periplasmic expression
of rSf1a. The coding region includes a MalE signal sequence (MalESS) for periplasmic export, a His6 affinity tag, an MBP fusion tag and a
codon-optimized gene encoding rSf1a, with a TEV protease recognition site inserted between the MBP and toxin-coding regions. The
locations of key elements of the vector are shown, including the ribosome-binding site (RBS), T7 promoter and lac operator. (B) Primary
structure of rSf1a. The non-native N-terminal Ser residue is highlighted in grey. Disulfide bridge connectivities are indicated above the
sequence. (C) SDS/PAGE gels illustrating different steps in the purification of rSf1a. Lanes are as follows: M, molecular mass markers;
lane 1, E. coli cell extract prior to IPTG induction; lane 2, E. coli cell extract after IPTG induction; lane 3, soluble periplasmic extract (the
His6–MBP–rSf1a fusion protein is evident at ~ 50 kDa); lane 4, Ni-NTA beads after loading the cell lysate; lane 5, eluate resulting from the
passage of cell lysate through Ni-NTA resin; lane 6, eluate from washing Ni-NTA resin with 10 mM imidazole; lane 7, eluate from washing
Ni-NTA resin with 500 mM imidazole; lane 8, sample after TEV protease cleavage, showing complete cleavage of the MBP–Sf1a fusion
protein. (D) RP-HPLC chromatogram showing the final step in the purification of rSf1a. The arrow denotes the peak corresponding to
correctly folded recombinant rSf1a. Inset is a MALDI-TOF MS spectrum showing the [M+H]+ ion for the purified recombinant toxin
(obs. = 5058.25 Da; calc. = 5056.98 Da). (E) Paralytic effects of two versions of recombinant Sf1a following injection in sheep blowflies
(L. cuprina). nat-Sf1a corresponds to the native sequence, whereas Ser-Sf1a is recombinant toxin with an additional non-native N-terminal
serine residue. Paralysis was determined 24 h after injection.
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The His6–MBP–rSf1a fusion protein was purified
using nickel affinity chromatography (Fig. 1C, lanes
1–4). There was minimal loss of fusion protein in the
flow through from the Ni-NTA beads (Fig. 1C, lanes
5,6). The bound fusion protein was eluted from the
column and cleaved with His6-tagged TEV protease
(Fig. 1C, lanes 7,8). The His6-tagged MBP and TEV
protease were then removed by passage through a SPE
column, and rSf1a subsequently purified using RP-
HPLC. rSf1a eluted as a single major disulfide-bond
isomer with a retention time of ~ 22 min under the
chosen experimental conditions (Fig. 1E). The purity
of rSf1a was assessed to be > 98% as judged by SDS/
PAGE and MALDI-TOF MS (Fig. 1D, inset). The
final yield of rSf1a was ~ 2 mg toxinL culture1.
rSf1a is lethal to insects
Depending on the dose, rSf1a induced uncoordinated
movements within 5–10 min following injection into
sheep blowflies (L. cuprina) and full paralysis within
15–60 min. Flies remained paralyzed until 24 h when
final paralysis statistics were recorded. Despite being
almost completely paralyzed and unable to make
whole-body movements, flies still showed minor move-
ments of the proboscis or extremities, even when
injected with the highest doses of Sf1a. Lethality at
24 h remained < 20%. The median paralytic dose
(PD50) values for native Sf1a and rSf1a were deter-
mined to be 2.2  0.2 and 1.5  0.3 nmolg1, respec-
tively (Fig. 1D), which were not significantly different
(unpaired t-test, n = 3, P > 0.05).
rSf1a is a NaV channel pore blocker
We first investigated whether rSf1a modulated the activ-
ity of insect NaV channels. Whole-cell sodium currents
(INa) were recorded from dorsal unpaired median
(DUM) neurons isolated from the American cockroach
Periplaneta americana. The voltage-clamp configuration
was used and depolarizing test pulses to 10 mV from a
holding potential (Vh) of 90 mV (Fig. 2Ba) were
employed to elicit fast activating and inactivating
inward INa. During a 5-min perfusion, 1 lM rSf1a
caused rapid inhibition of peak INa amplitude
(55.7  6.2% block of control peak INa, P < 0.05,
A Ba
C D
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Fig. 2. Inhibition of cockroach DUM
neuron NaV channels by rSf1a. (A, C)
Representative superimposed INa traces
before (black) and following (grey and
shaded), application of 1 lM (A) and 10 lM
(C) rSf1a. Dotted lines represent zero
current. (Ba) pulse protocol used to
generate INa shown in (A). (D) Incomplete
inhibition of INa by increasing
concentrations of rSf1a (grey bars) and
1 lM rSf1a–R31A–W33A (open bar). (E)
Typical time course of INa inhibition by
1 lM rSf1a. Data were fitted with Eqn (3).
(F) Effects of depolarizing post-pulses on
dissociation of rSf1a were assessed using
10-ms post-pulses to +140 mV applied
immediately following a test pulse to
10 mV from 90 mV as detailed in (Bb).
INa were normalized to peak control INa
before (●) and after (○), application of 1 lM
rSf1a.
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n = 4; Fig. 2A,E) that was only partially reversible
(~ 25% recovery) after prolonged washout in toxin-free
solution. Interestingly, even a very high rSf1a concen-
tration (10 lM) failed to completely block INa
(60.0  5.0% block of control peak INa, P < 0.05,
n = 3; Fig. 2C), whereas 300 nM rSf1a failed to produce
significant inhibition (7.0  0.6% block of control peak
INa, P > 0.05, n = 11; Fig. 2D). At both 1 and 10 lM,
rSf1a failed to alter the kinetics of NaV channel activa-
tion or inactivation (Fig. 2A,C). To test whether a series
of depolarizing pulses could cause dissociation of the
toxin, post-pulses to +140 mV were applied immediately
following a test pulse to 10 mV from a Vh of 90 mV
(Fig. 2Bb). However, the depolarizing post-pulses failed
to cause any significant relief from the fractional block
of INa by 1 lM rSf1a compared with currents recorded
in the absence of rSf1a (P > 0.05, n = 5; Fig. 2F).
To investigate whether rSf1a-induced inhibition of
peak INa was because of a depolarizing shift in the
voltage dependence of NaV channel activation, peak
INa amplitude was tested as a function of membrane
potential (INa–V). Families of INa were elicited using a
test pulse (Vtest) that depolarized the cell from a Vh of
90 mV to +70 mV for 50 ms in 10-mV increments
(Fig. 3A) before (Fig. 3C) and after (Fig. 3D) applica-
tion of 1 lM rSf1a. Peak INa values were then normal-
ized against the maximum peak INa in the control and
plotted against membrane potential (Vm) to establish an
INa–V curve. Peak INa were then fitted to Eqn (1) using
nonlinear regression analysis (Fig. 3E). In the absence
of toxin, INa activated at around 50 mV, which did
not shift in the presence of rSf1a (Fig. 3E). The voltage
at half maximum NaV channel activation (V0.5) in con-
trol cells was only marginally shifted (1.4 mV) in the
depolarizing direction in the presence of 1 lM rSf1a
(control: V0.5 = 21.4  1.3 mV; slope factor = 5.1 
1.0 versus toxin: V0.5 = 20.0  1.1 mV; slope fac-
tor = 5.4  0.8; n = 4, P > 0.05; Fig. 3E). This is more
clearly observed as a lack of any significant shift in
the voltage dependence of activation when currents
A B
C D
E F
G H
Fig. 3. The effects of rSf1a on the
voltage-dependence of NaV gating in
cockroach DUM neurons. (A, B) Voltage
protocols used to generate INa. (C, D)
Typical superimposed families of INa are
shown before (C) and after (D) application
of 1 lM rSf1a. Currents were generated
using the test pulse protocol shown in (A).
(E, F) Normalized INa–V relationships
before (●), and after (○ and shaded),
application of 1 lM rSf1a generated using
the pulse protocol in (B). Data were fitted
with Eqn (1) (see Materials and methods).
Currents were normalized against
maximum peak INa in controls (E) and
maximum peak INa (F). (G, H) Effects of
rSf1a on steady-state NaV channel
inactivation (h∞) were determined using a
two-pulse protocol detailed in (B). Peak INa
recorded during the test pulse before (●),
and after (○ and shaded), application of
1 lM rSf1a were normalized to maximum
inward INa in controls (G) and maximum
inward INa (H) and plotted against pre-
pulse potential. The h∞–V curves were
fitted with Eqn (2) (see Materials and
methods).
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recorded in the presence of toxin were normalized to the
peak inward INa in the presence of toxin (Fig. 3F). This
also revealed that the inhibition of NaV channels by
1 lM rSf1a was voltage independent and the binding of
the toxin to the channel was not relieved at increasing
membrane potentials, supporting the finding of the
experiments using depolarizing post-pulses.
The effects of rSf1a on the voltage dependence of
steady-state NaV channel inactivation (h∞V) were also
examined to determine whether the reduction of peak
INa was due to stabilization of the inactivated (closed)
state of the channel, and hence a reduction in channel
availability, as opposed to a pore blocking mechanism.
Accordingly, experiments were conducted using a two-
pulse protocol that utilized a 1-s conditioning prepulse
(Vprepulse) from 120 to 0 mV in 10-mV increments, fol-
lowed by a 50-ms test pulse (Vtest) to 10 mV (Fig. 3B).
In the presence of 1 lM rSf1a, INa were inhibited to
51  2% (n = 3) of control peak amplitude (parameter
‘A’ in Eqn 2; Fig. 3G). Normalization of the toxin data
to the maximum peak INa in the presence of toxin
revealed that the curves almost completely overlap
(Fig. 3H) with no significant shift in h∞V (control:
V0.5 = 33.8  0.3 mV and toxin: V0.5 = 35.5 
0.8 mV: P > 0.05, n = 3; Fig. 3H). Thus, the 49%
reduction in INa does not appear to be the result of a
reduction in NaV channel availability due to stabiliza-
tion of the channels in the closed-inactivated state.
Thus, rSf1a appears to be a NaV channel pore blocker.
rSf1a has no significant effect on CaV or KV channels
Given that NaV channel-targeting spider toxins may
also interact with CaV channels [26], we tested the abil-
ity of rSf1a to modulate the activity of insect CaV
channels. At least two subtypes of CaV channel cur-
rents have been demonstrated in cockroach DUM neu-
rons, including high-voltage-activated (HVA) and mid/
low-voltage-activated (M–LVA) CaV channel currents
[27–30]. Unfortunately, despite differences in the
kinetic and pharmacological properties of M–LVA
and HVA CaV channel currents, there remains no
mechanism for recording one current in isolation from
the other because no peptide or organic blockers are
available that exclusively block one type of current
[27]. As previously described, depolarizing voltage
command pulses to different levels were used to inves-
tigate actions on M–LVA and HVA CaV channels,
respectively [27,30,31]. CaV channel barium currents
(IBa) were evoked by 50-ms depolarizing pulses from a
Vh of 90 mV at 7-s intervals to 30 mV for genera-
tion of predominantly M–LVA CaV channel currents
and to +20 mV to evoke mainly HVA CaV channel
currents (Fig. 4Ca) [27,30]. Depolarizations to
30 mV caused an inward IBa with slow inactivation,
consistent with a reduction in Ca2+-dependent fast
inactivation caused by the use of Ba2+ as the charge
carrier [27], whereas depolarizations to +20 mV elicited
a smaller IBa with a faster inactivating component
(Fig. 4A,B). Following a 5-min perfusion, 1 lM rSf1a
caused only weak inhibition of both M–LVA and
HVA CaV channel currents. The M–LVA CaV channel
currents were reduced by 31.5  44.0% (P > 0.05,
n = 5) and HVA CaV channel currents by
11.5  9.7% (P > 0.05, n = 5). There were also no sig-
nificant changes in M–LVA and HVA IBa activation
and inactivation kinetics (Fig. 4A,B).
To investigate whether there was any shift in the
threshold of CaV channel activation, IBaV relation-
ships were established from families of IBa generated by
100-ms depolarizing test potentials from Vh of 90 to
+40 mV, at 10-mV increments every 7 s (Fig. 4Cb).
Families of peak inward IBa were normalized against the
maximum control inward peak IBa and plotted against
the membrane potential. In controls, DUM neuron CaV
channels activated between 50 and 40 mV. In the
presence of 1 lM rSf1a this threshold was shifted slightly
in the hyperpolarizing direction (Fig. 4D). This may be
the cause of the large variance in the magnitude of inhi-
bition of M–LVA CaV channel currents, detailed above.
However, there was no significant shift in the V0.5 of
channel activation (control: V0.5 = 29  1 mV versus
toxin: V0.5 = 27  1 mV; n = 5, P > 0.05) and cur-
rents were essentially superimposable when the toxin
Fig. 4. Effects of rSf1a on CaV and KV channel currents in cockroach DUM neurons. (A–D) Inhibition of barium currents through cockroach
DUM neuron CaV channels by rSf1a. (A, B) Representative superimposed IBa traces before (black) and following (grey and shaded)
application of 1 lM rSf1a to M-LVA (A) and HVA (B) channels. Dotted lines represent zero current. Currents were generated using the test
pulse protocol shown in (Ca). (D) Normalized IBa–V relationships before (●) and after (○ and shaded) application of 1 lM rSf1a. Currents were
generated using the test pulse protocol shown in (Cb). Normalized IBa–V relationships were fitted using Eqn (2). (E–H) Inhibition of
cockroach DUM neuron KV channels by rSf1a. (E) Representative superimposed IK traces before (black) and following (grey and shaded)
application of 1 lM rSf1a. Dotted lines represent zero current. Currents were generated using the test pulse protocol shown in (Fa). (G, H)
Normalized global IK–V relationships before (●) and after (○ and shaded), application of 1 lM rSf1a on peak (G) and late (H) IK. Currents were
generated using the test pulse protocol shown in (Fb) and measurements for peak and late current were measured at the circle and square
(50 ms) shown in (E), respectively. Normalized IK–V relationships were fitted using Eqn (2).
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data was normalized to the maximum peak IBa in the
presence of toxin (dotted line, Fig. 4D).
For completeness, we also determined the effect of
rSf1a on the major outward voltage-gated potassium
(KV) channel current subtypes present in cockroach
DUM neurons. These include a slowly activating
delayed-rectifier [IK(DR)], transient ‘A-type’ [IK(A)], and
large-conductance Ca2+-activated [IBK(Ca)] KV channel
currents [32]. To determine the effects of 1 lM rSf1a
on KV channels, global KV channel currents (IK) were
generated by 50-ms depolarizing test pulses to +30 mV
from a Vh of 80 mV, every 5 s (Fig. 4Fa). Global IK
were measured at the peak (circles) and at the end of
the test pulse (50 ms, squares). The early peak global
IK results mainly from the contribution of rapidly acti-
vating IK(A) and IBK(Ca), whereas the late global IK
results from the slowly activating IK(DR) and slow
inactivating component of the IBK(Ca). Application of
1 lM rSf1a caused a nonsignificant inhibition of out-
ward global IK reducing the peak global IK by
18  15% and the late global IK by 18  13%
(P > 0.05 in both cases, n = 3; Fig. 4E). This lack of
overt activity was mirrored by the lack of effect on the
voltage dependence of global IK activation. Global IK–
V relationships generated by the pulse protocol shown
in Fig. 4(Fb) were not significantly altered, with no
marked differences in V0.5 values between the IK–V for
controls (V0.5 = 5  2 mV for early and 8  4 mV
for late IK) versus toxin (V0.5 = 7  3 mV for early
and 8  4 mV for late IK) (P > 0.05; n = 3; Fig. 4G,
H). Currents were essentially superimposable when the
toxin data was normalized to maximum peak global
IK in the presence of toxin (dotted lines, Fig. 4G,H).
High-resolution solution structure of rSf1a
Buffer conductivity and pH can have a pronounced
effect on NMR spectra and thus several conditions
were screened to optimize NMR data quality, includ-
ing 20 mM phosphate buffer, pH 6, 20 mM Mes buffer,
pH 6, 20 mM acetate buffer, pH 5, 20 mM citrate buf-
fer, pH 4.0 and 20 mM citrate buffer, pH 3.5. These
buffer screens revealed that the side chain of Trp33
exists in several stable conformations and that the
population of the minor conformations was reduced at
low pH and high temperature. Trp33 is adjacent to
Pro32 and therefore cis–trans isomerization of the
Arg31–Pro32 peptide bond might be responsible for
the observed conformational isomerism [33]. Such con-
formational dynamics are known to be both tempera-
ture and pH dependent [34].
Consequently, NMR data were collected at 40 °C
using 13C/15N-labeled rSf1a dissolved in 20 mM citrate
buffer, pH 3.5. 1HN,
15N, 13Ca,
13Cb and
13C reso-
nance assignments were obtained from analysis of
amide-proton strips in 3D HNCACB, CBCA(CO)NH
and HNCO spectra. Side chain 1H and 13C chemical
shifts were obtained using a 4D HCC(CO)NH-TOCSY
experiment, which has the advantage of providing side
chain 1H–13C connectivities [35]. A fully assigned
1H–15N HSQC spectrum of rSf1a is shown in Fig. 5.
Complete chemical shift assignments have been depos-
ited in BioMagResBank (accession number 19535).
CYANA was used for automated NOESY assign-
ment and structure calculation [36]. Disulfide-bond
connectivities were determined from 15N and 13C NO-
ESY spectra and confirmed by performing structure
calculations without inclusion of disulfide-bond
restraints. The following connectivities were unambigu-
ously established following this procedure: Cys3–
Cys19, Cys10–Cys22, Cys18–Cys42 and Cys24–Cys40,
which correspond to a 1–4, 2–5, 3–8, 6–7 framework,
as described previously for Aps III [8]. For structure
calculations, interproton distance restraints were sup-
plemented with 75 dihedral angle restraints (36 /,
39 w) derived from TALOS+ chemical shift analysis [37].
Two hundred structures were calculated from random
starting conformations, and the 20 structures with the
lowest target function values were selected to represent
the solution structure of rSf1a. Coordinates for the
final ensemble of structures have been deposited in the
Protein Data Bank (accession number 2MF3).
The final ensemble of structures revealed that Sf1a
contains a canonical ICK motif [38] (Fig. 6A) in which
the Cys10–Cys22 and Cys3–Cys19 disulfide bonds and
the intervening section of the peptide backbone form a
ring that is pierced by the Cys18–Cys42 disulfide bond
(Fig. 6B). The Cys24–Cys40 disulfide acts as a ‘molecu-
lar staple’ to hold together the ends of the extended
b-hairpin loop. This loop was poorly defined in the cal-
culated structures and analysis of random coil indices
using TALOS+ clearly shows that this loop is disordered
(S2 ~ 0.65 compared with average of ~ 0.8 for the core
of the molecule). When the disordered hairpin loop and
N-terminal residues are excluded, the ensemble of 20
structures overlay very well, with backbone and heavy-
atom rmsd values of 0.13 and 0.43 A, respectively, over
residues 4–26 and 39–45. Based on precision and Rama-
chandran plot quality (see Table 1), the structure ranks
as high resolution [39]. The structure has high stereo-
chemical quality with a mean MolProbity [40] score of
1.55  0.18, placing it in the 93rd percentile relative to
other protein structures.
A search for structural homologs [41] revealed that
rSf1a has similar topology to numerous other spider
toxins containing the ICK motif. However, this search
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also revealed close structural homology to tachysta-
tin B (PDB 2DCV), an antimicrobial ICK-containing
peptide isolated from the Japanese horseshoe crab
Tachypleus tridentatus [42]. Tachystatin B does not
contain the extended hairpin loop found in rSf1a but
the two peptides overlay well over their core ICK
regions (Fig. 6C). A similarly large hairpin loop is
present in the structure of the insecticidal spider-
venom peptide Aps III (l-CUTX-As1a) [8]. In
Aps III, this loop is comprised of 14 residues, which is
larger than found in typical ICK peptides, but signifi-
cantly shorter than the 19-residue loop present in
rSf1a. An overlay of the structures of rSf1a and
Aps III reveals that the placement of the non-ICK
disulfide bond is very different in the two peptides
(Fig. 6C).
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Fig. 5. 2D 1H–15N HSQC NMR spectrum
of rSf1a acquired at 900 MHz. Sequence-
specific resonance assignments are
indicated. Backbone amide assignments
are annotated using the one-letter amino
acid code. Assignments are also shown
for the side chain (SC) NH correlations of
Trp33, the side chain NH2 groups of the
four Asn residues, and the aliased peak
from the side chain of Arg31. (Note:
numbering according to the native
sequence).
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Fig. 6. 3D structure of rSf1a. (A) Ensemble of 20 NMR-derived structures. b-Strands are green, and the disulfide bonds are shown as
yellow sticks. The dominant extended and largely disordered loop is highlighted in red. (Note: numbering according to the native sequence.)
(B) The ensemble is rotated such that the ICK motif is clearly visible. The ICK ring formed by two disulfide bonds is shown in magenta and
the third ICK disulfide bond piercing this ring is also shown. The remainder of the molecule is made transparent for clarity. (C) Overlay of
rSf1a (red) with structural homologs tachystatin B (PDB 2DCV; blue) and Aps III (PDB 2M36; green). The structures are made transparent
and the disulfide bonds are shown as solid sticks, illustrating the alignment of the ICK motif. The position of the extra disulfide bond that
serves as a molecular staple in Sf1a and Aps III is also shown.
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Functional importance of the b-hairpin loop
The b-hairpin loop in spider-venom ICK peptides
often houses functionally critical residues [7]. The
unusually large b-hairpin loop found in Sf1a contains
an Arg–Pro–Trp (RPW) motif that is strictly con-
served in this family of toxins [14] and we therefore
wondered whether this motif might be critical for the
toxin’s insecticidal activity.
We produced a mutant of rSf1a in which residues
R31 and W33 were both replaced with alanine. The
mutant peptide (rSf1a–R31A/W33A) was purified and
characterized as described above for rSf1a and shown
to adopt the same fold as the native peptide by com-
parison of their 2D 1H–15N HSQC spectra. In striking
contrast to rSf1a (PD50 = 1.5 nmolg1), the R31A/
W33A double mutant was not insecticidal to blowflies
at doses up to 95.4 nmolg1 (i.e. there were no signs
of paralysis or lethality up to 24 h after injection).
Moreover, at a concentration of 1 lM, the rSf1a–
R31A/W33A mutant failed to significantly inhibit INa
in DUM neurons (5.9  1.8% block of control peak
INa, P > 0.05, n = 3; Fig. 2D), consistent with its lack
of insecticidal activity. We therefore conclude that the
b-hairpin loop, and in particular the conserved RPW
motif, is critical for the activity of Sf1a.
Discussion
Molecular target of Sf1a
We examined the effect of rSf1a on insect NaV, CaV
and KV channels that represent common targets for
insecticidal spider toxins. The main effect of rSf1a was
to produce a rapid, but incomplete, block of insect
NaV channels that occurred in the absence of: (a) a
shift in the voltage dependence of activation; (b) a
shift in the voltage dependence of steady-state inactiva-
tion; or (c) depolarization-induced dissociation of
binding. Furthermore, Sf1a failed to modulate the gat-
ing or kinetics of NaV channel currents and the inhibi-
tion of INa was not relieved by depolarizing pulses. We
also showed that rSf1a does not significantly affect the
activity of insect CaV channels or delayed-rectifier,
‘A-type’ or BKCa potassium channels that are the
major contributors to the global outward KV channel
current in cockroach DUM neurons. Thus, rSf1a
appears to be a channel blocker that selectively plugs
the outer vestibule of NaV channels in a manner
similar to l-conotoxins [44]. The incomplete block of
Na+ flux induced by rSf1a is consistent with the toxin
binding to the channel outer vestibule rather than lod-
ging deep into the pore region and causing complete
steric block of the insect NaV channel pore. [43].
Most other NaV channel blockers isolated from spider
venoms act as ‘gating-modifiers’ that reduce INa by
causing a depolarizing shift in the voltage dependence of
NaV channel activation, thereby inducing a flaccid or
‘depressant’ phenotype. This results from an interaction
with one or more of the four NaV channel voltage
sensors [45]. These spider toxins include the depressant
theraphotoxins b-TRTX-Cm1a, -Cm1b and Cm2a
(ceratotoxin-1, -2 and -3) from Ceratogyrus marshalli
and b-theraphotoxin-Ps1a from Paraphysa scrofa [46].
By contrast, rSf1a inhibits insect NaV channel conduc-
tance in the absence of any depolarizing shift in the volt-
age dependence of activation. Given this distinct lack of
any voltage-dependent shift in channel activation, Sf1a
belongs to a growing group of spider l-toxins that
appear to occlude the outer vestibule of the insect NaV
channel. This includes Aps III (l-CUTX-As1a) from
the unrelated spider Apomastus schlingeri [8]. Unlike
Aps III, which acts on both NaV and to a lesser extent
CaV channels, rSf1a selectively blocks insect NaV chan-
nels. Furthermore, Sf1a is marginally more potent than
two other l-theraphotoxins that are pore blockers:
l-TRTX-Hhn2b (hainantoxin-I) and l-TRTX-Hh1a
(huwentoxin-III) from two different species of Chinese
Haplopelma tarantulas. These two toxins block insect
NaV channels presumably via binding to neurotoxin
Table 1. Structural statistics for ensemble of 20 NMR structures
of rSf1a. All statistics are given as mean  SD.
Experimental restraintsa
Interproton distance restraints
Intraresidue 147
Sequential 225
Medium range (i–j < 5) 58
Long range (i–j ≥ 5) 134
Disulfide-bond restraints 12
Dihedral-angle restraints (36 /, 39 w) 75
Total number of restraints per residue 13.9
R.m.s.d from mean coordinate structure (A)
All backbone atoms (residues 1–45) 0.80  0.18
All heavy atoms (residues 1–45) 1.24  0.19
Backbone atoms (residues 4–26, 39–45) 0.13  0.03
Heavy atoms (residues 4–26, 39–45) 0.43  0.06
Stereochemical qualityb
Residues in most favored Ramachandran
region (%)
82.4  2.4
Ramachandran outliers (%) 0.4  0.9
Unfavorable side chain rotamers (%) 6.8  3.1
Clash score, all atomsc 0.0  0.0
Overall MolProbity score 1.55  0.18
aOnly structurally relevant restraints, as defined by CYANA, are
included.
bAccording to MolProbity (http://molprobity.biochem.duke.edu).
cDefined as the number of steric overlaps > 0.4 A per thousand
atoms.
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receptor site 1 near the mouth of the channel with IC50
concentrations for block of the channel between 1.1 and
4.5 lM [47,48]. Although the IC50 for Sf1a on insect
NaV channels was not definitively determined in the
present study, it is < 1 lM because this concentration
caused a 60% block of cockroach DUM neuron INa.
Thus, although both l-TRTX-Hhn2b and l-TRTX-
Hh1a selectively inhibit insect NaV channels, rSf1a
targets the insect NaV channel with higher affinity,
consistent with its modest, but irreversible, depressant
paralytic activity (PD50 = 1.5 nmolg1).
An additional mechanism that can lead to an inhibi-
tion of INa is a decrease in NaV channel availability, as
observed with l-TMTX-Hme1a from venom of the
spider Heriaeus melloteei [49]. This mechanism of
action causes an increase in the number of NaV chan-
nels stabilized in the closed-inactivated state as
observed by a hyperpolarizing shift in the voltage
dependence of steady-state inactivation. By contrast to
l-TMTX-Hme1a, rSf1a failed to produce any signifi-
cant hyperpolarizing shift in the voltage dependence of
steady-state NaV channel inactivation, lending further
support to the notion that the toxin occludes the outer
vestibule of the channel.
Finally, voltage-dependent dissociation of bound
toxins from mammalian and insect NaV channels has
also previously been demonstrated with a range of spi-
der, scorpion and sea anemone toxins [50–54]. How-
ever, there was no indication of voltage-dependent
dissociation of rSf1a from DUM neurons using depo-
larizing post-pulse protocols.
In summary, rSf1a inhibits NaV channels via partial
block of the channel pore. This inhibition occurs in
the absence of any alteration to the kinetics of NaV
channel inactivation as observed for spider d-toxins
[55] and Sf1a fails to produce any hyperpolarizing shift
(as seen for excitatory b-toxins) [56] or a depolarizing
shift (as observed for depressant b-toxins) [46] in the
voltage dependence of NaV channel activation. Based
on the pharmacology described here, rSf1a should be
renamed l-segestritoxin-Sf1a (l-SGTX-Sf1a) based on
the rational nomenclature recently proposed for spi-
der-venom peptides [57]. This is consistent with its
action to induce flaccid paralysis, in contrast with the
spastic paralysis observed with spider d-toxins [58] and
excitatory b-toxins [59].
The incomplete block of NaV channels is unlikely to
be the sole cause of Sf1a toxicity. Given the weak effects
of Sf1a on neuronal calcium channels, an additional
target might be the HVA-like dihydropyridine-sensitive
CaV channels found on the surface of invertebrate
skeletal muscle [28], which are critical for conduction of
muscle action potentials.
Unusual structure of Sf1a
The ICK/knottin topology is by far the dominant struc-
tural scaffold found in spider venoms [8] and it is there-
fore not surprising to find that rSf1a conforms to this
paradigm. Many spider-venom knottins are elaborated
with a fourth non-ICK disulfide bond such as the d-
hexatoxins with 1–4, 2–6, 3–7, 5–8 connectivity [60] and
the j-hexatoxins that contain a rare vicinal disulfide
bond leading to 1–6, 2–7, 3–4, 5–8 connectivity [61,62].
However, the 1–4, 2–5, 6–7, 3–8 disulfide connectivity
seen in rSf1a is rare and has only been described for the
following spider toxins: Aps III (PDB 2M36) [8],
U2-hexatoxin-Hi1a (PDB 1KQH/1KQI) [33], x-agatox-
in IVA (PDB 1IVA) [63], d-palutoxin IT2 (PDB 1V91)
[64] and l-agatoxin I (PDB 1EIT) [65]. In all these
structures except Aps III, the non-ICK disulfide bond
delineates the boundaries of a 4–6-residue loop, poten-
tially as a mechanism for decoupling the dynamics of
the loop from the ICK core. In Aps III, the auxiliary
disulfide bond appears to stabilize a dynamic glycine-
rich segment within the loop [8]. Notably, in rSf1a this
loop comprises 19 residues, a third of the entire peptide
sequence, making it by far the largest such loop
described for any ICK peptide in this class. Cis–trans
isomerization of the Tyr29–Pro30 peptide bond in the
loop region of U2-hexatoxin-Hi1a leads to equilibrium
between two equally populated conformers. In rSf1a,
we observed multiple conformations of the tryptophan
residue adjacent to Pro32, but the minor conformers
made up a small fraction of the equilibrium population.
The unusual b-hairpin loop in rSf1a was found to be
functionally critical. Simultaneous mutation of R31 and
W33 within the conserved RPW motif in the b-hairpin
loop led to a mutant toxin that lacked insecticidal activ-
ity and was able to inhibit insect NaV channel currents.
This is also consistent with previous studies showing
that Trp and Arg are the two residues most commonly
found at the interface between interacting proteins [66].
The only other peptide in this class of knottins for which
the pharmacophore has been mapped is d-palutoxin IT2
and in this case the b-hairpin loop was also found to be
functionally important [64].
Finally, we note that the second closest structural
homolog of rSf1a is tachystatin B, an antimicrobial
peptide isolated from the Japanese horseshoe crab
Tachypleus tridentatus [42]. The two peptides overlay
very closely over their core ICK regions, but deviate
significantly over the unusually large disordered loop
of rSf1a. The origin of the ICK fold remains under
debate; there is conflicting evidence about whether the
ICK motif evolved from an ancestral two-disulfide,
disulfide-directed b-hairpin fold by addition of a disul-
11FEBS Journal (2015) ª 2015 FEBS
N. S. Bende et al. Structure and function of the spider toxin Sf1a
fide bond [61,67] or vice versa [68]. The presence of
the ICK fold in an ancient marine arthropod suggests
that the ICK fold may have already been present prior
to its recruitment into the venom of arthropods. In
this scenario, the ICK fold would be the plesiotypic
state with the two-disulfide, disulfide-directed b-hairpin
fold subsequently evolving via loss of a disulfide bond.
This would provide an alternative explanation for the
rarity of two-disulfide, disulfide-directed b-hairpin pep-
tides in arachnid venoms [67].
Sf1a as a bioinsecticide
We found that Sf1a caused long-lasting, irreversible
paralysis in sheep blowflies that eventually led to death
by starvation. Because of methodological issues (i.e.
high mortality in controls beyond 24 h), we could not
determine the PD50 over longer periods. However, flies
paralyzed by high doses of rSf1a remained paralyzed
48 h after injection The observed effects of rSf1a in
blowflies are similar to those recently reported for the
spider-venom peptide Aps III, although Aps III is
threefold more potent with a PD50 value of
700 pmolg1 [8]. Given the observed insecticidal
effects of rSf1a in blowflies, it seems likely that it
would produce similar effects in dipteran pests such as
mosquitoes and tsetse flies that vector human diseases.
Because rSf1a is also active against lepidopteran
[14,17] and hemipteran [21] pests, but inactive against
vertebrates [14], it appears to be a suitable lead for the
development of novel bioinsecticides [4]. Although the
moderate potency of Sf1a would require large amounts
to be applied in the field for efficient pest control,
delivery of the toxin to pest insects via genetic engi-
neering of crops or via insect-specific pathogens (e.g.
entomopathogenic fungi) might provide efficient deliv-
ery of the toxin at effective concentrations.
In summary, we have shown that Sf1a is a NaV-chan-
nel-specific insecticidal toxin that acts via a nonvoltage-
dependent mechanism. This is an atypical mode of
action that has previously only been observed in one
other spider toxin, namely Aps III. Although less potent
than Aps III, the specificity of Sf1a towards NaV chan-
nels makes it an attractive pharmacological tool.
Materials and methods
Chemicals
All chemicals were purchased from Sigma-Aldrich Australia
(Castle Hill, NSW, Australia), Sigma-Aldrich USA (St
Louis, MO, USA) or Merck Chemicals (Kilsyth, Victoria,
Australia) with the exception of IPTG (Life Technologies,
Victoria, Australia) and HPLC-grade acetonitrile (RCI
Labscan, Bangkok, Thailand). 13C6-glucose and
15NH4Cl
were purchased from Sigma-Aldrich Australia. Recombi-
nant His6–TEV protease (EC 3.4.22.44) was produced in-
house using a previously described protocol [69].
Nomenclature
Based on the rational nomenclature proposed for spider-
venom peptides [57], SFI1 should be renamed l-segestritox-
in-Sf1a (l-SGTX-Sf1a) based on its source and activity on
NaV channels.
Production of recombinant Sf1a
A synthetic gene encoding Sf1a, with codons optimized for
expression in E. coli, was synthesized and cloned into the
pLIC–MBP expression vector by GeneArt (Invitrogen,
Regensburg, Germany). This vector (pLIC–NSB2), which
was designed as described earlier [8], encodes an IPTG-
inducible LacI promoter, a MalE signal sequence for peri-
plasmic export, a His6 tag for nickel affinity purification,
MBP fusion tag to enhance solubility, and a TEV protease
cleavage site between the MBP and Sf1a coding regions
(Fig. 1A). The plasmid was transformed into E. coli strain
BL21(kDE3) for rSf1a production. Cultures were grown in
Terrific Broth (TB) medium using baffled flasks at 37 °C
with shaking at 110 rpm. Expression of the toxin gene was
induced with 1 mM IPTG at D600 = 0.9–1.0, then cells were
grown at 18 °C for a further 15 h and harvested by centrifu-
gation for 12 min at 8967 g. For production of uniformly
13C/15N-labeled Sf1a, cultures were grown in minimal med-
ium supplemented with 13C6-glucose and
15NH4Cl as the sole
carbon and nitrogen sources, respectively.
The His6–MB–rSf1a fusion protein was extracted from
the bacterial periplasm by cell disruption at 27 kPa (TS
Series Cell Disrupter, Constant Systems Ltd, Daventry,
UK), then captured by passing the periplasmic extract (buf-
fered in 40 mM Tris, 450 mM NaCl, pH 8.0) over Ni-NTA
Superflow resin (Qiagen) followed by washing with 10 mM
imidazole to remove any products that bound nonspecifi-
cally to the resin. The fusion protein was then eluted with
500 mM imidazole. The eluted fusion protein was concen-
trated to 5 mL and the buffer was exchanged to remove
imidazole. Reduced and oxidized glutathione were then
added to 0.6 and 0.4 mM, respectively, to maintain TEV
protease activity. Approximately 100 lg of His6-tagged
TEV protease was added per mg of fusion protein, and the
cleavage reaction was allowed to proceed at room tempera-
ture for 12 h. The cleaved His6–MBP and His6–TEV were
removed by using SPE columns; the mixtures were loaded
onto the column and the peptide eluted with 40% elution
solvent (Solvent B: 0.043% trifluoroacetic acid in 90%
acetonitrile). The eluate was lyophilized and then semi-pure
rSf1a was subjected to further purification using RP-HPLC.
12 FEBS Journal (2015) ª 2015 FEBS
Structure and function of the spider toxin Sf1a N. S. Bende et al.
RP-HPLC was performed on a Vydac C18 column
(250 9 4.6 mm, particle size 5 lm) at a flow rate of
1 mLmin1 and a gradient of 20–40% Solvent B in Sol-
vent A (0.05% trifluoroacetic acid in water) over 20 min.
MALDI-TOF mass spectrometry
Peptide masses were determined using MALDI-TOF MS
employing a Model 4700 Proteomics Bioanalyser (Applied
Biosystems, Carlsbad, CA, USA). RP-HPLC fractions were
mixed 1 : 1 (v/v) with a-cyano-4 hydroxycinnamic acid matrix
(5 mgmL1 in 50 : 50 acetonitrile/H2O) and MALDI-TOF
spectra were acquired in positive reflector mode. All reported
masses are for monoisotopic [M+H]+ ions.
Blowfly toxicity assay
Insect toxicity assays were performed as described previ-
ously [8] Briefly, rSf1a, nat-Sf1a or rSf1a-R31A/W33A were
injected into the ventro-lateral thoracic region of sheep
blowflies (Lucilia cuprina) weighing 19.5–25.9 mg. Three
separate experiments were conducted for each Sf1a homo-
log, each comprising 3–10 doses, with each dose injected
into 10 flies. Paralytic and lethal effects were measured
24 h post injection. PD50 values were calculated as
described previously [8] with statistical analysis and
unpaired Student’s t-tests performed using PRISM 6.
Structure determination
NMR spectra were acquired at 40 °C on a 900 MHz NMR
spectrometer (Bruker BioSpin, Germany) equipped with a
cryogenically cooled probe. 15N/13C-labeled rSf1a was dis-
solved in 20 mM citrate, pH 3.5 at a final peptide concentra-
tion of 420 lM, followed by addition of 5% D2O. The sample
was filtered using a low-protein-binding Ultrafree-MC cen-
trifugal filter (0.22 lm pore size; Millipore, Bedford, MA,
USA), then 300 lL was added to a susceptibility matched
5 mm outer-diameter microtube (Shigemi Inc., Allison Park,
PA, USA).
3D and 4D spectra used for resonance assignments were
acquired using nonuniform sampling [70]. Sampling sched-
ules that approximated the signal decay in each indirect
dimension were generated using SCHED3D [35]. Nonuniform
sampling data were processed using the Rowland NMR
toolkit (www.rowland.org/rnmrtk/toolkit.html) and maxi-
mum entropy parameters were automatically selected as
previously described [71]. 13C- and 15N-edited HSQC-NO-
ESY spectra (mixing time of 200 ms) were acquired using
uniform sampling. Separate 13C-edit HSQC-NOESY spec-
tra were acquired for the aliphatic and aromatic regions of
the carbon spectrum.
Dihedral angles were derived from TALOS+ chemical shift
analysis [37] and the restraint range for structure calcula-
tions was set to twice the estimated standard deviation.
NOESY spectra were manually peak picked and integrated,
peak lists were then automatically assigned, distance
restraints extracted, and an ensemble of structures calcu-
lated using the torsion angle dynamics package CYANA 3.0
[36]. The tolerances used for CYANA were 0.02 ppm in the
direct 1H dimension, 0.04 ppm in the indirect 1H dimen-
sion, and 0.4 ppm for the heteronucleus (13C/15N). During
the automated NOESY assignment/structure calculation
process, CYANA assigned 92% of all NOESY cross-peaks
(1447 of 1566). The four disulfide bonds were assigned
based on preliminary structure calculations; subsequent cal-
culations included distance restraints for these disulfide
bonds as described previously [72].
Electrophysiological measurements on insect
neurons
DUM neurons were isolated from unsexed adult American
cockroaches (Periplaneta americana) as described previously
[8]. Briefly, terminal abdominal ganglia were removed and
placed in normal insect saline (NIS) containing 180 mM
NaCl, 3.1 mM KCl, 10 mM Hepes and 20 mM D-glucose.
Ganglia were then incubated in 1 mgmL1 collagenase
(type IA) for 40 min at 29 °C. Following enzymatic treat-
ment, ganglia were washed twice in NIS and resuspended
in NIS supplemented with 4 mM MgCl2, 5 mM CaCl2, 5%
fetal bovine serum and 1% penicillin/streptomycin (Life
Technologies, Victoria, Australia) (NIS+) and triturated
through a fire-polished Pasteur pipette. The resultant cell
suspension was then distributed onto 12-mm diameter glass
coverslips precoated with 2 mgmL1 concanavalin A
(type IV). DUM neurons were maintained in NIS+ at
29 °C and 100% humidity. Ionic currents were recorded in
voltage-clamp mode using the whole-cell patch-clamp tech-
nique, employing version 10.2 of the pCLAMP data acqui-
sition system (Molecular Devices, Sunnyvale, CA, USA).
Data were filtered at 5–10 kHz with a low-pass Bessel filter
with leakage and capacitive currents subtracted using P–P/4
procedures. Digital sampling rates were set between 15 and
25 kHz depending on the length of the protocol. Single-use
0.8–2.5 MΩ electrodes were pulled from borosilicate glass
and fire-polished prior to current recordings. Liquid junc-
tion potentials were calculated using JPCALC [73], and all
data were compensated for these values. Cells were bathed
in external solution through a continuous pressurized per-
fusion system at 1 mLmin1, and toxin solutions were
introduced via direct pressurized application using a perfu-
sion needle at ~ 50 lLmin1 (Automate Scientific, San
Francisco, CA, USA). Control data were not acquired
until at least 20 min after whole-cell configuration was
achieved to eliminate the influence of fast time-dependent
shifts in steady-state inactivation resulting in rundown of
INa from NaV channels. All experiments were performed at
ambient room temperature (20–23 °C). To record INa, the
external bath solution contained: 230 mM NaCl, 5 mM
13FEBS Journal (2015) ª 2015 FEBS
N. S. Bende et al. Structure and function of the spider toxin Sf1a
CsCl, 1.8 mM CaCl2, 50 mM tetraethylammonium chloride,
5 mM 4-aminopyridine, 10 mM Hepes, 0.1 mM NiCl2 and
1 mM CdCl2, adjusted to pH 7.4 with 1 M NaOH. The pip-
ette solution contained: 34 mM NaCl, 135 mM CsF, 1 mM
MgCl2, 10 mM Hepes, 5 mM EGTA and 3 mM ATP-Na2,
adjusted to pH 7.4 with 1 M CsOH. To eliminate any influ-
ence of differences in osmotic pressure, all internal and
external solutions were adjusted to 400  5 mOsmolL1
with sucrose. Because of the reported current rundown
with calcium as a charge carrier [27], BaCl2 replaced CaCl2
in all experiments on voltage-gated CaV channels. The
external bath solution for IBa recordings contained:
140 mM Na acetate, 30 mM TEA-Br, 3 mM BaCl2 and
10 mM Hepes, adjusted to pH 7.4 with 1 M TEA-OH. The
external solution also contained 300 nM tetrodotoxin to
block NaV channels. Pipette solutions contained: 10 mM
Na acetate, 110 mM CsCl, 50 mM TEA-Br, 2 mM ATP-
Na2, 0.5 mM CaCl2, 10 mM EGTA and 10 mM Hepes,
adjusted to pH 7.4 with 1 M CsOH. The external bath
solution for recording global KV channel currents (IK)
contained: 200 mM NaCl, 50 mM K gluconate, 5 mM
CaCl2, 4 mM MgCl2, 0.3 mM tetrodotoxin, 10 mM Hepes
and 10 mM D-glucose, adjusted to pH 7.4 with 1 M NaOH.
The pipette solution consisted of: 135 mM K gluconate,
25 mM KF, 9 mM NaCl, 0.1 mM CaCl2, 1 mM MgCl2,
1 mM EGTA, 10 mM Hepes and 3 mM ATP-Na2, adjusted
to pH 7.4 with 1 M KOH.
Experiments were rejected if there were large leak cur-
rents or currents showed signs of poor space clamping.
Curve fitting and statistical analysis
Peak current amplitude was analyzed offline using AXOG-
RAPH X v. 1.5.3 (Molecular Devices). Current amplitudes
were normalized against maximal control current ampli-
tude, or maximal current amplitude in the presence of
1 lM rSf1a, for all curve-fitted data. All curve fitting was
performed using PRISM 6 for Windows (GraphPad Soft-
ware Inc., San Diego, CA, USA) using nonlinear regres-
sion and a least-squares method. Comparisons of two
sample means were made using a paired Student’s t-test.
A test was considered to be significant when P < 0.05. All
data represent the mean  SEM of n independent experi-
ments.
The data for the voltage dependence of channel activa-
tion, for all channel types, were fitted using the following
current–voltage (I–V) formula:
I ¼ gmax 1 ð 1
1þ exp½ðV V0:5Þ=sÞ
 
ðV VrevÞ ð1Þ
where I is the amplitude of the current at a given test
potential V, gmax is the maximal conductance, V0.5 is
the voltage at half-maximal activation, s is the slope
factor and Vrev is the apparent reversal potential.
The data for voltage dependence of NaV channel steady-
state inactivation (h∞/V) were amplitude inverted and fitted
using the following Boltzmann equation:
h1 ¼ A
1þ exp½ðV V0:5Þ=k ð2Þ
where A is the fraction of control maximal peak INa,
V0.5 is the midpoint of inactivation, k is the slope fac-
tor, and V is the conditioning prepulse potential.
On-rates were determined by fitting time course data
with the following single exponential association function:
Y ¼ Y0 þ ðA Y0Þ  ð1 expðk tÞÞ ð3Þ
where Y0 is the maximal peak INa, A is the minimum
peak INa, K is the rate constant and t is time. The on-
rate (son) was subsequently determined from the
inverse of the rate constant (K).
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A distinct sodium channel voltage-sensor
locus determines insect selectivity of the
spider toxin Dc1a
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b-Diguetoxin-Dc1a (Dc1a) is a toxin from the desert bush spider Diguetia canities that
incapacitates insects at concentrations that are non-toxic to mammals. Dc1a promotes
opening of German cockroach voltage-gated sodium (Nav) channels (BgNav1), whereas
human Nav channels are insensitive. Here, by transplanting commonly targeted S3b–S4
paddle motifs within BgNav1 voltage sensors into Kv2.1, we ﬁnd that Dc1a interacts with the
domain II voltage sensor. In contrast, Dc1a has little effect on sodium currents mediated by
PaNav1 channels from the American cockroach even though their domain II paddle motifs are
identical. When exploring regions responsible for PaNav1 resistance to Dc1a, we identiﬁed
two residues within the BgNav1 domain II S1–S2 loop that when mutated to their PaNav1
counterparts drastically reduce toxin susceptibility. Overall, our results reveal a distinct region
within insect Nav channels that helps determine Dc1a sensitivity, a concept that will be
valuable for the design of insect-selective insecticides.
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I
nsect voltage-gated sodium (Nav) channels share a common
architecture with their mammalian orthologues1. The pore-
forming subunit consists of four connected domains (DI–IV),
each with six transmembrane segments (S1–S6). These
homologous, but not identical, domains each contain a voltage
sensor (S1–S4) and a portion of the pore through which Naþ can
diffuse (S5–S6)2. While they have yet to be identiﬁed in insect Nav
channels, each voltage-sensing domain within mammalian and
bacterial Nav channels contains an S3b–S4 helix-turn-helix motif,
the voltage-sensor paddle, which drives voltage-sensor activat-
ion3–6. Aside from its vital role in channel gating, the paddle
motif is also an important pharmacological target, as peptide
toxins interact with this region to modify channel opening3,4,7.
Insect Nav channels likely possess similar motifs since residue
substitutions in homologous regions can abolish channel
susceptibility to toxins found in animal venoms1. Even though
voltage-sensing domains are extensively targeted by naturally
occurring peptides, commercially available insecticides such as
pyrethroids and oxadiazines typically interact with the channel
pore region or intracellular linker between S4 and S5 to disrupt
opening or closing (that is, gating)8,9. However, insects have
responded to this threat by mutating residues at strategic
locations within the channel that result in a reduced sensitivity
to these compounds9. Moreover, the conserved nature of the Nav
channel pore throughout the animal kingdom often leads to
undesired biological activity of insecticides in beneﬁcial insect
orders or mammals8–10. Since the amino acid composition of
voltage-sensing domains varies considerably between related Nav
channel isoforms, these regions may replace the pore as a target
for designing insecticides with a higher degree of phyletic
selectivity, an intriguing notion that has yet to be fully explored.
Nav channels have been governing electrical excitability in a
wide range of organisms for millions of years, even before
the development of neurons2,11. Thus, it is not surprising that
ancient organisms such as spiders developed an arsenal of
toxins geared towards incapacitating prey by modulating Nav
channel function12–15. One intriguing specimen is the desert
bush spider (Diguetia canities) whose habitat spans the
Southwestern deserts of the United States16,17. The venom of
this relatively unexplored primitive weaving spider contains
a 57-residue peptide known as DTX9.2 (or b-diguetoxin-Dc1a18,
hereafter Dc1a; Fig. 1a), one of the most potent insect-selective
neurotoxins found in arthropod venoms19. Although its
precise molecular target has yet to be elucidated, neurophysiolo-
gical studies on houseﬂy larvae revealed excitation of sensory
and neuromuscular preparations on Dc1a application that
could be blocked by the Nav channel-blocking compound
tetrodotoxin20.
Here, we show that Dc1a potently promotes opening of the
German cockroach Nav channel BgNav1 (ref. 21) by interacting
with the paddle motif in domain II. Surprisingly, Dc1a has little
effect on PaNav1-expressing neurons isolated from the American
cockroach (Periplaneta americana)22, even though the toxin-
binding site is identical in these two cockroach channels. By
exploring regions responsible for the remarkable insect-family
speciﬁcity of Dc1a, we uncovered an important role for the
domain II S1–S2 loop in determining PaNav1 resistance to Dc1a.
Together with the unique solution structure of Dc1a, our results
provide a proof of concept that toxins—and by extension small
molecules—can selectively target insect Nav channels by
interacting with their voltage-sensing domains, thus facilitating
the development of new insecticides.
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Figure 1 | Recombinant production of Dc1a. (a) Primary structure of rDc1a. The non-native N-terminal Ser residue that is a vestige of the TEV protease
cleavage site used for recombinant toxin production is highlighted in grey. Disulphide bridge connectivity is shown above the sequence. (b) Schematic
representation of the pLIC-NSB3 vector used for periplasmic expression of rDc1a. The coding region includes a MalE signal sequence (MalESS) for
periplasmic export, a His6 afﬁnity tag, an MBP fusion tag and a codon-optimized gene encoding rDc1a, with a TEV protease recognition site inserted
between the MBP and toxin-coding regions. The locations of key elements of the vector are shown, including the ribosome-binding site (RBS).
(c) SDS-polyacrylamide gel electrophoresis gels illustrating different steps in the puriﬁcation of rDc1a. Lanes contain: M, molecular weight markers; lane 1,
E. coli cell extract before IPTG induction; lane 2, E. coli cell extract after IPTG induction; lane 3, soluble periplasmic extract (the His6-MBP-rDc1a fusion
protein is evident at B50 kDa); lane 4, Ni-NTA beads after loading the cell lysate; lane 5, eluate-1 from washing Ni-NTA resin with 600mM imidazole;
lane 6, elute-2 from washing Ni-NTA resin with 600mM imidazole; lane 7, eluate-3 from washing Ni-NTA resin with 600mM imidazole; lane 8,
Ni-NTA beads after elution-3; lane 9, fusion protein sample before TEV protease cleavage; lane 10, fusion protein sample after TEV protease cleavage
showing almost complete cleavage of fusion protein to His6-MBP. (d) RP-HPLC chromatogram showing the ﬁnal step in the puriﬁcation of rDc1a.
The arrow head denotes the peak corresponding to correctly folded recombinant rDc1a. Inset is a MALDI-TOF MS spectrum showing the [MþH]þ ion
for the puriﬁed recombinant toxin (obs.¼6,484Da; calc.¼6,485.39Da).
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Results
Production of recombinant Dc1a. We ﬁrst produced recombi-
nant Dc1a peptide (rDc1a) using a novel approach that addresses
the challenge of correctly folding disulphide-rich spider toxins
in E. coli23. To this end, we created an isopropyl-b-D-
thiogalactopyranoside (IPTG)-inducible construct (Fig. 1b) that
allows for export of a His6-MBP-Dc1a fusion protein to the
E. coli periplasm, where the enzymes involved in disulphide-
bond formation are located23. On recovery from the soluble
cell fraction, the fusion protein was puriﬁed using nickel
afﬁnity chromatography (Fig. 1c). Subsequent cleavage and
chromatographic puriﬁcation yielded a single major disulphide-
bond isomer with a purity of 498% as assessed by SDS-
polyacrylamide gel electrophoresis and matrix-assisted laser
desorption/ionization time-of-ﬂight (MALDI-TOF) mass
spectrometry (Fig. 1d). Note that, with four disulphide bonds,
there are 105 possible disulphide-bond isomers of rDc1a. Overall,
the ﬁnal yield was B1.1mg of toxin per litre of culture. Since
native Dc1a was unavailable to us, we conﬁrmed the insecticidal
activity of rDc1a by injection into the blowﬂy Lucilia cuprina and
the houseﬂy Musca domestica, which yielded LD50 values of
231±32 pmol g 1 and 493±52 pmol g 1, respectively (n¼ 3)
(Supplementary Fig. 1). We therefore conclude that rDc1a
has a similar lethality to agricultural pests when compared
with native toxin19.
Solution structure of rDc1a. The development of an efﬁcient
bacterial expression system allowed us to produce uniformly
13C/15N-labelled rDc1a protein for structure determination using
heteronuclear NMR. 1HN, 15N, 13Ca, 13Cb, and 13C0 resonance
assignments for the toxin were obtained from analysis of
amide-proton strips in three-dimensional (3D) HNCACB,
CBCA(CO)NH, and HNCO spectra. Sidechain 1H and 13C
chemical shifts were obtained using a four-dimensional (4D)
HCC(CO)NH-TOCSY experiment, which has the advantage of
providing sidechain 1H–13C connectivities24. Complete chemical
shift assignments have been deposited in BioMagResBank
(Accession Number 19666). CYANA was used for automated
NOESY assignment and structure calculation25. The disulphide-
bond pattern (1–4, 2–5, 3–8, 6–7) was unambiguously
determined from preliminary structures calculated without
disulphide-bond restraints26 and is identical to the framework
predicted in the UniProtKB entry for Dc1a (P49126). Of the 200
structures that were calculated from random starting
conformations, 20 conformers with high stereochemical quality
(as judged by MolProbity27) were selected to represent the
solution structure of rDc1a (Fig. 2a). Atomic coordinates for the
ﬁnal ensemble of 20 structures are available from the Protein
Data Bank (PDB; Accession Number 2MI5).
Statistics highlighting the high precision and stereochemical
quality of the ensemble of rDc1a structures are shown in
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Supplementary Table 1. The average MolProbity score of 1.24
places the ensemble in the 99th percentile relative to all other
structures ranked by MolProbity. The high stereochemical quality
of the ensemble stems from a complete absence of bad close
contacts and an excellent Ramachandran plot quality (499% of
residues in the most favoured region). The structural ensemble is
also highly precise with backbone and heavy-atom root-mean-
square deviation (r.m.s.d.) values over all the structural ordered
regions (residues 3–42, 52–56) of 0.27±0.07Å and 0.70±0.11Å,
respectively. The ensemble of rDc1a structures ranks as ‘very high
resolution’ based on these measures of precision and stereo-
chemical quality28.
Three of the four disulphide bonds in rDc1a form a classical
inhibitor cysteine knot (ICK) motif in which the Cys13–Cys26
and Cys20–Cys40 disulphide bonds and the intervening sections
of the polypeptide backbone form a 23-residue ring that is pierced
by the Cys25–Cys54 disulphide bond (Fig. 2b). This ICK motif is
commonly found in spider toxins, and this particular scaffold
provides these peptides (so-called ‘knottins’) with an unusually
high degree of chemical, thermal and biological stability15.
However, the structure of rDc1a differs markedly from other
ICK toxins, and a DALI search29 of the PDB returned no
structural homologues. First, rDc1a contains an additional
disulphide bond (Cys42–Cys52) that appears to serve as a
molecular staple which limits the ﬂexibility of a disordered serine-
rich hairpin loop (residues 43–51) (Fig. 2b). Stapled hairpins of
this kind have been observed in only a small number of spider
toxins30. Second, the extended N terminus of rDc1a along with an
unusually large loop between Cys26 and Cys40 enables the
formation of an amino-terminal (N-terminal) three-stranded
antiparallel b-sheet that is not found in any other knottin
(Fig. 2b,c). The uniqueness of the rDc1a structure can readily be
seen by comparison with the structure of As1a, a typical spider
venom–derived knottin that modulates the activity of insect NaV
channels30. The two toxins can be aligned over their core ICK
regions with an rmsd of 1.9 Å (Fig. 2c) consistent with them both
being members of the knottin family. However, when aligned
over this ICK region, the N-terminal b-sheet of rDc1a is entirely
separate to the region of structural overlap (Fig. 2c). Despite its
structural uniqueness, the molecular surface of rDc1a contains a
relatively uniform distribution of charged residues (Fig. 2d);
moreover, there are no distinct clusters of hydrophobic residues
that might mediate an interaction with lipid bilayers7,31
(Supplementary Movie 1).
rDc1a opens the German cockroach Nav channel BgNav1.
Diguetia spiders are generalist predators and their diet consists of
various insects ranging from small ants to sizeable prey such as
grasshoppers and cockroaches16,32. As such, we decided to test
whether rDc1a inﬂuences the gating properties of BgNav1, a
well-studied Nav channel isoform cloned from the German
cockroach8,21. We functionally expressed BgNav1 in Xenopus
oocytes and applied various concentrations of rDc1a. At 1 mM,
rDc1a produced robust opening of BgNav1 at voltages where the
channel is normally closed. This was achieved by a drastic shift in
channel activation to more negative potentials (V1/2 was shifted
from  27.3±0.2mV (mean±s.e.m.) (slope 4.0±0.2) to
 49.4±0.4mV (slope 3.5±0.3) in the presence of 1 mM
rDc1a; Fig. 3a) whereas steady-state inactivation (or channel
availability) was only slightly affected (V1/2 was shifted from
 52.2±0.1mV to  55.1±0.1mV in the presence of 1 mM
rDc1a; Fig. 3a). The rate of recovery from fast inactivation was
also not signiﬁcantly altered (t is 2.1±0.1ms versus 2.2±0.1ms;
Fig. 3b). On addition of 1 mM rDc1a to channels depolarized to
 60mV every 5 s, sodium currents became rapidly visible as a
result of the  22mV shift in voltage-dependent opening of
BgNav1 (Fig. 3c). Moreover, rDc1a similarly affects the channel
when voltage-steps to  60mV were applied every 50 s, suggesting
that the toxin can access its binding site when BgNav1 is in the
resting state12. Channels completely recovered following washout in
toxin-free solution (Fig. 3c). The persistent nature of the emerging
current does not stem from the inhibition of fast inactivation by
rDc1a since wild-type (WT) BgNav1 inherently possesses these
characteristics at mildly depolarizing voltages33. Fitting the Hill
equation to the concentration dependence for toxin-induced
current potentiation, as determined by shifts in V1/2, yielded an
EC50 of 65±1 nM and a Hill coefﬁcient of 1.19±0.02 (Fig. 3d),
suggesting that the toxin may interact with only one binding site.
Interestingly, 1 mM rDc1a did not affect any of the tested
vertebrate Nav channel isoforms or the hERG channel34,
a member of the cardiac voltage-gated potassium (Kv) channel
family and an Food and Drug Administration-mandated
screening target for potential off-target drug effects
(Supplementary Fig. 2a). These results are consistent with the
report that Dc1a has no effect in mice when injected
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Figure 3 | rDc1a promotes opening of BgNav1 channels. (a) Comparison
of the gating properties of BgNav1 before (black), and after (red), addition of
1mM rDc1a. Shown are the normalized deduced conductance (G)–voltage
(ﬁlled circles) (G/Gmax) and steady-state inactivation (open circles; I/Imax)
relationships. Currents were elicited by 5-mV step depolarizations from a
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bars represent s.e.m. Descriptive values resulting from Boltzmann ﬁts can
be found in the Results section. (b) Recovery from fast inactivation of WT
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determined by a double-pulse protocol to  30mV with a varying time
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Data represents n¼4 experiments, and error bars represent the s.e.m.
(c) On addition of 1mM rDc1a to channels depolarized to  60mVevery 5 s
(red open circles) or 50 s (green open circles; holding voltage was
 100mV), BgNav1-mediated sodium currents become rapidly visible.
Channels completely recover after toxin washout. Inset shows current trace
before (black), and after (red), addition of 1 mM rDc1a at 60mV (5 s
pulses). Noticeable is the persistent current that appears at this voltage,
even in control experiments. Abscissa scale is 10ms, ordinate scale is
0.3 mA. (d) Concentration dependence of rDc1a-induced current
potentiation determined from shifts in the midpoint of channel activation
(V1/2). Line represents a ﬁt of the data with the Hill equation resulting in a
half-maximal concentration (EC50) of 65±1 nM and a slope factor of
1.19±0.02; n¼ 5 and error bars represent s.e.m.
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intraperitoneally or intracerebroventricularly at doses of 4.1 and
1.0mg kg 1, respectively19.
rDc1a interacts with the domain II paddle motif in BgNav1.
Subsequently, we were interested in identifying the receptor sites
for rDc1a within insect Nav channels that result in such a
profound shift in the voltage dependence of activation. Our
experiments with BgNav1 suggest that rDc1a functions as an
excitatory toxin to activate insect Nav channels at membrane
voltages where they are normally closed. Hence, the toxin may
interact with S3b–S4 paddle motifs within BgNav1 voltage sensors
in a manner analogous to previously described b-scorpion
toxins3,35,36. In order to test this hypothesis, we ﬁrst needed to
establish whether BgNav1 contains paddle motifs with similar
functions as in Kv channels37–39 and in mammalian Nav channel
isoforms where they have been identiﬁed (rNav1.2a, rNav1.4,
rNav1.8, rNav1.9, and hNav1.9)3,4. To this end, we employed a
previously reported approach in which speciﬁc S3b–S4 regions
from each voltage-sensing domain of a Nav channel were
transplanted into homotetrameric Kv channels (Fig. 4a)3,4,7.
After several attempts (Fig. 4a), we were able to generate
functional chimeras between BgNav1 and Kv2.1 using known
paddle motif boundaries3,4 (Fig. 4a,b). All of the constructs
contain the crucial basic residues that contribute to gating charge
movement in Kv channels40,41, suggesting that each of the four
voltage-sensing domains in BgNav1 contain paddle motifs that
are capable of sensing membrane voltage changes.
Examination of the conductance–voltage (G–V) relationships
for the BgNav1/Kv2.1 chimeras reveals that each of the four
voltage-sensor paddles has a distinct effect on the gating
properties of Kv2.1. This was evidenced by marked differences
in the midpoints of activation for the G–V relations for the
domain I, II and IV constructs which are Z50mV, 13±2mV,
and  9±2mV, respectively (Fig. 4c). The G–V relationship for
the domain III BgNav1/Kv2.1 construct is bimodal, suggesting
that the functional coupling between the voltage-sensing domains
and the pore has been considerably altered. Although the
underlying mechanism is unclear, it is possible that pore opening
in this particular chimera may occur when: (1) not all four voltage
sensors are fully activated42; or (2) each voltage sensor has
transferred only a portion of its charge across the hydrophobic
septum43–45. The latter scenario seems more likely since in the
related Shaker Kv channel, all four voltage sensor need to be in the
active position before the pore opens42,46. Moreover, intermediate
states have also been observed when measuring gating currents of
the Shaker Kv channel in which a mutation immobilized voltage-
sensor movement between the resting and activated states,
thereby shifting the voltage activation of the ionic currents47.
Finally, it is worth mentioning that the domain III BgNav1/Kv2.1
construct may display multiple open states according to a model
that has been described for N-type Cav channels48.
Remarkably, domain IV paddle motifs from rNav1.2a and
rNav1.4 slow activation kinetics when transplanted into Kv
channels. These observations support the notion that the domain
IV paddle motif contributes substantially to the overall rate of
voltage-sensor activation3,4. To explore whether the domain IV
paddle motif serves a similar role in BgNav1, we measured
the kinetics of activation and deactivation of the four BgNav1
paddle constructs in response to membrane depolarization and
repolarization, respectively. Similar to previously studied chimeric
channels, the activation and deactivation kinetics observed for the
domain IV construct of BgNav1/Kv2.1 are slower over a wide
voltage range when compared with the other domains (Fig. 4d),
suggesting that this particular domain may indeed contribute
to fast inactivation in insect Nav channels49–51. We obtained
additional evidence for the functional role of the domain IV
paddle motif in BgNav1 gating from experiments with BomIV,
a classic insect-selective a-scorpion toxin from the venom of
Buthus occitanus mardochei that inhibits fast inactivation in
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American cockroach neurons52. To determine whether BomIV
inﬂuences BgNav1 in a similar fashion, we applied 10 nM to
channel-expressing Xenopus oocytes and observed that the toxin
indeed slows down fast inactivation (Supplementary Fig. 2b).
Subsequent testing on the BgNav1/Kv2.1 chimeras revealed that
BomIV does not affect WT Kv2.1 or the domain I, II, and III
constructs. However, a dramatic toxin-induced inhibition of the
domain IV chimera corroborates the importance of this particular
voltage-sensing domain in toxin binding and BgNav1 fast
inactivation (Supplementary Fig. 2b).
We next investigated whether rDc1a modulates the activity of
any of the four BgNav1/Kv2.1 paddle chimeras and found that
1 mM rDc1a exclusively interacts with the domain II construct
whereas domains I, III, IV, and WT Kv2.1 are unaffected (Fig. 4e,
Supplementary Fig. 2c). This result suggests that rDc1a
speciﬁcally targets the domain II voltage sensor within BgNav1
to inﬂuence channel opening.
rDc1a distinguishes between cockroach Nav1 channels. Since
the domain II paddle motif in BgNav1 (ref. 21) is identical to that
in PaNav1 (ref. 22), we expected a similar effect of rDc1a in
whole-cell patch-clamp recordings from American cockroach
dorsal unpaired median (DUM) neurons. Surprisingly, 1 mM
rDc1a had little effect on sodium current amplitude or kinetics in
DUM neurons as reﬂected in the threshold, or V1/2, of Nav
channel activation or the V1/2 of steady-state inactivation
measurements (Supplementary Fig. 3). Furthermore, there were
no signiﬁcant use-dependent effects on sodium current amplitude
or kinetics.
Due to the unexpectedly weak effects of 1 mM rDc1a on
voltage-dependent activation of P. americana DUM neurons
compared with BgNav1 channels from B. germanica, acute
toxicity assays were expanded to include both cockroach species
(Fig. 5a,b). Remarkably, these bioassays revealed lethal toxicity of
rDc1a in B. germanica compared with only mild, reversible effects
in P. americana. At doses up to 5 nmol g 1, rDc1a generated
only minor spastic contractions of the abdomen, some shaking
and evidence of reduced motor activity in P. americana. Even
though these effects were completely reversible, a very small
percentage of cockroaches did develop paralysis after 24 h (7±7%
knockdown, n¼ 3). One explanation for these observations may
be toxin binding to a subset of Nav channel splice variants53 or
the presence of endogenous pharmacologically active auxiliary
subunits54. Conversely, B. germanica underwent dose-dependent
ﬂaccid or contractile paralysis, and lethality was observed after
8 h at all doses tested (Fig. 5a). The KD50 and LD50 values at 24 h
post injection were 3.0±1.2 nmol g 1 and 4.2±3.4 nmol g 1
(n¼ 3), respectively. These observations suggest that residues
in regions outside of the domain II paddle motif may underlie
the remarkably different sensitivity of BgNav1 and PaNav1
to rDc1a.
The S1–S2 loop modulates Nav channel sensitivity to rDc1a.
Sequence alignment of BgNav1 with PaNav1 reveals a highly
conserved S1–S4 voltage sensor in domain II with only three
amino acid substitutions (Fig. 6a; Supplementary Fig. 4). Of
those, two residues in the S1–S2 loop are potentially accessible for
a peptide toxin applied from the extracellular environment
(His805 and Asp812 in BgNav1 which correspond to a Tyr and
Glu in PaNav1, respectively). On mutating these residues in
BgNav1 to their PaNav1 counterparts, the resulting BgNav1YE
construct functionally expressed in Xenopus oocytes with a
voltage-dependent activation V1/2 of  41.5±0.3mV and a
steady-state inactivation V1/2 of  56.4±0.2mV (Fig. 6b).
Unfortunately, a functional PaNav1 clone was unavailable to
undertake gain-of-function experiments. Strikingly, 100 nM
rDc1a was no longer sufﬁcient to open BgNav1YE whereas
this concentration generated large inward sodium currents
when applied to WT channels (Fig. 6c, inset). When surveying
higher concentrations of rDc1a, it becomes clear that
concentrations of more than 1 mM are required to achieve a
potentiation with BgNav1YE that is comparable to the WT
channel (EC50B65 nM; Fig. 6c). Although we cannot exclude the
possibility that rDc1a interacts with other PaNav1 domains at
such concentrations, administering high doses of the toxin is
indeed mildly toxic to P. americana (Fig. 5a,b). Thus, our
mutagenesis experiments have uncovered a novel region within
insect Nav channels that helps determine their sensitivity to
spider toxins. This locus contributes to the drastically reduced
sensitivity of the American cockroach to rDc1a from the venom
of the desert bush spider whereas its German counterpart is
highly susceptible.
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Discussion
The initial goal of this study was to explore the mechanism
underlying the efﬁcacy of Dc1a, a potent insecticidal peptide
toxin produced by desert bush spiders. To this end, we ﬁrst
produced recombinant rDc1a and determined its solution
structure using heteronuclear NMR (Figs 1 and 2). Next, we
tested rDc1a on the heterologously expressed German cockroach
channel BgNav1 and discovered that the toxin dramatically
promotes channel opening (Fig. 3). By taking advantage of the
portable nature of S3b–S4 paddle motifs within voltage-sensing
domains3,4,7,38, we demonstrated that such motifs also exist in
each of the four voltage-sensing domains of BgNav1, and that
rDc1a selectively interacts with the paddle motif in domain II, a
feature that it shares with an extensive list of animal toxins that
target this particular paddle motif3,4,12,55,56, albeit with a high
degree of insect selectivity (Fig. 4). Remarkably, our insect assays
revealed that German cockroaches are highly susceptible to rDc1a
whereas the closely related American cockroach is virtually
insensitive despite the fact that the domain II paddle motif in
BgNav1 is identical to that in PaNav1 (Fig. 5; Supplementary
Fig. 4). To elucidate the machinery responsible for this
discrepancy, we mutated two residues in the S1–S2 loop that
differ between BgNav1 and PaNav1 (His805 and Asp812) and
found that the susceptibility of the resulting BgNav1YE construct
to rDc1a is dramatically reduced (Fig. 6). Interestingly,
mammalian Nav channel isoforms possess a Tyr and Ser at the
corresponding positions, which presumably contributes to their
insensitivity to rDc1a; however, their domain II paddle motif
differs as well (Supplementary Fig. 4).
It is interesting to consider potential mechanisms that may
underlie the insect-family speciﬁcity of rDc1a. For example, the
b3–b4 hairpin (Fig. 2b) often houses the pharmacophore in
spider ICK toxins that target voltage-gated ion channels57, but the
unusual architecture of rDc1a (Fig. 2c) and its unique ability to
dramatically promote opening of insect Nav channels (Fig. 3)
suggests that it might interact with the voltage sensors of these
channels in a unique manner. As such, the domain II S1–S2 loop
may play a role in positioning the toxin into a water-ﬁlled cavity
adjacent to the S3–S4 paddle motif58, thereby placing particular
toxin residues in strategic positions to stabilize the domain II
voltage sensor in an activated position. This hypothesis is
strengthened by the observation that the substitution of two
residues in the domain II S1–S2 loop within mammalian Nav1.2
channels decreases sensitivity to the functionally related
b-scorpion toxin CssIV by a factor of four59. Another possible
mechanism is that rDc1a binding to the domain II S1–S2 loop in
BgNav1 allosterically inﬂuences channel opening. Such a
hypothesis was postulated when a domain III S1 splice variant
of BgNav1 revealed an increased susceptibility to the insect-
selective b-scorpion toxin Lqh-dprIT3 (ref. 60). However, one
caveat is that a depolarizing prepulse is needed to potentiate the
maximal effect of CssIV and Lqh-dprIT3 (refs 49,50). Similar to
the structurally unrelated spider toxin Magi5 which activates rat
Nav1.2 channels by binding to the domain II voltage sensor61,
rDc1a does not require such a prepulse.
In summary, the current study provides a molecular explana-
tion for the remarkable insect selectivity of Dc1a, the most potent
insecticidal toxin identiﬁed in the venom of the desert bush
spider. Moreover, we have uncovered a novel toxin receptor site
within insect Nav channels that provides a new framework for the
design of molecules capable of targeting speciﬁc insect families.
This knowledge may be used in the future to develop insecticides
that target speciﬁc insect pests without affecting beneﬁcial insects
or endangering human health.
Methods
Chemicals. All chemicals were purchased from Sigma-Aldrich Australia (Castle
Hill, NSW, Australia), Sigma-Aldrich USA (St Louis, MO, USA), or Merck
Chemicals (Kilsyth, Victoria, Australia) with the exception of IPTG and strepto-
mycin (Life Technologies, Victoria, Australia), tetrodotoxin (Alomone Labs, Israel),
and high-performance liquid chromatography (HPLC)-grade acetonitrile (RCI
Labscan, Bangkok, Thailand). 13C6-glucose and 15NH4Cl were from Sigma-Aldrich
Australia. Recombinant His6-TEV protease (EC 3.4.22.44) was produced in-house
using a published protocol62.
Production of recombinant rDc1a. A synthetic gene encoding Dc1a, with codons
optimized for expression in Escherichia coli, was produced and cloned into a
variant of the pLIC-MBP expression vector by GeneArt (Invitrogen, Regensburg,
Germany). This vector (pLIC-NSB3) encodes a MalE signal sequence for
periplasmic export, a His6 tag for afﬁnity puriﬁcation, a maltose-binding protein
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(See Supplementary Fig. 4 for more details). In the extracellular loop connecting S1 to S2, all residues are identical except the H805Y and D812E
substitutions (grey background). The T797M substitution within S1 is unlikely to be toxin-accessible. (b) Gating properties of the mutant BgNav1
YE channel.
Shown are the normalized deduced conductance (G)–voltage (ﬁlled circles) (G/Gmax) and steady-state inactivation (open circles; I/Imax) relationships.
Descriptive values can be found in the Results section. Currents were elicited by 5 mV step depolarizations from a holding voltage of 90mV or
 100mV, respectively. n¼ 3–5, and error bars represent s.e.m. (c) Afﬁnity measure for rDc1a interaction with BgNav1YE (red) compared with WT BgNav1
(grey). Concentration dependence for toxin-induced current potentiation (as determined by shifts in V1/2) is shown. It is clear that alterations in
channel opening on rDc1a exposure are less pronounced with the BgNav1
YE mutant when compared with WT BgNav1. n¼ 5 and error bars represent
s.e.m. Inset shows premature channel opening after addition of 100nM rDc1a to WT BgNav1 (grey) whereas BgNav1
YE is not yet affected (red).
Current traces were evoked by a 50-ms depolarization to  55mV from a holding potential of 90mV.
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(MBP) fusion tag to aid solubility, and a tobacco etch virus (TEV) protease
recognition site directly preceding the codon-optimized Dc1a gene23. The plasmid
encoding Dc1a was transformed into E. coli strain BL21(lDE3) for recombinant
toxin production. Protein expression and puriﬁcation were performed as described
previously30 with minor modiﬁcations. In summary, cultures were grown in Luria-
Bertani broth at 37 C with shaking. Toxin gene expression was induced with
500mM IPTG at an OD600 of 1.0–1.1, then cells were grown at 20 C for a further
12 h before collecting by centrifugation for 15min at 10,500 g. For production of
uniformly 13C/15N-labelled rDc1a, cultures were grown in minimal medium
supplemented with 13C6-glucose and 15NH4Cl as the sole carbon and nitrogen
sources, respectively. The His6-MBP-toxin fusion protein was extracted from the
bacterial periplasm by cell disruption at 27 kPa (TS Series Cell Disrupter, Constant
Systems Ltd, Northants, UK), and then captured by passing the extract (buffered in
40mM Tris, 450mM NaCl, pH 8.0) over Ni-NTA Superﬂow resin (Qiagen,
Chadstone, Australia). Proteins bound non-speciﬁcally were removed by washing
with 10mM imidazole then the fusion protein was eluted with 600mM imidazole.
The eluted fusion protein was concentrated to 10ml and the buffer was exchanged
to remove imidazole. Reduced and oxidized glutathione were then added to a ﬁnal
concentration of 0.6mM and 0.4mM, respectively, to maintain TEV protease
activity and promote folding of the protein. Approximately, 100 mg of His6-tagged
TEV protease was added per mg of rDc1a, then the cleavage reaction was allowed
to proceed at room temperature for 12 h. The cleaved His6-MBP and His6-TEV
were precipitated by addition of 1% triﬂuoroacetic acid (TFA), then the sample was
centrifuged at 16,000 g. The supernatant was ﬁltered using a 0.45-mm syringe ﬁlter
(Millipore, MA, USA) and subjected to further puriﬁcation using RP-HPLC.
RP-HPLC was performed on a Vydac C18 column (250 4.6mm, particle size
5 mm) using a ﬂow rate of 1mlmin 1 and a gradient of 20–45% Solvent B (0.043%
TFA in 90% acetonitrile) in Solvent A (0.05% TFA in water) over 30min. rDc1a
contains a non-native N-terminal serine residue (a vestige of the TEV protease
cleavage site), making it one residue longer than native Dc1a.
Mass spectrometry. Toxin masses were conﬁrmed by MALDI-TOF mass
spectrometry using a Model 4700 Proteomics Bioanalyser (Applied Biosystems,
CA, USA). RP-HPLC fractions were mixed (1:1 v-v) with a-cyano-4
hydroxycinnamic acid matrix (5mgml 1 in 50/50 acetonitrile/H2O) and
MALDI-TOF spectra were acquired in positive reﬂector mode. All reported
masses are for monoisotopic [MþH]þ ions.
Structure determination. Several buffer conditions were screened to optimize
quality of NMR data recorded for rDc1a, including 20mM phosphate buffer, pH
6.0; 20mM MES buffer, pH 6.0 and 20mM acetate buffer pH 5.0. Initial buffer
screening revealed the acetate buffer, pH 5.0 was optimal for acquisition of NMR
data. Recombinant 15N/13C-labelled rDc1a was dissolved in 20mM acetate buffer,
pH 5.0 to a ﬁnal concentration of 350 mM. 5% 2H2O was added, then the sample
was ﬁltered using a low-protein-binding Ultrafree-MC centrifugal ﬁlter (0.22 mm
pore size; Millipore, MA, USA) and 300ml was added to a susceptibility matched
5mm outer-diameter microtube (Shigemi Inc., Japan). NMR data were acquired at
25 C using a 900MHz NMR spectrometer (Bruker BioSpin, Germany) equipped
with a cryogenically cooled probe. 3D and 4D data used for resonance assignments
were acquired using non-uniform sampling. Sampling schedules that approximated
the signal decay in each indirect dimension were generated using sched3D26.
Non-uniform sampling data were processed using the Rowland NMR toolkit
(www.rowland.org/rnmrtk/toolkit.html) and maximum entropy parameters
were automatically selected as previously described63. 13C- and 15N-edited
HSQC-NOESY (mixing time of 200ms) experiments were acquired using uniform
sampling. All experiments were acquired in H2O containing 5% 2H2O. Dihedral
angles (f, c) were derived from TALOSþ chemical shift analysis64 and the
restraint range for structure calculations was set to twice the estimated s.d. The
Gly9–Pro10 and Arg36–Pro37 peptide bond was determined to be in the trans
conformation on the basis of characteristic NOEs and the Ca and Cb chemical
shifts of Pro residues. NOESY spectra were manually peak picked and integrated,
then peak lists were automatically assigned, distance restraints extracted and an
ensemble of structures calculated using the torsion angle dynamics package
CYANA 3.0 (ref. 25). The tolerances used for CYANA 3.0 were 0.025 p.p.m. in the
direct 1H dimension, 0.03 p.p.m. in the indirect 1H dimension and 0.3 p.p.m. for
the heteronucleus (13C/15N). During the automated NOESY assignment/structure
calculation process, CYANA assigned 92% of all NOESY crosspeaks (2,271 out
of 2,469).
Insecticidal assays. rDc1a was dissolved in insect saline and injected into the
ventro-lateral thoracic region of adult sheep blowﬂies (Lucilia cuprina;), adult
houseﬂies (M. domestica), adult American cockroaches (Periplaneta americana)
and adult German cockroaches (Blattella germanica)65. Injections were made using
a 1.0ml Terumo Insulin syringe (B-D Ultra-Fine, Terumo Medical Corporation,
Maryland, USA) with a ﬁxed 29G needle ﬁtted to an Arnold hand micro-applicator
(Burkard Manufacturing Co. Ltd., England). A maximum volume of 2 ml was
injected per L. cuprina, M. domestica and B. germanica and 5 ml for the larger
P. americana. Thereafter, ﬂies were individually housed in 2-ml tubes and provided
with 10% sucrose while cockroaches were housed in closed Petri dishes and
provided with dry food and water. The paralytic activity was then determined over
a 24-h period. For each acute toxicity assay up to fourteen doses of rDc1a (n¼ 10
insects per dose) and the appropriate control (insect saline; n¼ 10 insects) were
used. The assay was repeated three times. Median knockdown (KD50) and median
lethal (LD50) doses were calculated as described previously66 and averaged to
produce KD50 and LD50 values.
Electrophysiological measurements on DUM neurons. DUM neurons were
isolated from unsexed adult American cockroaches (P. americana) as described
previously30. Brieﬂy, terminal abdominal ganglia were removed and placed
in normal insect saline (NIS) containing (in mM): NaCl 180, KCl 3.1,
N-hydroxyethylpiperazine-N-ethanesulfonic acid (HEPES) 10 and D-glucose 20.
Ganglia were then incubated in 1mgml 1 collagenase (type IA) for 40min at
29 C. Following enzymatic treatment, ganglia were washed three times in NIS and
triturated through a ﬁre-polished Pasteur pipette. The resultant cell suspension was
then distributed onto 12-mm diameter glass coverslips pre-coated with 2mgml 1
concanavalin A (type IV). DUM neurons were maintained in NIS supplemented
with 5mM CaCl2, 4mM MgCl2, 5% foetal bovine serum and 1% penicillin and
streptomycin (Life Technologies, Victoria, Australia), and maintained at 29 C,
100% humidity. Ionic currents were recorded in voltage-clamp mode using the
whole-cell patch-clamp technique employing version 10.2 of the pCLAMP data
acquisition system (Molecular Devices, Sunnyvale, CA). Data were ﬁltered at
5–10 kHz with a low-pass Bessel ﬁlter with leakage and capacitive currents
subtracted using P-P/4 procedures. Digital sampling rates were set between 15 and
25 kHz depending on the length of the protocol. Single-use 0.8–2.5MO electrodes
were pulled from borosilicate glass and ﬁre-polished prior to current recordings.
Liquid junction potentials were calculated using JPCALC, and all data were
compensated for these values. Cells were bathed in external solution through a
continuous pressurized perfusion system at 1mlmin 1, while toxin solutions
were introduced via direct pressurized application via a perfusion needle at
B50 ml min 1 (Automate Scientiﬁc, San Francisco, CA). Control data were not
acquired until at least 20min after whole-cell conﬁguration was achieved to
eliminate the inﬂuence of initially fast time-dependent shifts in steady-state
inactivation resulting in NaV channel current (INa) rundown. All experiments were
performed at ambient temperature (20–23 C). To record INa, the external bath
solution contained (in mM): NaCl 80, CsCl 5, CaCl2 1.8, tetraethylammonium
chloride 50, 4-aminopyridine 5, HEPES 10, NiCl2 0.1, and CdCl2 1, adjusted to pH
7.4 with 1M NaOH. The pipette solution contained (in mM): NaCl 34, CsF 135,
MgCl2 1, HEPES 10, ethylene glycol-bis(2-aminoethylether)-N,N,N0 ,N0-tetraacetic
acid 5, and ATP-Na2 3, adjusted to pH 7.4 with 1M CsOH. To eliminate any
inﬂuence of differences in osmotic pressure, all internal and external solutions were
adjusted with sucrose to 400±5 mOsmol l 1. Experiments were rejected if there
were large leak currents or currents showed signs of poor space clamping.
Off-line data analysis was performed using Axograph X version 1.3 or Clampﬁt
10 (Molecular Devices, USA). Voltage–activation relationships were obtained by
measuring steady-state currents elicited by stepwise depolarizations of 5–10mV
from a holding potential of –90mV and calculating peak conductance (GNa) using
the following equation: G¼ INa/(Vm–Erev) where G is peak conductance, INa is
peak inward sodium current, Vm is the test potential and Erev is the reversal
potential. Reversal potentials were individually estimated for each data set67 by
ﬁtting the INa-V data with the following equation: INa¼ [1þ exp(–0.03937 z
 (Vm–V1/2))] 1 g (Vm–Vrev) where z is the apparent gating charge, g is a
factor related to the number of channels contributing to the macroscopic whole-
cell INa, Vm is equal to the voltage potential of the pulse, and V1/2 is the voltage at
half-maximal activation. The normalized conductance was ﬁtted to a two-state
Boltzmann function of the form: G/Gmax¼ 1/(1þ exp((–0.3937 z (Vm–V1/2)))
where G, z, Vm and V1/2 have the same meaning. The voltage dependence of
steady-state Nav channel inactivation (hN/V) data were normalized to the
maximum peak current in the control or maximum peak current and ﬁtted using
the following Boltzmann equation: hN¼A/(1þ exp((Vm–V1/2)/k)) where A is the
fraction of control maximal peak INa (value of 1.0 under control conditions), V1/2 is
the midpoint of steady-state inactivation, k is the slope factor and Vm is the
prepulse voltage. The rate of recovery from fast inactivation data were ﬁtted to the
following single-exponential function: I/Imax¼ 1 exp(–t/t) where t is the time
constant of current recovery. Dose–response curves to determine LD50 and KD50
values were ﬁtted using the following form of the logistic equation: y¼ 1/(1þ [x]/
Dose50)nH where x is the toxin dose, nH the Hill coefﬁcient (slope parameter) and
Dose50 is the median inhibitory dose causing lethality (LD50) or knockdown
(KD50). Non-linear curve-ﬁtting of data were performed using GraphPad Prism
version 6.00c for Macintosh (GraphPad Software, San Diego) or Origin 8
(OriginLab, MA, USA). Comparisons of two sample means were made using a
paired Student’s t-test and differences were considered to be signiﬁcant if Po0.05.
All data are presented as mean±s.e.m. of n independent experiments.
Electrophysiological measurements on oocytes. Chimeras and channel mutants
were generated using sequential PCRs with Kv2.1D7 (ref. 68) and BgNav1 (ref. 21)
as templates. The Kv2.1D7 construct contains seven point mutations in the outer
vestibule, rendering the channel sensitive to agitoxin-2. The DNA sequence of all
constructs and mutants was conﬁrmed by automated DNA sequencing and cRNA
was synthesized using T7 polymerase (mMessage mMachine kit, Life Technologies,
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USA) after linearizing the DNA with appropriate restriction enzymes. Channel
constructs including hNav1.1–hNav1.7 and hERG were expressed in Xenopus
oocytes by themselves or, in the case of BgNav1, together with the TipE subunit69
(1:5 molar ratio), and studied following 1–2 days incubation after cRNA injection
(incubated at 17 C in 96mM NaCl, 2mM KCl, 5mM HEPES, 1mM MgCl2 and
1.8mM CaCl2, 50mgml 1 gentamycin, pH 7.6 with NaOH) using two-electrode
voltage-clamp recording techniques (OC-725C, Warner Instruments, USA) with a
150-ml recording chamber. Data were ﬁltered at 4 kHz and digitized at 20 kHz using
pClamp software (Molecular Devices, USA). Microelectrode resistances were
0.5–1MO when ﬁlled with 3M KCl. For most Kv channel experiments, the external
recording solution contained (in mM): 50 KCl, 50 NaCl, 5 HEPES, 1 MgCl2, 0.3
CaCl2, pH 7.6 with NaOH. For Nav channel experiments, the external recording
solution contained (in mM): 96 NaCl, 2 KCl, 5 HEPES, 1 MgCl2 and 1.8 CaCl2, pH
7.6 with NaOH. All experiments were performed at room temperature (B22 C).
Leak and background conductances, identiﬁed by blocking the channel with
agitoxin-2 (Alomone labs) or tetrodotoxin, were subtracted for most of the Kv or
BgNav1 currents shown.
Voltage–activation relationships were obtained by measuring tail currents for
Kv channels or steady-state currents and calculating conductance for Nav channels.
Protocols for other measurements are described in the ﬁgure legends. After
addition of the toxin to the recording chamber, the equilibration between the toxin
and the channel was monitored using weak depolarizations elicited at 5-s intervals.
For all channels, we recorded voltage–activation relationships in the absence and
presence of toxin. Off-line data analysis was performed using Clampﬁt 10 (Molecular
Devices, USA), Origin 8.0 (Originlab) and Microsoft Solver (Microsoft Excel).
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Viruses, microorganisms and fungi that cause diseases to insects have been studied and 
evaluated for many years, but very few of them are widely used as a bioinsecticdes.  The reasons 
for this failure are poor efficacy, inconsistency in performance and inability to compete with 
chemical insecticides140. Better understanding of fungal pathogenesis in insects and the 
introduction of genetic manipulation techniques is allowing construction of transgenic strains with 
improved efficacy. Most studies have utilized entomopathogenic fungi themselves as a source of 
genes to improve efficacy141. For example, insertion of a transgene encoding cuticle degrading 
protease Pr1 into the genome of Metarhizium anisopliae resulted in a 25% improvement in LT50 
(time to kill 50% of test insects) towards Manduca sexta as compared to the wild type strain142. In 
another example, overexpression of chitinase CHIT1, which is capable of degrading chitin in the 
insect cuticle, improved the virulence of Beauveria bassiana by 23%143.  
 
Surprisingly, in spite of their potential for improving the efficacy of entompathogens, insecticidal 
peptides have not been widely exploited141. However, it was recently demonstrated that 
engineering M. anisopliae to express AaIT, a NaV channel blocker from scorpion venom, improved 
fungal performance against the lepidopteran Manduca sexta and the malaria vector Anopheles 
gambiae by 22-fold and 9-fold, respectively117. Toxins from Australian funnel-web spiders found to 
improve performance even more than AaIT in this system (GF King and R St Leger, unpublished 
data). Hence, we decided to examine whether the efficacy of Metarhizium strains against 
mosquitoes and triatomid bugs could be significantly improved by engineering then to express 
highly insecticidal spider-venom peptides (ISVPs). 
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6.1 Metarhizium Strain selection  
 
There are >2000 Metarhizium strains available through the ARS collection of Entomopathogenic 
Fungal Cultures (ARSEF). Metarhizium strains generally have a broad host range, with the primary 
exception being M. acridum which is specific to acridids, To date, it has not proved possible to 
isolate Metarhizium strains with activity wholly restricted to mosquitoes (dipterans) or tritomid bugs 
(hemipterans)106. After an extensive search of the ARSEF catalogue and experimental validation, 
we selected M. anisopliae-1548 for triatomid bugs. M. anisopliae-1630 which also known as M. 
anisopliae var. anisopliae (Mestch.) Sorokin. This strain was originally isolated by Dr N. Maniania 
in 1989 from tsetse fly near Kendu Bay, western Kenya144. M. anisopliae-1548 was isolated from 
the adult black rice bug, Scontinophara coarctata (Hemiptera) in 1984 at Arbor Lan, Palawan, 
Philippines. These wild-type strains were acquired from ARSEF. 
 
6.2 ISVP selection for Metrhizium genetic engineering  
 
 
An efficient E. coli periplasmic expression system was developed to produce sufficient amount of 
ISVPs for insecticidal and functional bioassays. Based on the blowfly toxicity assays described in 
Chapter 2, we shortlisted five ISVPs for engineering into Metarhizium, namely the NaV channel 
blocker U2-CUTX-As1a (As1a), the KCa/CaV blocker ω/κ-hexatoxin-Hv1a (Hybrid), the NaV channel 
activator µ-DGTX-Dc1a (Dc1a), the CaV channel blocker ω-hexatoxin-Hv1a (Hv1a), and U1-AGTX-
Ta1a (Ta1a), whose molecular target remains to be determined. In addition, the scorpion 
neurotoxin AaIT was chosen as a positive control for comparison with the five ISVPs.  
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6.3 Material and Methods  
 
6.3.1 Vector construction  
 
Vector pPK2-bar-GFP-pMCL1 was kindly provided by Prof. Raymond St Leger, University of 
Maryland, USA. A two-point mutation was performed on this vector to enable subcloning of 
synthetic IVSP genes using AvrII and EcoRV restriction sites.  Synthetic genes encoding the 
selected ISVPs (i.e., Hybrid, Hv1a, As1a, Ta1a, and Dc1a), with codons optimised for expression 
in Metarhizium, were produced and cloned into a variant of pPK2-bar-GFP-pMCL1 vector in order 
to produce the ISVP-encoding vectors pPK2-bar-GFP-pMCL1-Hybrid, pPK2-bar-GFP-pMCL1-
Hv1a, pPK2-bar-GFP-pMCL1-As1a, pPK2-bar-GFP-pMCL1-Ta1a, pPK2-bar-GFP-pMCL1-Dc1a 
and pPK2-bar-GFP-pMCL1-AaIT. The IVSP genes are linked to a pMCL1 promoter in order to 
target their expression to the hemocoel of infected insects. Co-expression of GFP enables 
verification of the specificity of this promoter, while the herbicide gene and kanamycin resistance 
genes provide selective growth of transformants (See Figure 6.1).   
 
 
 
Figure 6.1: Map of the vector pPK2-bar-GFP-pMCL1-Hybrid. The construct contains a herbicide resistance gene 
(bar), a kanamycin resistance gene, and it encodes GFP (green fluorescent protein) in addition to the Hybrid IVSP. The 
AvrII and EcoRV restriction sites  were used for subcloning IVSP genes.  
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6.3.2 Metarhizium transformation 
 
 
Metarhizium strains were transformed using Agrobacterium tumefaciens strain AGL-1 harbouring 
the binary vector pPK2-bar-GFP-pMCL1 (AGL1::pPK2-bar-GFP-pMCL1) using a protocol 
described previously145 with minor  modifications. In summary, an AGL1::pPK2-bar-GFP-pMCL1-
ISVP colony from a 2–3 day old plate was inoculated into 10 ml of liquid broth (LB) medium 
containing 50 µg/ml kanamycin, followed by incubation at 270C for 16–20 h under constant 
agitation (250 rpm). Picked colonies were tested for the presence of the gfp gene by performing 
PCR using gfp primers. Once an OD600 of 0.4–0.8 was attained, the liquid culture was diluted to an 
OD600 of 0.15 with induction medium containing 200 µM acetosyringone (AS, a virulence gene 
inducer) (IMAS solution; Appendix 6.1) and then re-incubated at 270C for 4–5 h (OD600 ~0.4–0.8) 
under constant agitation (250 rpm). Meanwhile Metarhizium conidia from a 12-day-old plate were 
harvested into 5 ml of 0.05% sterile Triton-X (Triton-X helps to separate spores). The mixture was 
vortexed for 2 min then filtered through sterile glass wool to remove mycelial mass. The conidia 
concentration was calculated using a haemocytometer (Reichert Bright-Line, USA) and readjusted 
to a final concentration of 1×106 conidia/ml with IMAS solution. 100 µl of this conidial suspension 
was mixed with an equal volume of AGL1::pPK2-bar-GFP-pMCL1-ISVP cells (OD600 ~ 0.4–0.8) by 
gentle inversion and the mixture was spread evenly on black filter paper (autoclaved Whatman 
0.18mm thickness) deposited onto freshly poured IMAS plates (Appendix A). All steps were 
performed under sterile conditions. 
 
After 2 days of co-cultivation at 27 °C, the black filter paper was transformed onto freshly poured 
M-100 plates (Appendix A) containing 400 µg/ml cefotaxime and 200 µg/ml glufosinate-ammonium 
PESTANAL (phosphinothricin, PPT). Cefotaxime was used to kill the remaining Agrobacterium 
cells and the PPT was used as a herbicide-selective agent. After 1 day incubation at 27 °C, the 
black filter paper was overlaid with freshly prepared M-100 agar containing 200 µg/ml PPT and the 
plates were incubated again at 27 °C. Putative recombinants started to become visible after 5–6 
days and were collected every day or so until the plates were fully covered and no more individual 
recombinants could be picked up. Recombinant colonies were transferred to M-100 plates and 
grown for 1 week. The 1-week-old colonies, which had bright fluorescence, were selected for 
further culturing on Potato Dextrose Agar (PDA) plates. As a positive control, the same 
Metarhizium strain was transformed with AGL1::pPK2-bar-GFP-pMCL1 without using the selective 
agent PPT. This control indicated that the fungus is viable on the medium used for transformation 
(IMAS and M-100). As a negative control, the same Metarhizium strain was transformed with 100 
µl IMAS solution instead of AGL1::pPK2-bar-GFP-pMCL1. This control indicated that only 
transformed cells carrying the PPT resistance gene (bar) could grow on the selection plates (M-
100 + 200 µg/ml PPT). Methods for all chemicals and medium plates used for transformation are 
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detailed in Appendix A. Basic spore viability and germination test was conducted for all transgenic 
Metarhizium strains by incubating spore mix on Teflon coated slides for 48 h at 300C.  Germination 
of transgenic Metarhizium was compared with wild type strains. The colonies of transgenic 
Metarhizium, which produced equal amount of spores as of wild type strains, were preserved and 
used for further culturing.  
 
6.3.3 Transgenic Metarhizium genomic DNA extraction  
 
In order to validate the presence of ISVP genes in the Metarhizium genome, genomic DNA 
extraction was performed. The extraction procedure was based on a protocol previously 
described146 with few changes. In summary, a scoop of Metarhizium transformant was transferred 
into a sterile eppendorf tube containing 500 µl of fungal DNA extraction buffer [0.2 M TrisCl (pH 
7.5) + 0.5 M NaCl + 10 mM EDTA (pH 8.0) + 1% SDS]. A micro-homogeniser (Thomas Scientific, 
USA) was used to disrupt the cells. To this cell lysate, 500 µl of phenol-chloroform-isoamylalcohol 
(25:24:1) was added, then the mixture was vortexed for 5 min at room temperature (RT). The 
mixture was then centrifuged at RT/10,000 rpm for 10 min, and the aqueous top layer (essentially 
containing DNA) transferred to new sterile eppendorf tube. Chloroform (500 µl) was then added to 
remove any residual phenol, then the solution was centrifuged at RT/10,000 rpm for 10 min. 10 µl 
of RNase solution was added then the mixture was incubated at 370C for 1 h to degrade RNA. 500 
µl of phenol-chloroform-isoamylalcohol was added to separate degraded RNA from DNA, then the 
solution was centrifuged at RT/10,000 rpm for 10 min and the aqueous top layer transferred to new 
sterile eppendorf tube. 500 µl of 100% ethanol was added and mixed by gentle inversion to 
precipitate DNA. The sample was then centrifuged at RT/12000 rpm for 10 min, then the tube was 
decanted to remove the ethanol and the remaining pellet was dissolved in ultra pure water. This 
genomic DNA was used as a template for PCR. PCR products from each of the transformants 
(M1630-As1a, M1630-Dc1a, M1630-Ta1a, M1630-Hv1a, M1630-Hybrid, M1548-As1a, M1548-
Dc1a, M1548-Ta1a, M1548-Hv1a, M1548-Hybrid) were electrophoresed on agarose gel; DNA 
bands were excised and sequenced to confirm the presence of ISVP transgenes in transformed 
Metarhizium strains.  The primers used in this study and their respective usage are summarised in 
Table 6.2. 
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Table 6.1: Primers used in this study and their respective usage. 
 
Primers Sequences Usage of Primers 
ISVP-5 TAA TTC GTT CCT GGC TCA AAT TCT TTT C To amplify ISVPs present in 
genomic DNA of transformed 
Metarhizium ISVP-3 TCA AGC TGT TTG ATG ATT TCA GTA ACG 
GFP-5 GGATCCTTACTTGTACAGCTCGTCCA To amplifyi GFP in transformed 
Agrobacterium colony GFP-3 CTCAGAATGGTGAGCAAGGGCGAG 
ISVP-qPCR-5 GTTCTCGCCCTTT CGGGCTTG To detect ISVP gene 
expression 
ISVP-qPCR-3 ATCTCGGTGACGGGCAGGAC 
GPD-qPCR-5 
 CGATGTCATCTCCAACGCTTCCTGC 
 
To detect GPD gene 
expression 
GPD-qPCR-3 TTCTGGGTGGCGGTGTAGGAG  
 
6.3.4 Characterization of expression of ISVP’s in Metarhizium 
 
The expressions of ISVP’s in Metarhizium were determined with qPCR as described previously117 
with minor modifications. Transformed Metarhizium strains (M1630-As1a, M1630-Dc1a, M1630-
Ta1a, M1630-Hv1a, M1630-AaIT and M1630-Hybrid) were cultured in Sabouraud dextrose broth 
(SDB) for 2 days. The grown mycelial inoculums for each strain from SDB cultures were incubated 
with M. sexta hemolymph at 27 0C for 2 hours. Same amount of mycelia were also collected before 
incubation and used as a control.  To extract RNA, mycelium was separated from hemolymph and 
total RNA was isolated using the RNeasy Mini Kit (Qiagen) and genomic DNA was eliminated with 
the RNAse free DNAse set (Qiagen). 1 ug of total RNA was used for cDNA synthesis 
(ThermoFisher Scientific), and 10 ng of cDNA was used for qPCR. GPD gene (glyceraldehyde-3-
phosphate dehydrogenase) was used as a reference.  qPCR was performed with the Maxima 
SYBR Green/ROX qPCR Master Mix (ThermoFisher Scientific) using a Lightcycler 480 (Roche, 
Indianapolis, IN). Each sample was tested in triplicate on a 96 well PCR plate.  Relative transcript 
levels of toxin gene versus the GPD gene (ΔCp) were calculated for each sample. The changes of 
the relative transcript levels in 2h versus 0h of hemolymph incubation were then calculated (ΔΔCp) 
for each toxin strains. 
 
6.3.5 Mosquitocidal Bioassay 
 
 
Spores from a 12-day-old plate of each transformed strain (M1630-As1a, M1630-Dc1a, M1630-
Ta1a, M1630-Hv1a, M1630-AaIT and M1630-Hybrid) and the wild-type strain (M1630-WT) were 
harvested into 5 ml of 0.01% sterile Tween-80, vortexed and filtered using glass wool to remove 
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the mycelial mass. The spore concentration was calculated using a haemocytometer (Reichert 
Bright-Line, USA) and readjusted to a final concentration of 1×106 spores/ml. 5 ml of this spore 
suspension was added to a sprayer (details) for application to test mosquitoes (See Figure 6.2). 
Fungi were applied by spraying spore suspensions onto cold (4 0C) anesthetized adult female 
mosquitoes (Anopheles gambiae). Briefly, mosquitoes were placed on filter paper in a Petri dish, 
which was kept on ice to maintain anaesthesia, then mosquitoes were sprayed with spore solution. 
A separate sprayer was used for each strain only once.  
 
 
Figure 6.2: Growth and sporulation of 
wild type and transgenic M. anisopliae-
1630 strains expressing selected ISVPs. 
The panel shows 12-day-old PDA plates of 
(a) transgenic M. anisopliae 1630-As1a; (b) 
transgenic M. anisopliae 1630-Ta1a; (c) 
transgenic M. anisopliae 1630-Hv1a; (d) 
transgenic M. anisopliae 1630-Dc1a; (e) 
transgenic M. anisopliae 1630-Hv1a; (f) 
transgenic M. anisopliae 1630-Hybrid and; 
(g) wild-type M. anisopliae 1630 strain. 
Panel (h) shows the sprayers used for 
mosquitocidal bioassays filled with spore 
solution (106 spores/ml) of wild type, 
transgenic strains and control (0.01% 
Tween-80) treatment.  
 
 
 
 
 
 
 
 
Twenty mosquitos were used for each treatment, and three replicates were performed. Each group 
of 20 mosquitoes was sprayed eight times with a suspension of 106 spores/ml from a distance of at 
least 1 foot. This technique delivers approximately 45 spores per mosquito147. In total, six 
transformed strains, namely M1630-As1a, M1630-Dc1a, M1630-Ta1a, M1630-Hv1a, M1630-
Hybrid, and M1630-AaIT, were assayed, with the wild-type isogenic strain also included for 
comparison. 0.01% Tween-80 treatment was used as a control. In order to test for synergistic 
effects, a combination experiment was performed in which 2 ml of 106 spores/ml of M1630-Dc1a 
was mixed with an equal amount of 106 spores/ml of M1630-Hybrid. The mixture was vortexed and 
sprayed on mosquitoes.  
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The treatment and control mosquitoes were provided 15% glucose diet (soaked into cotton balls) in 
a plastic cage (Figure 6.3A). The mosquito cages were designed to allow removal of dead 
mosquitoes during the course of treatment (Figure 6.3B). The mosquito cages were maintained at 
260C with 60% relative humidity. Mortality was recorded every 12 h. To confirm mortalities were 
due to Metarhizium infection, dead mosquitoes were transferred to a Petri dish containing a wet 
paper towel to provide humidity for fungal growth (Figure 6.3C). The mosquitoes that were killed by 
other factors were not considered for determination of LT50 values. The LT50 for all transgenic 
strains were calculated using the SPSS statistical package (IBM, USA). 
 
 
Figure 6.3: Mosquito bioassay. Panel A shows the treatment cages used for the bioassay. Cotton balls soaked in 15% 
glucose were provided. Panel B shows the design of the mosquito cage, which allowed removal of dead mosquitoes 
through a cage window covered with a rubber sheet to restrict flying of live mosquitoes. Panel C shows a Petri dish 
containing dead mosquitoes from one of the treatment protocols, with a wet paper towel providing humidity for fungal 
growth 
 
Mosquito blood feeding tendency was tested during the course of these experiments. The blood –
feeding experiments were conducted by inserting sweaty socks in treatment cages at every 24 h 
interval. Mosquitos those are not attracted towards socks are considered as they stopped blood 
feeding.  
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6.4 Results and Discussion  
 
6.4.1 Genetic transformation of Metarhizium  
 
Designing suitable genetic engineering methods always represents a challenge. Over the past few 
years, transformation methods such as electroporation, Agrobacterium mediated transformation, 
and biostatic transformation have been assessed for fungal transformation. All techniques need 
case-by-case optimization prior to application to fungal strains of interest148. Another important 
factor to be considered is selection of promoter to direct expression of the transgene of interest, in 
our case ISVP transgenes.    We selected the MCL1 (Metarhizium collagen-like-1) promoter, 
pMCL1, to direct expression of ISVPs to the insect hemolymph149. We optimized and employed 
Agrobacterium-mediated transformation using Agrobacterium tumefaciens strain AGL-1. ISVP 
transgenes were chemically synthesized with the MCL1 signal peptide to allow secretion and 
cloning in the common transfer plasmid pPK2-bar-GFP-pMCL1. The selected ISVP transgenes 
were individually cloned into M. anisopliae strain 1630 (mosquito strain) and M. anisopliae strain 
1548 (triatomid bug strain). Three colonies of each recombinant Metarhizium were preserved. PCR 
primers were designed to track the presence of ISVPs in the recombinant Metarhizium; DNA 
fragments from the PCR reactions were extracted from agarose gels and sequenced (See Figure 
6.4). The sequencing results confirmed the presence of ISVP transgenes in each of the 
transformed strains. 
 
Figure 6.4: Agarose gel showing PCR-based 
detection of ISVP transgenes in transformed 
M. anisopliae-1630. Lane 1, PCR product from 
M1630-As1a; Lane 2, PCR product from 
M1630-Dc1a; Lane 3, PCR product from 
M1630-Hv1a; Lane 4, PCR product from 
M1630-Hybrid; Lane 5, PCR product from 
M1630-Ta1a. IN each case, the size of the 
PCR product matches that expected for each 
IVSP transgene. Lane M contains DNA size 
markers, with the size in bp indicated.  
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6.4.2 ISVP gene expression is induced by insect hemolymph 
 
To confirm the ISVP genes in transgenic Metarhizium strains can be induced by insect 
hemolymph, qPCR was performed from samples collected before (0 hour) and 2 hours after 
incubation with M. saxta hemolymph. All 5 transgenic Metarhizium strains (M1630-As1a, M1630-
Ta1a, M1630-Dc1a, M1630-Hv1a, M1630-Hybrid, M1630-AaIT) had higher ISVP expression after 
2h incubation in hemolymph than before incubation (See Figure 6.5). Primers used in this study 
are listed in Table 6.1.  
 
Figure 6.5: Quantification of ISVPs in transgenic 
Metarhizium. qPCR analysis of transgenic Metarhizium revealed 
the ISVP expression is induced by Manduca hemolymph. After 2h 
incubation of transgenic strains in Manduca hemolymph, 
transcript levels of As1a is increased by 4.44 fold, Dc1a by 2.78 
fold, Hv1a by0.44 fold, Hybrid by 1.35 fold and Ta1a by 6.11 fold. 
 
 
 
 
 
6.4.3 Transgenic M. anisopliae-1630 is more virulent to mosquitos   
 
 
The virulence of each transformant was compared by calculating the median lethal time LT50 (i.e., 
the time taken to kill 50% of the test mosquito population). Each mosquito received ~45 spores147. 
The majority of the mosquitoes started dying from day 2 of the treatment. Metarhizium sporulated 
on >98% of the dead mosquitos under humid conditions, confirming that the reason for the death 
of mosquitos was fungal (Metarhizium) infection. When dead mosquitoes were observed under a 
fluorescence microscope, bright green fluorescence from co-expressed GFP was visible in the 
abdomen of the mosquitoes, confirming that the pMCL1 promoter was directing transgene 
expression to the insect hemolymph (see Figure 6.6, C&D). After 5–7 days of treatment, fungal 
growth was visible on treated mosquitoes whereas there was no fungal growth on control 
mosquitoes (See Figure 6.6, A&B). 
 
 All of the strains expressing ISVPs killed mosquitoes much faster than the isogenic wild-type 
strain. Expression of As1a, Ta1a, Dc1a, Hv1a, Hybrid or AaIT transgenes reduced the LT50 by 
32.8%, 33.40%, 56.30%, 48.5%, 52.2% and 41% respectively (See Figure 6.7). Expression of the 
Dc1a and Hybrid IVSPs caused mosquitoes to die significantly faster than expression of As1a, 
Ta1a, and AaIT. Metarhizium expressing As1a or Ta1a killed mosquitoes with similar speed. The 
LT50 values for each of the recombinant Metarhizium strains are listed in Table 6.2. All of the 
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recombinant Metarhizium strains showed a greater reduction in blood feeding than the wild-type 
strain. If mosquitoes do not blood feed they cannot transmit disease, and hence the reduction in 
blood feeding is just as important as the reduction in time it takes to kill mosquitoes.  
 
 
                             Table 6.2: Bioassay of transgenic M. anisopliae strains against A. gambiae. 
Treatment Strain Dose LT50 (Days ± STD) 
M1630-As1a 106 spores/ml 6.39 ± 0.27 
M1630-Ta1a 106 spores/ml 6.34 ± 0.13 
M1630-Dc1a 106 spores/ml 4.16 ± 0.21 
M1630-AaIT 106 spores/ml 5.61 ± 60 
M1630-ω-Hv1a 106 spores/ml 4.90 ±0.52 
M1630-ω/κ -Hv1a (Hybrid) 106 spores/ml 4.55 ± 0.80 
M1630-Wild type 106 spores/ml 9.52 ± 0.41 
M1630-Dc1a+M1630-Hybrid 106 spores/ml 3.82 ± 0.26 
 
 
 
  
Figure 6.6: Effect of transgenic Metarhizium on mosquitoes. Panel A shows a control mosquito without infection; 
Panel B shows an infected mosquito 7 days after treatment with transgenic Metarhizium expressing Dc1a; Panel C is a 
photo taken under white light of a mosquito 3 days after infection with transgenic Metarhizium expressing Dc1a; Panel D 
is the same mosquito shown in panel C, but the photo was taken using a fluorescence microscope. The green 
fluorescence from GFP is present only in the abdomen of mosquito, confirming that the pMCL1 promoter directs 
transgene expression to the insect hemolymph.  
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Figure 6.7: Bioassay of transgenic Metarhizium against mosquitoes (A. gambiae). The LT50 of each of the 
transgenic Metarhazium strains is significantly improved compared to the wild-type strain LT50 of 9.5 days.  A) The LT50 
of the M1630-As1a (green) is 6.4 days; B) LT50 of the M1630-AaIT (orange) is 5.6 days; C) LT50 of the M1630-Ta1a  
(purple) is 6.3 dyas; D) LT50 of the M1630-Hv1a (pink) is 4.9 days; E) LT50 of the M1630-Hybrid (cyan) is 4.6 days and F) 
LT50 of the M1630-Dc1a (red) is 4.2 days.  
 
Combined effect on blood feeding efficiency and killing potency of mosquito is significantly 
improved in transgenic Metarhizium strains. For example, at day 4, M1630-Dc1a knocked down > 
95% of test mosquitos and M1630-As1a, M1630-Ta1a, M1630-AaIT, M1630-Hybrid, M1630-Hv1a 
knocked down ~ 80% of test mosquitos compare to ~40% of mosquitos with WT strain. (See figure 
6.8)  
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Figure 6.8 Combined effects on blood feeding 
efficiency and killing potency of transgenic and 
wild type Metarhizium strains at day 4. Histogram 
illustrates percentage of total affected (mosquito died 
+ mosquito stop blood feeding) test mosquitos. 
M1630-Dc1a knocked down > 95% of test mosquitos 
and M1630-As1a, M1630-Ta1a, M1630-AaIT, M1630-
Hybrid, M1630-Hv1a knocked down ~ 80% of test 
mosquitos compare to only  ~40% of mosquitos with 
WT strain.  
 
 
 
 
As Dc1a targets NaV channels whereas the Hybrid toxin targets CaV and KCa channel, we decided 
to examine whether these two toxins might have synergistic effects. Thus, mosquitoes were 
sprayed with an equal quantity of the Metarhizium strains expressing Dc1a and Hybrid toxin; this 
combination reduced the LT50 to 3.8 days, which was lower than any of the single IVSP-expressing 
Metarhizium strains (See Figure 6.9 & Table 6.2). But, it is statistically not significant. In ideal case, 
it is important to expresses these two toxins in a single Metarhizium strain to confirm if they act 
synergistically to kill mosquitoes.   
 
 
Figure 6.9 Combined effect of M1630-Dc1a and 
M1630-Hybrid. Equal amount of M1630-Dc1a and 
M1630-Hybrid sprayed on mosquito resulted in LT50 of 
3.8 days which is lower than any single treatment with 
M1630-Hybrid (4.6 days) and M1630-Dc1a(4.2days). 
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6.4.4 Transgenic M. anisopliae -1548  
 
The bug specialist strain M. anisopliae-1548 was successfully transformed to express each of the 
selected ISVPs (i.e., As1a, Dc1a, Ta1a, Hv1a and Hybrid). Each transformed strain (M1548-As1a, 
M1548-Dc1a, M1548-Hv1a, M1548-Hybrid and M-1548-Ta1a) were grown on PDA plates and 
spores were preserved for bioassays (See Figure 6.10). Genomic DNA extraction and sequencing 
results confirmed the presence of ISVPs transgenes in each transgenic strain. In future 
experiments we aim to examine the efficacy of these transgenic strains against triatomid bugs in 
comparison to the wild-type isogenic M. anisopliae-1548 strain. 
                   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.10: Growth and sporulation of 
transgenic M. anisopliae-1548 strains 
expressing selected ISVPs. 12-day-old PDA 
plates showing growth of: (a) transgenic 
M. anisopliae 1548-As1a; (b) transgenic 
M. anisopliae 1548-Ta1a; (c) transgenic 
M. anisopliae 1548-Dc1a; (d) transgenic 
M. anisopliae 1548-Hv1a; and (e) transgenic 
M. anisopliae 1548-Hybrid  
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6.4.5 Recombinant Metarhizium as a bioinsecticide  
 
 
More than 1000 known species of entomopathogens are major mortality factors for insects. Some 
of these entomopathogens offer environmental advantages in addition to the ability to tackle insect 
populations that have become resistant to chemical insecticides. However, fungal pathogens have 
been underused because of their longer kill times compared to chemical insecticides and 
inconsistency in results140. In this study we significantly enhanced the virulence of Metarhizium 
strains by engineering them to express ISVPs. Although these transgenic strains need to pass 
stringent ecological laws and field trials, current data suggest that they will be safe under field 
conditions. The ISVPs are insect-selective and safe to humans and other vertebrates. Injection of 
high doses of these IVSPs into mice is non-toxic150, 151, 152.  Furthermore, expression of the ISVPs 
will be limited to the hemocoel of infected insects due to use of the insect-hemolymph specific 
promoter, pMCL1. This will restrict the release of ISVPs into the environment117.  
 
Despite the environmental safety of fungal entomopathogens, the cost of production and the 
requirement for high spore doses have limited their use on large-scale insect vector control 
programs. The recombinant ISVP-expressing Metarhizium strains produced in this study are more 
virulent than the wild-type strain, which reduces both the kill time and the effective dose. This 
means the infection rate would be increased and equivalent insect kill could be achieved with 
fewer spores, which translates into reduced costs.  
  
Even though the ISVPs we used have different molecular targets (NaV, CaV and KCa channels), 
they all increased fungal virulence. Moreover, a synergistic effect can be obtained with two 
Metarhizium strains expressing different toxins (Dc1a and Hybrid) with different molecular targets. 
This raises the possibility of engineering Metarhizium strains that express two or more ISVPs 
which, in addition to decreasing kill time and spore dose, is likely to reduce the development of 
target-site resistance since in order to become resistant insects would need to evolve resistance 
mutations on multiple molecular targets simultaneously153, 14.  
 
At present, commercially available fungal insecticidal products are mainly used as a preventive 
measure148. But, reduction in insect survival time and feeding damage increases possibility of 
applying transgenic Metarhizium as a primary treatment. Considering the scope of this study we 
tested transgenic Metarhizium only in mosquitoes. But, in theory, the same technique could be 
employed for other disease vectors and insect crop pests.  
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                     7              Summarizing	  Discussion  
 
7.1 Research findings    
 
The long-term goal of the research described in this thesis is to develop bioinsecticides to control 
vectors of human diseases, with a particular emphasis on malaria and Chagas disease. To this 
end, transgenes encoding insecticidal spider venom peptides (ISVPs) were used to improve the 
insecticidal potency of the entomopathogenic fungus M. anisopliae with a view to improving the 
potential of M. anisopliae as a commerically viable bioinsecticide.  
 
7.1.1 Recombinant ISVP production 
The first objective of this thesis was the recombinant production of ISVPs. This provided a means 
to produce sufficient amount of each ISVP for structural and functional studies. The multiple 
cysteine residues present in each of the ISVPs provided a particular challenge as they can form 
non-native disulfide bond connectivities154. As described in Chapter 2, an efficient E. coli 
recombinant expression system was developed to overcome these difficulties. The overall success 
rate using this system for disulfide rich peptide production is ~75%124. Here, however, we noted a 
slightly lower (~65%) success rate of ISVP expression (see Table 7.1). Throughout this project, 
expression conditions were systematically modified in an attempt to optimise the expression of the 
each ISVP. The failure of these extensive efforts for some ISVPs suggests that alternative peptide 
expression systems or chemical synthesis approaches need to be employed to produce the 
remaining ISVPs for further studies. Although solid-phase peptide synthesis offers a good 
alternative, a range of folding conditions typically need to be screened to enable formation of the 
correct native disulfide-bond connectivity and in some cases such screens prove fruitless in 
providing high yields of natively folded peptide155. Moreover, isotopic labelling of the peptide with 
15N and 13C for heteronuclear NMR is currently prohibitively expensive using chemical synthesis. 
Yeast expression systems have proven to be very successful for production of disulfide-rich venom 
peptides from snakes and scorpions156,157. While this may ultimately provide a good alternative 
approach for production of unlabelled ISVPs, the costs of 13C labelling for NMR studies remains 
high for yeast expression systems. 
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7.1.2 Insect bioassay of ISVPs  
The second objective of this thesis was to investigate the insecticidal activity of recombinantly 
produced ISVPs in mosquitoes and triatomine bugs. To achieve an unbiased comparison of the 
insecticidal potency of peptide toxins, it is very critical to test all compounds using the same 
experimental conditions (e.g., injection volume, dose of toxin, species of test insect, life stage of 
the test insect, injector used for injection, food provided to test insect etc.136). Even factors such as 
temperature and relative humidity at which the insect kept after toxin injection can have a 
significant impact on the outcomes158. The ISVPs studied here were previously tested using a wide 
range of test insects and experimental conditions. Thus it was imperative to assay the selected 
ISVPs under the same experimental conditions, in the same test species, in order to quantify their 
relative toxicities.  
 
As described in Chapter 2, seven of the 11 target ISVPs were produced in sufficient amounts to 
perform insecticidal assays. ISVPs were tested against sheep blowflies and then against female 
anopheline mosquitoes and triatomine bugs. Our unbiased comparisons of seven ISVPs indicated 
that the following toxins were the best candidates for engineering of toxin transgenes into 
Metarhizium: As1a, ω/κ-hexatoxin-Hv1a (Hybrid), Dc1a, Hv1a, and Ta1a. Outcome of insect 
bioassays are summarised in table 7.1. 
 
 
 
Table 7.1 Summary of the insect bioassays of selected ISVPs  
 
ISVPs LD50 Blowflies (L Cuprina) LD50 Mosquitoes (A. 
aegypti) 
LD50 Triatomine (R. prolixus) 
ω/κ -hexatoxin-Hv1a 259 ± 17 pmol/g 37.4 ± 9.7 pmol/g 15.8 ± 4.5 pmol/g 
ω-hexatoxin-Hv1a 278 ± 7 pmol/g 64.4 ± 3.5 pmol/g 47.4 ± 14.5 pmol/g 
κ-hexatoxin-Hv1c 463 ± 22.7 pmol/g              –              – 
U1-AGTX-Ta1a 198 ± 33 pmol/g              –              – 
µ-DGTX-Dc1a 231 ± 32 pmol/g              –              – 
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7.1.3 Mechanism of action of ISVPs  
 
Determining the mechanism of action of the five ISVPs selected for Metarhizium transformation 
was one of the priorities of this thesis. The molecular targets of ω/κ-hexatoxin-Hv1a (Hybrid)137 and 
ω-hexatoxin-Hv1a159 were previously determined. Thus, as described in Chapters 3, 4 and 5, we 
used electrophysiology to find the molecular targets of the remaining ISVPs. We used patch-clamp 
electrophysiological recordings of ion channel currents in dorsal unpaired median (DUM) neurons 
isolated from the terminal abdominal ganglion of the American cockroach Periplaneta americana 
and also using two-electrode voltage-clamp electrophysiology to examine the effect of some ISVPs 
on the German cockroach (Blattella germanica) NaV channel heterologously expressed in Xenopus 
oocytes. These experiments revealed that As1a and Sf1a blocks insect NaV channels whereas 
Dc1a is a potent activator of insect NaV channels. NaV channel block by As1a and Sf1a was 
voltage-independent. As1a appears to be a pore blocker that plugs the outer vestibule of the Nav 
channel and to a lesser extent acts on Cav channel. Sf1a appears to be selective Nav channel pore 
blocker. In striking contrast, Dc1a promotes opening of insect NaV channels by interacting with the 
domain II voltage sensor and shifting the voltage-dependence of activation to more negative 
potentials. The molecular target of Ta1a remains elusive (see Table 7.2), despite extensive testing 
against common ion channels targets. 
 
Knowing the molecular targets of the ISVPs allows exploration of the effect of combining ISVPs 
with different modes of action. For example, the preliminary data shown in Chapter 6 suggest that 
a synergistic effect could be obtained by engineering a Metarhizium strain that expressed two 
different ISVPs (Dc1a and Hybrid) with different molecular targets. In addition to decreasing the kill 
time and spore dose, it is likely that such synergistic combinations would substantially reduce the 
likelihood of the targeted insect pest developing target-site resistance, since the insects would 
need to evolve resistance mutations on multiple molecular targets simultaneously160,161.   
 
7.1.4 Structure determination of ISVPs  
As described in Chapters 3, 4 and 5, we employed NMR spectroscopy to determine high-resolution 
3D structures of selected ISVPs. For proteins smaller than 10 kDa, which includes the vast 
majority of venom polypeptides, NMR spectroscopy is the dominant approach for structure 
determination162. The E. coli-based recombinant protein expression system we used to produce 
the toxins allows facile incorporation of isotopic labels, introduced by expressing the peptide toxin 
in a defined minimal medium enriched with 15NH4Cl and 13C-glucose as the sole nitrogen and 
carbon sources, respectively. Thus, replacing these nuclei with stable and NMR-sensitive 13C and 
15N isotopes enabled the use of a wide variety of 3D/4D heteronuclear NMR experiments162. The 
3D structure of Hybrid, ω-Hv1a, κ-Hv1a, and Ta1a were previously determined. During the course 
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of this project we determined the 3D structure of As1a, Dc1a and Sf1a (See Table 7.2). The quality 
of the NMR structures can be compared in terms of precision and stereochemical quality. Based 
on the measurement of precision (RMSD values) and stereochemical quality (MolProbity score), 
the 3D structures of As1a, Sf1a and Dc1a rank as high-resolution structures162.  
 
 
 
Table 7.2 Summary of the outcomes of ISVP characterisation in this thesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
- no expression; ++ good expression of soluble peptide; +++ excellent expression of soluble peptide 
Toxin E. coli 
expression 
Yield of pure 
toxin 
High resolution 
3D structure 
Mode of action 
ω/κ -hexatoxin-
Hv1a 
Yes +++ Yes Cav & Kv blocker 
ω-hexatoxin-Hv1a Yes +++ Yes Cav blocker 
κ-hexatoxin-Hv1c Yes +++ Yes Kv blocker 
U1-AGTX-Ta1a Yes +++ Yes In progress 
µ-DGTX-Dc1a Yes ++ Yes Nav activator  
U2-CUTX-As1a Yes +++ Yes Nav blocker 
U2-SGTX-Sf1a Yes +++ Yes In progress 
µ-AGTX-Aa1d Yes (Multiple 
isomers) 
  - No Nav blocker 
U1-PLTX-Pt1a Yes (Multiple 
isomers 
  - No Unknown  
U1-CUTX-As1c Yes (Insoluble)   - No Unknown 
δ-CNTX-Pn1a Yes (Multiple 
isomers 
  - No Nav blocker 
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7.1.5 Metarhizium genetic engineering 
The key objective of this thesis was to express potent ISVPs in selected Metarhizium strains using 
genetic engineering techniques. We employed Agrobacterium-mediated transformation of 
Metarhizium using Agrobacterium tumefaciens strain AGL-1. As described in Chapter 6, we 
successfully transformed a panel of the most potent ISVPs (Hybrid, ω-Hv1a, As1a, Dc1a, Ta1a & 
AaIT) into Metarhizium strains suitable for infection of mosquitoes (M. anisopliae strain 1630) or 
triatomine bugs specialist (M. anisopliae strain 1548) using a specially designed construct pPK2-
bar-GFP-pMCL1. The highly expressed pMCL1 promoter was chosen as it specifically directs 
expression of ISVP to the insect hemolymph163. This genetic modification of M. anisopliae-1630 
reduced the time required for achieving mortality in mosquitoes. For example, genetically modified 
(GM) M. anisopliae-1630-Dc1a reduced the LT50 to ~4.1 days compare to ~9.5 days for wild-type 
M. anisopliae-1630 Future experiments will be aimed at determining the LC50 (concentration to kill 
50% of test population) for all GM M. anisopliae strains. Based on previous experience with GM 
Metarhizium expressing AaIT164 and Hybrid toxin (St. Leger & King, unpublished data), it is most 
likely that the LC50 values against mosquitoes for GM Metarhzium expressing ISVPs will be 20–30 
fold lower than wild-type strains.  
 
The major obstacles for widespread use of entomopathogenic fungi are, first, the time required to 
achieve insect mortality and second, the high cost in comparison to chemical insecticides. Here we 
found that increasing the virulence of GM Metarhizium resulted in a reduction in LT50 and, most 
likely, LC50 values. These factors will decrease the dose of Metarhizium required for effective 
mosquito control and thereby minimise the cost. 
 
Restricting ISVP expression to hemolymph has safety consideration. It will restrict release of ISVP 
in environment during saprophytic growth of the fungi163,164. GM fungi need to pass stringent 
environmental and ecological criteria to become a practical means of insect control. 
Entomopathogenic fungi strains have a wide host range (exception, M. acridum). So their effect on 
non-target insect host needs rigours risk benefit analysis. For example, though DDT is harmful to 
non-target insect species and humans, it is still used for endemic malaria control165. GM fungi have 
the potential to pass the existing stringent safety laws, but the major hurdle will be political and 
social resistance. Involving political and commercial establishment in educating people about GM 
fungus could help to improve social acceptance166. As there is increased demand for more 
effective and sustainable alternatives to conventional chemical insecticides, development of GM 
fungi that significantly reduce target insect populations and have no hazardous effect on the 
environment (ISVP expression specific to insect hemolymph) will gain social and regulatory 
acceptance.  
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Thus, the GM entomopathogenic fungi address the limitation of wild type entomopathogenic 
fungus (longer time and cost) and opens up the possibility of development of bioinsecticide.  
 
7.2 Future perspectives  
Although biological control of insects using entomopathogenic fungi is a well-established 
technology, it is only employed commercially on a large scale against agricultural insect pests; it is 
currently not used to control disease vectors such as mosquitoes and triatomine bugs. For 
example, in China and Brazil, more than 1 million hectares of cropland is treated annually with 
fungal biopesticide167. In Australia, Metarhizium based products are commonly used for locust 
control168. Thus, knowledge about implementation and production of fungal biopesticides for 
control of crop pests is available and this information will be useful for successful deployment of 
GM entomopathogenic fungi to control vectors of malaria and Chagas disease.  
 
7.2.1 Combining GM Metarhizium & insecticides  
A combination of pyrethroid insecticides, permethrin and entomopathogenic fungi (Metarhizium 
anisopliae or Beauveria bassiana) proved to be synergistic against highly pyrethroid-resistant 
strains of A. gambiae169. When used alone, Metarhizium or Beauveria took 9 days to cause 100% 
mortality, but when combined with permethrin  ~70% mortality was achieved in 4 days169. It would 
be informative to conduct similar studies with GM Metarhizium and panel of conventional 
insecticides against resistant strains of mosquitoes and triatomine bugs. 
7.2.2 GM Metarhizium expressing multiple ISVPs  
With established technology for genetic engineering of Metarhizium, it would be facile to produce 
GM Metarhizium expressing multiple ISVPs. Priority would be given to ISVPs with different 
molecular target in order to achieve synergistic effects. Expressing ISVPs with different molecular 
targets also has an advantage of reducing development of target-site resistance160. Further, 
peptides with anti-plasmodial properties could be considered for engineering in to Metarhizium 
along with ISVPs, which would provide dual action to control malaria at vector as well as parasite 
level.  
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7.2.3 GM Metarhizium to control agriculture pest  
 
In this thesis, GM Metarhizium was developed to control mosquitoes and triatomine bugs. But 
similar techniques could be employed to develop Metarhizium strains for targeting major 
agriculture pests. Although fungal bioinsecticdes have been used for decades, they claim only a 
small share of global pesticide market106. The main reason is the long time required to achieve 
mortality and it is expected that an increase in the market share will be proportional to reducing this 
time170. Engineering ISVP transgenes into Metarhizium strains that target insect pests could 
overcome this barrier by reducing the kill time.  
 
7.2.4 Optimizing fungal production and efficacy  
Optimization of fungal culture conditions such as temperature, culture medium and incubation time 
could enhance spore yield and spore quality171,172. One of the most important factors for successful 
field implementation of GM Metarhizium is the long-term effectiveness under field conditions. 
Several factors such as high temperature and UV-light can negatively affect spore shelf life and 
insecticidal activity173,174. Spore persistence can vary significantly among fungal strains and even 
between isolates of the same strains173. The fungal strains we used in this thesis (M. anisopliae-
1630 and M. anisopliae-1548) were selected on the basis of high virulence to mosquitoes and 
triatomine bugs, respectively. Extensive screening for more persistent fungal strains could be a 
valuable approach to improve long-term efficacy. Another option to enhance fungal persistence is 
genetic engineering of fungal strains to express highly efficient Halobacterium salinarum 
Cyclobutane Pyrimidine Dimers (CPD) photolyase. For example, expression of CPD photolyase 
increased photo repair > 30-fold in M. robertsii and B. bassiana. The transgenic strains were more 
resistant to sunlight and retained their virulence175. Long-lasting formulations have also been used 
to improve fungal spore tolerance to UV radiation and dryness due to high temperature176. These 
protective formulations include foam formulations177, oil-based suspension178, solvents with 
sunscreen adjuvants179 and photo-protective anionic dyes180. Microencapsulation techniques have 
also been explored to prolong fungal spore sustainability181. Thus, successful field implementation 
of fungal entomopathogens depends not only on the virulence of the fungus but also on its 
persistence and mass production efficiency; these factors remain to be explored in the context of 
the more virulent GM strains developed here. 
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7.2.5 Field trials of GM Metarhizium  
Evaluation of the efficacy of GM Metarhizium strains in the field under realistic environmental 
conditions will be the decisive step towards successful deployment of these bioinsecticides for 
insect vector control. Ambient temperature and relative humidity could both have a significant 
impact on fungal growth and virulence. Moreover, disease vectors (mosquitoes and triatomine 
bugs) can behave differently in different climates, which may affect their susceptibility to the 
fungus.  
 
Field trials take a long time and are expensive. Instead, a good starting point would be semi-field 
studies that provide near-natural realistic environmental conditions. For example, for mosquito 
trials, a malaria sphere could be created consisting of experimental huts (like traditional houses), 
sugar sources (plants, sugar baits), breeding sites (water in plastic containers) and natural climate 
conditions creating mosquito habitat141,182. For using GM Metarhizium as part of an integrated 
vector control (IVM) strategy, it will be important to test their combined impact with other 
insecticides.  
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7.3 Conclusion 
 
Overall, this thesis has contributed towards the development of entomopathogenic fungi for 
controlling vectors of human disease. Laboratory trials demonstrated that transgenic M. anisopliae-
1630 expressing ISVPs are significantly more virulent than the wild-type fungus, with drastically 
reduced LT50 values against malaria vectors. Moreover, in addition to reducing LT50, all GM 
M. anisopliae strains reduced blood-feeding frequency relative to wild-type fungus. The transgenic 
M. anisopliae-1630 strains expressing Dc1a and hybrid toxin stand out as the best strains in these 
trials. 
 
Based on studies with ISVPs alone (Chapter 6), we expect to achieve similar success with 
transgenic M. anisopliae-1548 strains we constructed that are targeted against triatomine bugs. 
Thus, it is anticipated that the results described in this thesis will serve as a useful guide for future 
experiments aimed at development of bioinsecticides for controlling other vectors of human 
diseases, such as tsetse flies and ticks. 
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Stock Solutions and Medium Plates  
 
  1) 2.5X MM salts for Induction Medium 
 
Salts 2.5X (1litre) 
KH2PO4 (Potassium phosphate monobasic) 3.625 g 
K2HPO4 (Potassium phosphate dibasic) 5.125 g 
NaCl  0.375 g 
MgSO4 (Magnesium sulfate anhydrous) 1.250 g 
CaCl2.2H2O (Calcium chloride dihydrate) 0.165 g 
FeSO4.7H2O  (ferrous sulfate) 0.0062 g 
(NH4)2SO4  (ammonium sulfate) 1.250 g 
  
 
2) 1 M MES Stock Solution (25X Buffer) 
Dissolve 19.52 g MES (2-(N-morpholino)ethanesulfonic acid) in 80ml dH2O. Adjust pH of the solution to 5.3 
with 5M KOH. Bring volume to 100 ml. Sterilize solution by filtering through 0.22um filter. Store in 9 ml 
aliquots at -200C.  
3) 5M KOH  
 Dissolve 7.013g KOH in dH2O. Bring final volume to 25 ml. 
 
4) 10mM Acetosyringone (AS) [50X Virulence Gene Inducer] 
Add 19.62 mg of AS to 10 ml of sterile water. Stir for 1 hour. Adjust the pH to 8.0 with 5 M KOH. Filter sterile 
and store in 5 ml aliquots at -200C  
 
5) M-100 Trace Element Solution  
 
Trace Element For 500 ml Solution 
H3BO3 30 mg 
MnCl2.4H2O 70 mg 
ZnCl2 200 mg 
Na2MoO4.2H2O 20 mg 
FeCl3.6H2O 50 mg 
CuSO4.5H2O 200 mg 
dH2O To 500 ml final volume 
 
 
 
 
 
 
 
 
 
 
6) M-100 Salt Solution  
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7) Induction Medium  
 
Ingredients For 200ml medium 
1X MM salts 80 ml of 2.5X stock 
10 mM Glucose/Dextrose 0.36 g 
0.5% Glycerol 1 ml 
dH2O  To 192 ml to final volume 
Autoclave. Cool to 500C and then add: 
40mM MES 
 
8 ml of 1 M stock solution 
 
Add AS (3 5-dimethoxy-4-hydroxyacetophenone) to liquid induction medium as needed just before use.   
 
8)Induction Medium plates  
Ingredients For 400ml medium 
1X MM salts 160 ml of 2.5X stock 
5 mM Glucose/Dextrose 0.36 g 
0.5% Glycerol 2ml 
dH2O  To 384 ml to final volume 
1.5% Agar 6 g 
Autoclave. Cool to 500C and then add 
40mM MES 
16 ml of 1 M stock solution 
 
9) Induction Medium Plates with 200uM Acetosyringone  
Make Induction Medium plate as mentioned above, but reduce dH2O to 376 ml and add 8 ml of 10mM AS 
after autoclaving and cooling the medium.   
 
10) M-100 Plates with 400ug/ml Cefotaxime and 200 ug/ml PPT   
 
Ingredients For 1 litre medium 
Chemicals For 1 Litre Solution 
KH2PO4 16g 
Na2SO4 4g 
KCl 8g 
MgSO4.7H2O 2g 
CaCl2 1g 
M-100 trace element 
solution 
8ml 
dH2O To 1 litre final volume 
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Glucose  10 g 
KNO3 3 g 
M-100 Salt Solution 62.5 ml 
dH20 To 1 litre final volume 
1.5% Agar 15 g 
 
After autoclaving and cooling the medium add cefotaxime to final concentration of 400ug/ml and PPT to final 
concentration of 200ug/ml 
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Abstract
Despite intensive control measures, insect pests cause enormous damage to crops and
stored grain. In addition, insects vector some of the world's most devastating human
diseases, including malaria, dengue and Chagas disease. Chemical insecticides remain
the dominant method of controlling insect pests but the arsenal of extant insecticides is
rapidly diminishing due to the evolution of resistance in pest species and a more dif-
ficult regulatory environment due to heightened concern about the potential adverse
impacts of chemical insecticides on human health and the environment. Along with
predatory beetles, spiders are the most successful insect predators on the planet and
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their venoms contain a diverse array of small, disulfide-rich insecticidal peptides. In addi-
tion to being potent and highly selective for insects, they collectively offer very diverse
pharmacology and should degrade to innocuous breakdown products in the field.
However, their major disadvantage is a low level of intrinsic oral activity. Consequently,
much research has been directed towards improving the oral activity of these peptide
toxins or, alternatively, obviating the oral activity problem altogether by incorporating
transgenes encoding the toxins into suitable biological delivery vehicles. Here, we dis-
cuss recent advances in both of these areas. We also discuss an approach that merges
the advantages of small-molecule and peptide-based insecticides, namely using the
pharmacophore of an insecticidal spider-venom peptide to rationally develop a
small-molecule mimetic that has improved oral activity, but retains activity for a novel
insecticide target.
1. INTRODUCTION
The human population is projected to reach to 9.3 billion by 2050
(Bloom, 2011). This expansion of the population will create enormous pres-
sure on food production since there is limited scope for increasing the
amount of cultivated land (Oerke, 2006). Despite intensive control mea-
sures, herbivorous insects reduce world crop yields by 10–14% (Oerke,
2006) and damage as much as 30% of stored grain (Boyer et al., 2012),
and hence their control is a key factor in determining food productivity.
Increases in human population density combined with global warming
and a dramatic escalation in international travel has also placed considerable
pressure on the public health sector to control the spread of insects that vec-
tor human diseases such as malaria, dengue and Chagas disease.
Unfortunately, the arsenal of chemical insecticides available to combat
insect pests is in rapid decline. This is largely due to the fact that most chem-
ical insecticides target a handful of enzymes, receptors and ion channels in
the insect nervous system, and consequently their long-term use has led to
widespread resistance in pest species (King and Hardy, 2013; Smith et al.,
2013). Concerns about the adverse impact of certain classes of chemical
insecticides on the environment and human health have also led to wide-
spread de-registrations and use cancellations; for example, over the period
2005–2009, the U.S. Environmental Protection Agency (EPA)
de-registered or limited the use of 169 insecticides, while only nine new
insecticides were registered during the same time period (Windley et al.,
2012). In simple terms, we have to combat an increasing insect pest problem
with a rapidly diminishing chemical arsenal.
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2. SPIDER VENOM PEPTIDES AS BIOINSECTICIDES
Spiders are among the most successful and abundant insect predators
on the planet. They play a key role in keeping insect populations at bay in a
wide range of ecosystems (Nyffeler and Sunderland, 2003). During more
than 300 million years of co-evolution with insects, spiders not only evolved
sophisticated ways of using silk for prey capture (Blackledge et al., 2009;
Vollrath and Selden, 2007), but also acquired powerful venoms that rapidly
paralyse insect prey. Spider venoms are complex chemical cocktails of salts,
small organic molecules, peptides and proteins, but the dominant compo-
nents in most spider venoms are small, disulfide-rich peptides (King and
Hardy, 2013; Kuhn-Nentwig et al., 2011). Individual spider venoms can
contain more than 1000 small peptides (Escoubas et al., 2006). These pep-
tides simultaneously attack virtually every component of the synaptic
machinery in the central or peripheral nervous system of envenomated prey,
which is tantamount to “shock-and-awe” at the molecular level
(Ikonomopoulou and King, 2013; King and Hardy, 2013).
Given that more than 44,500 extant species of spiders have been
described to date (Platnick, 2013), then a conservative estimate of 250 pep-
tides per venom indicates that as a group spider venoms are likely to contain
>10 million bioactive peptides (King, 2011), the vast majority of which are
expected to be insecticidal. Hence, spider venoms provide an almost inex-
haustible source of insecticidal molecules. To date, more than 200 disulfide-
rich insecticidal spider-venom peptides (ISVPs) have been sequenced,
ranging in size from3.3 to 9.0 kDa and containing three to six disulfide bonds
(King and Hardy, 2013). Several of these peptides are devoid of vertebrate
activity and sufficiently potent against pest insects (i.e. LD50<1500 pmol/g)
and to warrant serious consideration as bioinsecticides (Table 8.1).
Almost all ISVPs isolated to date contain a structural motif known as an
inhibitor cystine knot (King et al., 2002; Pallaghy et al., 1994) that provides
these peptides with remarkable chemical and thermal stability as well as resis-
tance to proteases (King and Hardy, 2013; Saez et al., 2010). Thus, in con-
trast with most other peptides and proteins, biological stability is not a
concern with respect to use of ISVPs as bioinsecticides. ISVPs should be sta-
ble during long periods of storage as well as in the field, and they should
degrade to innocuous breakdown products. Spider-venom peptides can also
be produced using a range of heterologous expression systems that enable
cost-effective large-scale production (Klint et al., 2013).
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Table 8.1 Properties of ISVPs with potential for development as bioinsecticidesa
Rational name Synonyms Species ArachnoServer IDb
Mass
(kDa)
Disulfide
bonds
Molecular
target
Phyletic
specificity
LD50
(pmol/g)c
Oral
activity
Vertebrate
activity
μ-AGTX-
Aa1d
μ-Agatoxin
IV
Agelenopsis
aperta
381 4.20 4 NaV
channel
D, L, Od 30 (D) N.D.e No
μ-CUTX-
As1a
Aptotoxin
3; Aps III
Apomastus
schlingeri
403 3.76 4 NaV
channel
D,d L 133 (L) N.D. N.D.
U1-
CUTX-As1c
Aptotoxin
6; Aps VI
Apomastus
schlingeri
407 8.31 4 N.D. L 2 (L) N.D. N.D.
U1-
NETX-Csp1a
Peptide A Calisoga sp. 28 4.30 4 N.D. L 551 (L) N.D. No
μ-DGTX-
Dc1a
DTX9.2 Diguetia
canities
352 6.39 4 NaV
channel
B,d D,d L 380 (L) N.D. No
κ-HXTX-
Hv1c
J-ACTX-
Hv1c
Hadronyche
versuta
174 3.76 4 KCa
channel
B, C,d D,
L, O
91 (D) Lowd No
ω-HXTX-
Hv1a
V-1 Hadronyche
versuta
193 4.05 3 CaV
channel
B, C, D,
H, L, O
77 (D) Lowd No
ω-HXTX-
Hv2a
– Hadronyche
versuta
204 4.48 3 CaV
channel
B,d C,d
D, O
160 (C) N.D. No
Γ-CNTX-
Pn1a
Tx4(5-5);
Pn4A
Phoneutria
nigriventer
279 5.17 5 Glu
receptor
(NMDA
subtype)
B, D, O <100
(D)
N.D. No
δ-CNTX-
Pn1a
Tx4(6-1);
PnTx4(6-1)
Phoneutria
nigriventer
280 5.24 5 NaV
channel
B, D 36 (D) N.D. No
δ-AMATX-
Pl1a
δ-palutoxin
IT1
Pireneitega
luctuosa
301 4.03 4 NaV
channel
D, H, L 2347 (L) No N.D.
U1-
PLTX-Pt1a
Plectoxin-
V/VI
Plectreurys
tristis
405 5.07 5 N.D. D,d L 14 (L) N.D. N.D.
U2-
SGTX-Sf1b
Toxin SF12;
Toxin F5.7
Segestria
florentina
117 5.12 4 N.D. L 1365 (L) N.D. No
U1-
TRTX-Sp1a
OAIP-1 Selenotypus
plumipes
1495 3.81 3 N.D. B, C, L 2 (C) Moderate N.D.
U1-
AGTX-Ta1a
TaITX-1 Tegenaria
agrestis
349 5.68 3 N.D. C, D,d L 780 (L) N.D. No
aTable is modified and updated fromKing andHardy (2013) and includes only ISVPs reported to have no toxicity on vertebrates. Phyletic specificity refers to the insect orders
in which activity has been reported: Blattaria (B), Coleoptera (C), Diptera (D), Hemiptera (H), Lepidoptera (L) and Orthoptera (O). NaV, voltage-gated sodium channel;
CaV, voltage-activated calcium channel; KCa, calcium-activated potassium channel.
bRefers to the toxin ID number in the ArachnoServer database. To navigate to the toxin card, use http://www.arachnoserver.org/toxincard.html?id¼ID-number.
cLD50 value is given for the insect order (in parentheses) in which the peptide was found to be most potent.
dV. Herzig, N. Bende, and G.F. King (unpublished data).
eN.D., not determined.
The biggest potential disadvantage of ISVPs is that they are not orally or
topically active. Spiders have solved the delivery problem by evolving fangs
that act like hypodermic syringes to deliver their venoms into the
haemolymph of prey, thus enabling ISVPs to access their targets in the insect
nervous system.We have found that the LD50 values for ISVPs fed to insects
are about 100-fold higher than when they are injected (Hardy et al., 2013;
King and Hardy, 2013), presumably due to a slow rate of absorption in
the insect gut, as observed previously for insect neuropeptides (Audsley
et al., 2008) and disulfide-rich peptides from scorpion and snake venoms
(Casartelli et al., 2005). Nevertheless, the low level of intrinsic oral activity
of ISVPs is not restricted to insects, as other arthropod pests such as ticks
were found to be sensitive to oral administration of ω-hexatoxin-Hv1a
(hereafter Hv1a) (Mukherjee et al., 2006).
There is growing evidence that some peptides and proteins can access
paracellular and transcellular transport routes in the insect midgut. Septate
junctions in insects are leaky for molecules smaller than 5 kDa (Casartelli
et al., 2005; Skaer et al., 1987), and this paracellular route might explain
the observed uptake of insect neuropeptides and ISVPs (Audsley et al.,
2007; Hardy et al., 2013). However, size alone is not the sole determinant
of uptake rate, as the 0.9-kDa insect neuropeptide cydiastatin-4 is translocated
across the midgut of the lepidopteran Manduca sexta at a rate 42 times lower
than for Hv1a, a 4-kDa ISVP (V. Herzig, N. Audsley, and G.F. King,
unpublished data). In addition to the paracellular route, the translocation of
large proteins such as albumin across the insect midgut epithelium involves
active energy-dependent processes such as transcytosis (Casartelli et al., 2005).
Even though our understanding of transport routes across the insect mid-
gut is still in its infancy, it is clear that some peptides can pass undegraded
through themidgut, consistentwith the observed insecticidal effects of ISVPs
after oral administration. Further research in this area might facilitate the
rational introduction of chemical modifications and/or the use of formula-
tions that will enhance the oral activity of ISVPs and facilitate their direct
deployment as bioinsecticides. However, the remainder of this chapter will
focus on alternative methods of delivering ISVPs to target insect species as
well as the option of developing orally active small-molecule ISVPmimetics.
3. TRANSCYTOSIS OF SPIDER VENOM PEPTIDES ACROSS
THE INSECT GUT EPITHELIUM VIA FUSION TO
MOLECULAR TRANSPORT VEHICLES
ISVPs appear to be able to access the insect haemolymph via para-
cellular transport. Although this route of uptake is extremely inefficient,
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it could be enhanced by formulation with appropriate solvents and adju-
vants. However, a more generic approach for improving the oral activity
of these peptides might be to fuse them to a protein that is capable of being
transcytosed across the insect gut epithelium. These fusion proteins would
thus serve as molecular transporters that could ferry ISVPs across the
insect gut.
This approach was first demonstrated via fusion of ISVPs to a plant lectin.
Lectins are protease-resistant, carbohydrate-binding proteins that are widely
distributed in animals, plants and micro-organisms. Insecticidal plant lectins
play an important role in defence against herbivorous insects (Michiels et al.,
2010).Galanthus nivalis agglutinin (GNA), a small 14-kDa mannose-specific
lectin from the snowdrop plant, is taken up by receptor-mediated endocy-
tosis in the insect midgut after binding to aminopeptidase N, a membrane-
bound glycoprotein. Subsequent transcytosis leads to its accumulation in
haemolymph,Malpighian tubules, fat bodies, ovarioles and the central nerve
cord (Fitches et al., 2001, 2012) (Fig. 8.1). Thus, the transcellular uptake of
GNA can be exploited as a mechanism for delivering ISVPs to the insect
haemolymph and nervous system (reviewed in Bonning and Chougule,
2014). For example, the oral activity of both Hv1a and the ISVP U2-
SGTX-Sf1a (SFI1) was improved dramatically by fusion to the
N-terminus of GNA. Second instar cabbage moths, Mamestra brassicae, fed
on cabbage leaves coated with 0.2% Hv1a–GNA fusion protein suffered
85% mortality after 10 days, whereas control mortality was <20%
(Fitches et al., 2012). Similarly, although neither GNA nor SFI1 was toxic
when fed to fourth instar tomato moths, Lacanobia oleracea, the inclusion of a
GNA–SFI1 fusion protein as 2.5% of dietary protein was insecticidal to first
instar larvae, causing 100% mortality after 6 days, and to fifth instar larvae,
causing 20% mortality and threefold reduced weight gain compared to con-
trols (Fitches et al., 2004).
An alternative fusion-protein approach recently introduced for specific
delivery of ISVPs to aphids (Bonning et al., 2014) relies on the fact that
aphids and other sap-sucking hemipterans vector a large number of plant
viruses. Luteoviruses are specifically vectored by aphids; the virus is ingested
during feeding on an infected plant and then it persists in the aphid without
replicating. Remarkably, the virus is able to move from the aphid gut into
the haemocoel via transcytosis, which relies on specific recognition of the
viral coat protein (CP) via gut receptors followed by receptor-mediated
endocytosis (Bonning and Chougule, 2014). Thus, as for GNA, the virus
CP can be used as a delivery vehicle for ISVPs. Hv1a has very little intrinsic
oral activity against aphids (Pal et al., 2013), but it was recently demonstrated
to be highly orally active against a wide range of aphids when fused to the
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C-terminus of the CP of pea enation mosaic virus (PEMV); the CP–Hv1a
fusion protein was even orally active against the soybean aphid, Aphis gly-
cines, which is not a vector for PEMV (Bonning et al., 2014). The CPs from
two other luteoviruses, barley yellow dwarf virus and soybean dwarf virus,
are also effective vehicles for ISVP delivery (Miller and Bonning, 2007).
A significant advantage of the GNA and CP delivery methods is that the
fusion proteins can be produced cheaply by recombinant techniques, and
transgenes encoding the fusion proteins can be engineered into
entomopathogens and plants (see Sections 4 and 5). GNA is a highly generic
Figure 8.1 Summary of methods for delivering ISVPs to the insect haemocoel: (1) Some
ISVPs appear to be able to access the haemocoel via paracellular uptake through leaky
septate junctions. (2) ISVPs can be fused to carrier proteins such as snowdrop lectin
(GNA) and the coat protein of pea enationmosaic virus, which are recognised by specific
receptors on gut epithelial cells. These fusion proteins can be taken up via receptor-
mediated endocytosis and delivered to the haemocoel by transcytosis. (3) Baculovirus
can be engineered to encode an ISVP transgene. Upon recognition by specific gut
receptors, budded virions infect gut epithelial cells and other body tissues and release
ISVPs. (4) Entomopathogenic fungi such as Metarhizium and Beauveria can also be
engineered to encode an ISVP transgene. Fungal spores (conidia) adhere to the insect
cuticle, germinate and then invade the integument. The fungus then proliferates in the
haemocoel in the form of wall-less blastopores, which produce and release ISVPs.
Adapted from Bonning and Chougule (2014).
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delivery vehicle as it has been used to deliver insecticidal peptides to lepi-
dopterans, hemipterans, coleopterans and dipterans. However, GNA does
have deleterious effects on some parasitoids, although only at very high doses
(Gatehouse et al., 2011). Thus, it will be important, especially in the context
of integrated pest management programs, to establish whether attachment to
GNA alters ISVP selectivity. In contrast with GNA, CP is a highly specific
delivery vehicle that is currently limited to aphids and possibly other sap-
sucking hemipterans. However, development of a deeper molecular under-
standing of the mechanism of CP recognition and uptake in the insect gut
might allow this technology to be adapted to the control of other insect pests
(Bonning and Chougule, 2014).
4. USE OF ENTOMOPATHOGENS FOR ISVP DELIVERY
4.1. Entomopathogens as bioinsecticides
Entomopathogens, which can be bacterial, viral or fungal, are pathogens that
kill or seriously disable insects. They play a vital role in natural regulation of
insect pests (Sandhu et al., 2012). A wide range of entomopathogens have
been studied and used as bioinsecticides, including the soil bacterium Bacillus
thuringiensis (Bt), baculoviruses and entomopathogenic fungi such as
Metarhizium and Beauveria species.
Bt is a naturally occurring spore-forming bacterium from the family
Bacillaceae. It is widespread in soil and lethal to a range of insects due to
the production of pore-forming Cry toxins (also known as δ-endotoxins)
(Gatehouse et al., 2011; Pardo-Lo´pez et al., 2013; also refer to Chapters
2, 3 and 6). Cry toxins are toxic to specific species of insects, especially larval
stages, and they have proved to be safe to humans and other vertebrates.
Heterologously expressed Cry toxins supply the insect-resistance trait in
Bt transgenic crops (see Section 5; Chapter 6).Most Bt species are only active
against Lepidoptera, Diptera and Coleoptera, although the subspecies Bt
israelensis is effective against the larval stage of mosquitoes (Nartey et al.,
2013; Chapter 3).
Baculoviruses are pathogenic to the larval stage of a limited range of
insects, mostly within the orders Lepidoptera, Hymenoptera and Coleoptera
(Bonning and Hammock, 1996; Inceoglu et al., 2006). As for Bt,
baculoviruses have to be ingested by the insect to cause mortality. Although
wild-type baculoviruses have been used successfully for control of soybean
and forest pests, they have not competed successfully with chemical insec-
ticides. This is because baculoviruses take 5–14 days to kill infected insects,
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during which time the insect continues to feed and cause crop damage
(Bonning and Hammock, 1996; Inceoglu et al., 2006).
There are 400–500 species of entomopathogenic fungi and some have
been used, without modification, for biocontrol of pest insects for 150 years
(Bailey and Boyetchko, 2010; Shah and Pell, 2003). Compared to other
micro-organisms, fungi infect a broader range of insects including lepidop-
terans, homopterans, hymenopterans, coleopterans and dipterans (Vilcinskas
et al., 1997). The EPA have registered more than 100 fungus-based insect
control products since 1995 (De Faria and Wraight, 2007; Shah and Pell,
2003). Mycotrol®, for example, is a Beauveria-based mycoinsecticide used
for control of whiteflies, thrips, mealybugs and aphids (De Faria and
Wraight, 2007), while Green Muscle® contains spores of Metarhizium
acridum, which are selectively pathogenic to locusts. GreenMuscle® showed
no detrimental effects on non-target organisms and it is now registered and
recommended for locust control by the UnitedNations (Lomer et al., 2001).
However, as for baculoviruses, a major disadvantage of entomopathogenic
fungi compared with chemical insecticides is their slow kill time (typically
>7 days).
4.2. Entomopathogens as a delivery vehicle for ISVPs
Since ISVPs are gene-encoded mini-proteins, transgenes encoding these
peptides could be engineered into a variety of entomopathogens, which
would mitigate two of their potential disadvantages. First, in this scenario,
ISVPs would be produced systemically in the insect host after
entomopathogen infection, and consequently their low level of oral activity
would not be an impediment to toxin deployment. Second, the phyletic
selectivity of the ISVP would become less important as the range of affected
insects would be determined primarily by the host range of the selected
entomopathogen. Off-target effects on predators and parasitoids could be
limited by choosing entomopathogens with restricted host selectivity; for
example, M. acridum exclusively infects locusts in the suborder Caelifera,
making it valuable as a locust-specific bioinsecticide.
Transgenic baculovirus have been engineered that express insecticidal
venom peptides from sea anemones, scorpions or spiders; in all cases, the
toxin transgene reduced the time between virus application and cessation
of feeding or death. The most dramatic improvement in insecticidal activity
resulted from incorporation of a transgene encoding an ISVP (Maggio et al.,
2010). The potency and speed of kill of entomopathogenic fungi can also be
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enhanced by engineering them to express insecticidal venom peptides. For
example, the time as well as the dose required for Metarhizium anisopliae to
kill the tobacco hornworm, M. sexta, and the dengue vector, Aedes aegypti,
was reduced when the fungus was engineered to express the scorpion-
venom peptide AaIT (Wang and St Leger, 2007). Entomopathogenic fungi
are desirable insect control agents as they directly parasitise arthropods via
penetration of the host integument, which sets them apart from bacteria
and viruses, which must be ingested to gain host entry (Bailey and
Boyetchko, 2010; Roberts, 1973). Engineering entomopathogenic fungi
to express ISVPs removes two of the major impediments to their commer-
cial development—the kill time is dramatically decreased and the spore dose
required for effective insect control is lowered, thereby reducing
application costs.
5. IN PLANTA EXPRESSION OF SPIDER VENOM PEPTIDES
The introduction of genetically modified (GM) crops in the mid-
1990s revolutionised global crop production. As of 2012, 170 million hect-
ares of GM crops were grown by 17.3 million farmers in 30 countries
( James, 2012). More than 90% of growers are small resource-poor farmers
in developing countries ( James, 2012). Four GM crops currently dominate
global agriculture: cotton (81% of all cotton planted globally), soybeans
(81%), maize (35%) and canola (30%) ( James, 2012).
The introduction of insect-resistant corn and cotton expressing insecti-
cidal Cry toxins fromBt dramatically reduced insecticide use, improved crop
yields and helped conserve beneficial natural enemies (Que et al., 2010;
Tabashnik et al., 2013; also refer to Chapter 6). However, constitutive
expression of the toxin in transgenic plants has expedited resistance devel-
opment in a number of pest species; field-evolved resistance to Bt corn has
been reported for the maize stalk borer, Busseola fusca; the Western corn
rootworm, Diabrotica virgifera virgifera; and the fall armyworm, Spodoptera
frugiperda; while resistance to Bt cotton has been reported for the corn
earworm, Helicoverpa zea, and the pink bollworm, Pectinophora gossypiella
(Gassmann et al., 2014; Tabashnik et al., 2013; this chapter). In China,
2.6% of the population of the cotton bollworm, Helicoverpa armigera, are
now resistant to Cry1Ac cotton, which might be a prognostic indicator
of future widespread resistance (Tabashnik et al., 2013). Moreover, since
Cry toxins primarily target lepidopterans and coleopterans, other insects
(especially sap-sucking hemipterans) that were only secondary pests prior
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to the introduction ofBt crops have now become amajor pest on some crops
(Bonning and Chougule, 2014).
Resistance to Bt crops can be delayed through the use of non-GM ref-
uges and/or by engineering Bt plants to express additional insecticidal genes
that act via different mechanisms, an approach known as pyramiding or trait
stacking (Moar and Anilkumar, 2007; Que et al., 2010; Chapter 6). ISVP
transgenes are good candidates for trait stacking with Bt since (i) they have
completely different mechanisms of action; (ii) they are likely to be
synergised by Cry toxins which lyse midgut epithelial cells (Sobero´n
et al., 2007), a property that should facilitate translocation of ISVPs into
the insect haemocoel; and (iii) whereas Bt toxins are largely specific for
the insect orders Lepidoptera and Coleoptera, ISVPs with complementary
selectivity, particularly against sap-sucking hemipterans, can be selected
for trait stacking.
Attempts to engineer plants expressing ISVPs began almost two decades
ago with the demonstration that transgenic tobacco expressing ω-HXTX-
Ar1a, a 37-residue insect-specific calcium channel blocker from the
Australian funnel-web spider, Atrax robustus, had enhanced resistance to
H. armigera ( Jiang et al., 1996). Transgenes encoding this ISVP (or its
orthologue Hv1a) have subsequently been engineered into cotton (Omar
and Chatha, 2012), tobacco (Khan et al., 2006) and poplar (Cao et al.,
2010). All of these ISVP-expressing transgenic plants were shown to have
significantly increased resistance to insect pests. For example, the mortality
of second instar H. armigera fed on transgenic tobacco expressing Hv1a was
75–100% after 72 h compared to 0% for larvae fed on untransformed plants,
regardless of whether the ISVP was expressed under the strong 35S pro-
moter (Khan et al., 2006) or weaker phloem-specific promoters (Shah
et al., 2011). It has even been claimed that transgenic cotton expressing
Hv1a is as effective as Bollgard II® cotton in controlling major cotton pests
(Omar and Chatha, 2012).
Tobacco plants engineered to express U7-HXTX-Mg1a (Magi-6), a
36-residue ISVP from the venom of the hexathelid spider Macrothele gigas
were found to be significantly more resistant than wild-type plants
against S. frugiperda (Hernandez-Campuzano et al., 2009). More recently,
transgenic Arabidopsis expressing Hv1a fused to the CP of PEMV were
shown to be resistant to a diverse range of aphid species (Bonning et al.,
2014). Thus, ISVP transgenes appear to have significant potential
either as a standalone insect-resistant plant trait or for trait stacking with
Cry toxins.
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6. ISVP MIMETICS
6.1. Synthetic mimics of venom peptides
Venom peptides present structural characteristics that are far from the norm
for synthetic agrochemicals and drugs (Tice, 2001), and their size and polar-
ity impede passive diffusion through cell membranes. Instead, their oral bio-
availability to targets beyond the gut lumen relies on paracellular or active
transport (see Section 2). Given the diversity and potential complexity of
mechanisms that can mediate such paracellular/active transit through the
physical barriers of the gut wall, it seems unlikely that a simple set of general
rules could be derived that describe the oral bioavailability of venom pep-
tides. While the oral activity of ISVPs might be improved by chemical mod-
ifications (e.g. PEGylation and acylation) or by packaging them in
liposomes, microparticles and/or nanoparticles, these are complex and
expensive modifications that would significantly increase production costs.
An alternative approach to improving oral activity is to create
peptidomimetics wherein the functionally critical chemical features of the
peptide are displayed on a smaller structural scaffold with better pharmaco-
kinetic properties.
This alternative has been most extensively pursued for the conotoxin
family of venom peptides. The physicochemical properties of Ziconotide/
Prialt® (ω-conotoxinMVIIA), a cone snail venom peptide used for manage-
ment of intractable pain, result in insignificant oral bioavailability and
consequently this drug requires intrathecal administration (Bingham et al.,
2010). In order to avoid the complexity of this drug delivery method, efforts
have been undertaken to design small-molecule mimetics that might show
oral bioavailability and blood–brain barrier permeability (Brady et al., 2013).
Peptidomimetics that could surmount these challenges are classifiable
into three types (Ripka and Rich, 1998): (Type I) molecules in which pep-
tide bonds are replaced with more tractable bioisosteres; (Type II) molecules
which use moieties that are not structurally equivalent to the native peptide
to interact with the receptor; and (Type III) molecules which utilise a scaf-
fold that can spatially display the critical amino acid residues in the same way
as the native peptide. Several papers have been published on the design of
Type-III mimetics of ω-conotoxins due to the medical and commercial
need (Baell et al., 2001, 2004; Menzler et al., 2000). Despite early progress,
the resultant conotoxin mimetics were much less potent than the native pep-
tide (Brady et al., 2013).
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Recently, we took a more aggressive approach in the design of Type-II
mimetics ofHv1a (Tedford et al., 2013). Hv1a is a 37-residue ISVP that blocks
insect but not mammalian voltage-gated calcium (CaV) channels (Fletcher
et al., 1997; Tedford et al., 2004b). It is harmless when injected into newborn
mice (Atkinson et al., 1998) and a closely related homologue (Ar1a) is inactive
against nerve–muscle preparations from chicken and rat (Chong et al., 2007).
We developed 3Dmodels of the Hv1a pharmacophore and deployed them as
search terms for an in silico screen of a database of millions of commercially
available compounds. Hits from this screen were sorted and filtered as part
of a multiple-round selection process, ultimately yielding an “Hv1a mimetic”
collection that was tested for activity against A. aegypti and Spodoptera exigua.
This testing identified several families of viable prototypemolecules, including
the VNX-000440 (VNX-440) family of triazine molecules that were further
optimised by iterative synthesis and analogue testing.
6.2. Hv1a pharmacophore analysis and modelling
The 3D solution structure of Hv1a comprises a core region rich in β turns
and disulfide bonds (residues 4–21) and a β hairpin (residues 22–37) that pro-
jects from the disulfide-rich core (Fletcher et al., 1997). Site-directed muta-
genesis and synthetic truncates were used to elucidate the Hv1a
pharmacophore (i.e. the set of key structural features contributing to insec-
ticidal activity, presumably by directing interactions with one or more classes
of insect CaV channels) (Tedford et al., 2001, 2004a). The primary
pharmacophore residues (Pro10, Asn27 and Arg35) form a small, contiguous
patch of 200 A˚2 on one face of the toxin (Tedford et al., 2001, 2004a). To
build a viable peptide pharmacophore model, key functionalities of the crit-
ical amino acids were converted into pharmacophoric features and mapped
out in three dimensions (Fig. 8.2). Analyses of the structure of Hv1a and
several related peptides suggested that certain chemical features not identi-
fied previously by scanning mutagenesis, such as the Gly8 carbonyl oxygen
and the hydrophobic Val33 isopropyl functionality, are involved in Hv1a
activity. This conclusion was taken into account while building different
versions of the pharmacophore model: the Val33 side chain was represented
in two versions of the pharmacophore model as a hydrophobic feature,
while the backbone carbonyl oxygen of Gly8 was included as a
hydrogen-bond acceptor (HBA) in one of the models (Table 8.2 lists fea-
tures built into each version of the pharmacophore models that were used
for database searches).
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Available SAR data suggested that the most functionally important res-
idue of Hv1a is Arg35 (Tedford et al., 2004a). This residue contributed three
features to the pharmacophore models: two hydrogen-bond donors (HBDs)
and one positively ionisable group. Asn27 contributed two features: one
HBD and one HBA. Pro10 and Val33 presumably mediate hydrophobic
interactions with CaV channels targeted by the peptide; hence, hydrophobic
features represented their side chains in the pharmacophore. Gly8, which
adopts an unusual backbone configuration (backbone dihedral angles:
ϕ¼90 and ψ¼20), is conformationally restricted by the cystine knot
in a way that allows the Gly8 carbonyl oxygen to contribute to the toxin
pharmacophore.
Figure 8.2 Development of small-molecule mimetics of Hv1a. (A) Richardson schematic
of Hv1a (first molecule in the PDB file 1AXH) showing the key chemical features that
were used for pharmacophore modelling (i.e. the side chains of Pro10, Asn27, Val33,
and Arg35 and the backbone carbonyl of Gly8). Hydrogen, carbon, oxygen and nitrogen
atoms are shown in white, orange, red and blue, respectively. The N- and C-termini are
labelled. (B) Bioassay screening hit VNX-440. (C) Three-dimensional stick representation
of VNX-440; atoms are coloured as in (A) except that carbons are grey and chlorine
atoms are green. Superimposed on VNX-440 are representations of the eight chemical
features of the residues that were included in pharmacophore models of the peptide.
Cyan spheres indicate hydrophobic features matching the hydrophobic side chains of
Val33 and Pro10; magenta spheres and sticks indicate hydrogen-bond donor (HBD)
features projecting from Asn27 and Arg35; green spheres and sticks indicate
hydrogen-bond acceptor (HBA) features projecting from Asn27 and Gly8 (leftmost
and rightmost residues, respectively). (D) Optimised lead compound VNX-443, an ana-
logue of VNX-440.
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The five toxin residues—Gly8, Pro10, Asn27, Val33 and Arg35—whose
substituents were used to derive features of the pharmacophore models—
are illustrated in the context of the overall structure of Hv1a in
Fig. 8.2A. The minimal set of pharmacophore features is formed by Arg35,
Pro10 and Asn27, yielding a 6-feature pharmacophore (see “6 point 1”,
Table 8.2).
The pharmacophore model was deployed to search the Accelrys
Chemicals Available for Purchasing (CAP) database. Low-energy con-
formers of the compounds were measured and scored for their fit to chemical
features of the pharmacophore. The “8-point” model proved too stringent
as a search term, so two 6-feature models were constructed and used to
query the CAP database. After searches using all three versions of the
pharmacophore (Table 8.2), 8773 compounds were identified as “hits” that
showed a substantial structural match to the Hv1a pharmacophore model.
A set of physical properties considered relevant for this exercise were then
used to filter, sort and annotate the hit compound set. This resulted in the
purchase of 1370 unique compounds that were each tested for insecticidal
activity againstA. aegypti larvae. This led to the identification of several fam-
ilies of compounds, including one containing the screening hit VNX-440
(Fig. 8.2B). VNX-440 is a commercially available compound that was pre-
viously shown to have modest antimicrobial activity (McKay et al., 2006).
The remarkable fit of VNX-440 to the pharmacophore model used for
in silico screening, presented in Fig. 8.2C, can be described as follows: a nitro-
gen of the triazine core ring and the oxygen of the morpholine functionality
of the compound overlap with the HBA features of the pharmacophore; two
amine substituents on the triazine core of the compound overlap with the
model’s HBD features; the basic nitrogen of the morpholine overlaps with
Table 8.2 Chemical features of key Hv1a residues used to build 3D pharmacophore
models
Model
version
Arg35 Asn27 Val33 Pro10 Gly8
HBD
(Nη1)
HBD
(Nη2)
PI
(Nε)
HBA
(Oδ1)
HBD
(Nδ2)
HPH (Cβ,
Cγ1, Cγ2)
HPH (Cβ,
Cγ, Cδ)
HBA
(O)
“8-point” Y Y Y Y Y Y Y Y
“6-point 1” Y Y Y Y Y N Y N
“6-point 2” N Y Y Y Y Y Y N
HBD, hydrogen-bond donor; PI, positively ionisable group; HBA, hydrogen-bond acceptor; HPH,
hydrophobe.
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the cationic feature; and, finally, the remaining anilide has modest overlap
with the two hydrophobic features.
6.3. Optimisation andmechanism of action of the Type II mimic
VNX-440
Iterative analoguing, guided by the results of bioassays performed against
A. aegypti and S. exigua, allowed us to further characterise the VNX-440
family of hits and to develop a lead molecule (VNX-443; Fig. 8.2D) with
significantly improved activity compared with the initial screening hit.
The structural changes between VNX-440 and the latter analogue are
summarised as follows (cf. Fig. 8.2B and D): first, the amine of the anilide
that roughly matched the hydrophobic features in the model was excised to
provide a direct connection of a phenyl group to the triazine core. Second,
the anilide that only matched a single HBD feature was replaced with het-
erocycles to improve water solubility. Third, the hydrophilic tail was altered
to change the positioning and basicity of the amine. These alterations
retained a match with HBD and cationic features of the model for this pen-
dant group and increased insecticidal activity. In aggregate, these structural
changes increased insecticidal activity as much as 2200-fold (against
S. exigua) and resulted in a class of novel compounds (Kennedy and
Steinbaugh, 2013).
To confirm that VNX-440 acted against insects via a mechanism similar
to Hv1a, its effect on insect ion channels was examined using whole-cell
voltage-clamp recordings from dorsal unpaired median (DUM) neurons
harvested from the ventral nerve cord of the American cockroach, Peri-
planeta americana (Tedford et al., 2013). Figures 8.3A and B show examples
of the effects of 100 μM VNX-440 on IBa (a measure of CaV channel activ-
ity) recorded from clamped DUM neurons. Control superfusion with bath
solution had no effect on IBa, but superfusion with 100 μM VNX-440
reduced IBa dramatically, with maximum inhibition reached within
10 min of exposure to VNX-440.
The IC50 for inhibition of peak IBa by VNX-440 was estimated from the
dose–response curve to be 23.1 μM (Fig. 8.3C), which is only 20 times
higher than the IC50 (1.08 μM) reported for inhibition of high voltage-
activated CaV channels by Hv1a (Chong et al., 2007). Unfortunately, this
activity was not replicated when VNX-443 was tested in this system.
Regardless, VNX-443 and various other analogues in this series caused
no adverse effects in an acute oral toxicity study in which rats were dosed
at 100 mg/kg (R.M. Kennedy, unpublished results).
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Figure 8.3 Inhibition of Ba2+ currents (IBa) in American cockroach DUM neurons by VNX-440. (A) IBa recorded at 10 mV: black trace shows
control IBa, green trace shows IBa during superfusion with bath solution and the red trace shows IBa following with superfusion with 100 μM
VNX-440. (B) Time course of peak IBa values recorded at a test potential of10 mV after addition of 100 μMVNX-440. (C) Dose–response curve
for VNX-440 inhibition of peak IBa at a test potential of10 mV. (D) I–V curves for IBa obtained before, and 10 min after, application of 100 μM
VNX-440.
6.4. Conclusions from development of Type-II mimetics
of Hv1a
Our in silico modelling and screening using the pharmacophore of Hv1a led
to a small-molecule hit (VNX-440) that showed properties consistent with
mimicry of the native peptide’s biological activity. To our knowledge, this
remains the only published example of the discovery of an insecticidal lead
compound through testing of a small set of candidate compounds chosen to
match the pharmacophore of a peptide. However, since the screening lead
VNX-440 was optimised solely via an in vivo assay (with insect mortality as
the read-out), it is not entirely clear if fidelity was maintained with respect to
the peptide’s mechanism of action, or if another property was optimised. An
additional consideration is that while VNX-443 has good per os activity, it
has only limited contact activity in adult mosquitocidal tests. The physico-
chemical properties enabling topical bioavailability are considerably stricter
than for oral bioavailability and may not allow full coverage of the 200 A˚2
pharmacophoric hot spot on peptides such as Hv1a.
7. OUTLOOK
An unmodified ISVP developed by Vestaron Corporation was
recently approved by the U.S. EPA for use against cabbage looper, Tricho-
plusia ni, marking the start of new era of peptide-based insecticides. ISVPs
have many properties that make them attractive as insect control agents: they
are potently insecticidal, highly selective for insects, stable to extremes of
temperature and should degrade in the field into innocuous breakdown
products. Although they typically have low levels of intrinsic oral activity,
simple formulation can improve their oral activity sufficiently to make them
competitive with chemical insecticides. The oral activity of ISVPs can also
be markedly improved by fusing them to proteins that ferry them via
transcytosis across the insect gut, including plant lectins and the CP of
insect-vectored viruses. Transgenes encoding these fusion proteins could
be incorporated into crop plants either as a standalone insect-resistance trait
or they could be pyramided with Bt transgenes in order to reduce the like-
lihood of resistance development and expand the range of susceptible
insects. Entomopathogens can also be engineered to express transgenes
encoding ISVPs or ISVP fusion proteins with enhanced oral activity. This
approach has the advantage that the selectivity of the ISVP can be tailored
by taking advantage of the limited host range of many entomopathogens.
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Thus, in summary, there are a wide variety of methods by which ISVPs can
be deployed as natural insecticides. We also recently demonstrated for the
first time that the pharmacophore of ISVPs can be used to rationally develop
small-molecule mimetics with improved oral activity, thereby providing
another approach by which these peptides can be exploited for the control
of insect pests.
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Supplementary Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Fig. 1: Effect of rDc1a on L. cuprina and M. domestica 
Dose–response curves for lethal effects of rDc1a determined 24 h after injection into sheep blowflies (L. 
cuprina; open circles) and houseflies (M. domestica; filled circles). Data were fitted according to equations 
indicated in Methods section.  
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Supplementary Fig. 2: rDc1a does not influence human Nav channels 
a, Effect of 1 µM rDc1a on hNav1.1–hNav1.7 and hERG (Kv11.1). Representative Nav channel currents 
were elicited at voltage ranging from –40 mV to –20 mV depending on the studied isoform (holding 
voltage was −90 mV). No significant toxin-induced effects (red) were seen at any of the tested voltages (n 
= 4). Normalized conductance-voltage (G/Gmax) relationships of hERG channels were determined by 
voltage steps from –100 mV to +50 mV in 10-mV increments for 2 s followed by a pulse to –60 mV for 2 s 
from a holding potential of –90 mV (n = 4). Shown are a representative control trace (black) and a trace in 
the presence of 1 µM rDc1a (red) at a voltage of -20 mV. b, First panel: effect of 10 nM BomIV, an insect-
targeting scorpion α-toxin capable of inhibiting Nav channel fast inactivation, on inward BgNav1 currents 
evoked by a 50 ms depolarization to -30 mV from an oocyte membrane holding potential of -90 mV. 
BomIV clearly slows down fast inactivation to the extent that a persistent sodium ion current becomes 
visible at the end of the depolarizing pulse. Other panels: potassium currents elicited by depolarizations 
near the foot (less than 1/3 of maximal activation) of the voltage-activation curve for WT Kv2.1 and 
BgNav1/Kv2.1 chimeric constructs. Currents are shown before (black) and in the presence of 1 µM 
BomIV. Our results reveal that Bom IV interacts with the DIV paddle motif in BgNav1. Consequently, this 
result supports a role for the BgNav1 domain IV voltage sensor in fast inactivation. c, Tail current voltage–
activation relationships for each chimeric construct (n = 3; error bars represent SEM) before (black) and 
following (colored) addition of 1 µM rDc1a. rDc1a clearly affects only the DII chimera. Holding voltage was 
−90 mV for DI, II, and IV, and –120 mV for DIII, and the tail voltage was −60 mV (−100 mV for DIII).  
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Supplementary Figure 3: Lack of effect of rDc1a on cockroach DUM neuron PaNav1 
a, Typical effects of 1 µM rDc1a on PaNav1. Traces show superimposed control (black) and toxin (grey 
and shaded) currents elicited by a 50-ms depolarizing test pulse (Vtest) as shown in the voltage protocol 
above the current traces. The lack of effect on INa amplitude and time course is highlighted in the inset. 
The dotted line represents zero current. b, Effect of rDc1a on the voltage-dependence of PaNav1 channel 
activation. Nav channel currents were elicited by the test pulse protocol shown above the GNa-V 
relationships. Currents recorded in the presence of 1 M rDc1a were normalized to the maximum inward 
INa in controls, converted into normalized GNa-V relationships and fitted with a Boltzmann function. Data 
shows GNa before (closed circles) and after (open circles) application of 1 µM rDc1a. Data were taken 
from panel (c) and fitted using linear regression. c, Lack of a use-dependent effect of rDc1a on PaNav1. 
Effects of 1 µM rDc1a on use-dependent decline in INa during 20 depolarizing test pulses from –90 mV to 
–10 mV at 30 Hz using the test pulse protocol at the top of the panel. Currents were normalized to the 
peak INa amplitude of the first pulse in the train in the absence (closed triangles), and presence (open 
circles and shaded), of 1 µM rDc1a. d, Effect of rDc1a on steady-state Nav channel inactivation (h∞). 
Steady-state inactivation was determined using a two-pulse protocol (see inset panel d). Peak INa, 
recorded during Vtest, were expressed as a fraction of maximum control INa and plotted against prepulse 
potential. Panel (d) shows the proportion of INa that is available for activation under control conditions 
(closed circles), and during perfusion with 1 µM rDc1a (open circles and shaded). All data are expressed 
as the mean ± SEM (n = 3). 
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Supplementary Fig. 4: Sequence alignment of domain II voltage-sensors  
Putative transmembrane segments (S1-S6) within the DII voltage-sensing domain of BgNav1 (Blatella 
germanica), PaNav1 (Periplaneta americana), MdNav1 (Musca domestica), and rNav1.2a are indicated 
with a green bar above the relevant amino acids. The BgNav1 residue count is indicated in italics. The H 
to Y and D to E substitutions discussed in the manuscript are highlighted in red against a gray 
background whereas the domain II S3b-S4 paddle motifs are indicated with a box. The third residue that 
differs between PaNav1 and BgNav1 is located in the S1 transmembrane segment and is indicated in red 
without a gray background. Underlined residues in the S1-S2 loop region were identified previously as 
playing a role in β-scorpion toxin binding to rNav1.2a1. 
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Supplementary Table 1: Structural statistics for the ensemble of rDc1a structuresa. 
 
Experimental restraintsb 
 Interproton distance restraints 
  Intraresidue   267 
  Sequential (|i–j| = 1)  253 
  Medium range (|i–j|  5)  106 
  Long range (|i–j|  5)  276 
 Disulfide-bond restraints    12 
  dihedral-angle restraints     44 
  dihedral-angle restraints     46 
 Total number of restraints per residue    17.6 
Violations of experimental restraintsc       0 
R.m.s. deviation from mean coordinate structure (Å)d 
 All backbone atoms  0.48 ± 0.09 
 All heavy atoms  0.90 ± 0.15 
 Backbone atoms, residues 3–42, 52–56 0.27 ± 0.07 
 Heavy atoms, residues 3–42, 52–56  0.70 ± 0.11 
Stereochemical qualitye 
 Residues in most favored Ramachandran region (%)  99.4 ± 1.2 
 Ramachandran outliers (%)    0.0 ± 0.0 
 Unfavorable sidechain rotamers (%)    9.2 ± 3.0 
 Clashscore, all atomsf    0.0 ± 0.0 
 Overall MolProbity score  1.24 ± 0.12 
 
a All statistics are given as mean ± S.D. 
b Only structurally relevant restraints, as defined by CYANA, are included. 
c There were no violations of any distance or dihedral-angle restraints in the final ensemble. 
d Mean r.m.s. deviation calculated over the entire ensemble of 20 structures. 
e According to MolProbity (http://molprobity.biochem.duke.edu) 
f Defined as the number of steric overlaps >0.4 Å per thousand atoms 
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